REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Title of each class |
Trading Symbol |
Name of each exchange on which registered | ||
“ |
||||
|
* | |
☒ | Accelerated filer | ☐ | ||||
Non-accelerated file | ☐ | Emerging Growth Company |
U.S. GAAP ☐ |
by the International Accounting Standards Board ☒ |
Other ☐ |
PAGE |
||||||
2 |
||||||
3 |
||||||
Item 1. |
5 |
|||||
Item 2. |
5 |
|||||
Item 3. |
5 |
|||||
Item 4. |
58 |
|||||
Item 4A. |
112 |
|||||
Item 5. |
113 |
|||||
Item 6. |
139 |
|||||
Item 7. |
154 |
|||||
Item 8. |
162 |
|||||
Item 9. |
163 |
|||||
Item 10. |
163 |
|||||
Item 11. |
181 |
|||||
Item 12. |
182 |
|||||
Item 13. |
184 |
|||||
Item 14. |
184 |
|||||
Item 15. |
185 |
|||||
Item 16. |
185 |
|||||
Item 16A. |
185 |
|||||
Item 16B. |
185 |
|||||
Item 16C. |
186 |
|||||
Item 16D. |
186 |
|||||
Item 16E. |
186 |
|||||
Item 16F. |
187 |
|||||
Item 16G. |
187 |
|||||
Item 16H. |
187 |
|||||
Item 16I |
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections |
|||||
Item 17. |
188 |
|||||
Item 18. |
188 |
|||||
Item 19. |
188 |
• | the initiation, timing, progress and results of our pre-clinical and clinical studies, and our research and development programs; |
• | our ability to advance product candidates into, and successfully complete, clinical studies; |
• | the timing of regulatory filings and the likelihood of favorable regulatory outcomes and approvals; |
• | regulatory developments in the United States and the European Union and its member countries, and other countries; |
• | the commercialization of our product candidates, if approved; |
• | the pricing and reimbursement of our product candidates, if approved; |
• | the regulatory qualification and certification of our in-house manufacturing facilities and their manufacturing capabilities and operations; |
• | our ability to contract on commercially reasonable terms with CROs, third-party suppliers of biological raw or starting materials and manufacturers; |
• | the implementation of our business model, strategic plans for our business, product candidates and technology; |
• | the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; |
• | the ability of third parties with whom we contract to successfully conduct, supervise and monitor clinical studies for our therapeutic product candidates; |
• | estimates of our expenses, future revenues, capital requirements and our needs for additional financing; |
• | our ability to obtain additional funding for operations; |
• | the potential benefits of our strategic licensing agreements with strategic licensees and our ability to enter into future strategic arrangements; |
• | the ability and willingness of strategic licensees pursuant to our strategic licensing agreements with strategic licensees to actively pursue development activities under our collaboration agreements; |
• | our receipt of milestone or royalty payments pursuant to our strategic licensing agreements with Allogene Therapeutics, Inc. (“Allogene”) and Les Laboratoires Servier (“Servier”); |
• | our ability to maintain and establish collaborations or obtain additional grant funding; |
• | the rate and degree of market acceptance of, and demand for, our product candidates; |
• | our status as a passive foreign investment company for U.S. federal income tax purposes; |
• | the financial performance and cash runway for our Therapeutics business; |
• | our ability to attract and retain key scientific and management personnel; |
• | our expectations regarding the period during which we qualify as a foreign private issuer; |
• | developments relating to our competitors and our industry, including competing therapies and technologies; |
• | Calyxt’s future financial performance, including its cash runway, and statements about Calyxt’s ability to continue as a going concern and Calyxt’s management’s plans to address Calyxt’s liquidity and capital resource needs; |
• | Calyxt’s product pipeline and development; Calyxt’s business model and strategies for the development, commercialization and sales of its commercial products; commercial demand for Calyxt’s synthetic biology solutions; the development and deployment of Calyxt’s PlantSpring technology platform; Calyxt’s ability to deploy and leverage its artificial intelligence and |
machine learning (AIML) capabilities; the ability to scale production capability for Calyxt’s BioFactory production system; potential development agreements, partnerships, customer relationships, and licensing arrangements and their contribution to Calyxt’s financial results, cash usage, and growth strategies; and |
• | the potential impact of the COVID-19 pandemic on our business and operating results; and anticipated trends in our business. |
ITEM 1. |
IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS |
ITEM 2. |
OFFER STATISTICS AND EXPECTED TIMETABLE |
ITEM 3. |
KEY INFORMATION |
A. |
[Reserved] |
B. |
Capitalization and Indebtedness |
C. |
Reasons for the Offer and Use of Proceeds |
D. |
Risk Factors |
• | Our operating history, which has focused primarily on research and development and advancing immunotherapy gene-editing clinical trials, makes it difficult to assess our future prospects. |
• | We have not generated significant revenues and have incurred significant operating losses since our inception. While the amount of our future net losses will depend, in part, on the amount of our future operating expenses and our ability to obtain funding, realize payments under our strategic licensing arrangements, and obtain reimbursements of research tax credit claims, we anticipate that we will continue to incur significant losses for the foreseeable future. |
• | We face substantial competition in our discovery, development and commercialization activities from competitors who may have significantly greater resources than we do. |
• | Because our product candidates all apply novel gene-editing technology, we are heavily dependent on the successful development of this technology. |
• | The extent to which the COVID-19 pandemic and resulting deterioration of worldwide economic conditions adversely impacts our business, financial condition, and operating results will depend on future developments, which are difficult to predict. |
• | We may need to raise additional funding, which may not be available on acceptable terms or at all, and our ability to raise additional share capital is limited by French corporate law. |
• | Our product candidates must undergo clinical trials that are time-consuming and expensive, the outcomes of which are unpredictable, and for which there is a high risk of failure, and which are susceptible under a variety of circumstances to additional costs, delays, suspensions and terminations. |
• | Initial, interim and preliminary data from our clinical trials may change as more data becomes available, and subsequent data may not bear out promising early results. |
• | Because we anticipate that our product candidates will initially receive regulatory approval as treatments for advanced disease or rare diseases, the size of the initial market for our product candidates may be limited. |
• | Our manufacturing process, which is highly complex and heavily regulated, may be difficult to efficiently and effectively operate and scale to the level required for advanced clinical trials or commercialization. |
• | Our manufacturing facilities may not obtain or maintain the required regulatory authorizations to supply commercial products. |
• | Acceptance and adoption of gene-editing and enrollment in our trials may be adversely affected by undesirable side effects, negative perceptions among the public or the medical community, or the inadequacy of payor coverage. |
• | Our future profitability depends, in part, on our ability to penetrate global markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. |
• | We rely on third parties for certain aspects of our discovery, development, manufacturing and commercialization, if any, of our product candidates and issues relating to such third parties, or their activities, which could result in additional costs and delays and hinder our research, development and commercialization prospects. |
• | Strategic license relationships may not be successful, including as a result of failures by our strategic licensees to perform satisfactorily or to devote resources to advance product candidates under our arrangements with them. |
• | We may encounter difficulties in managing our development and expansion, including challenges associated with recruiting additional employees, managing our internal development efforts and improving our operational, financial and management controls. |
• | The risk of product liability claims is inherent in the development and commercialization of therapeutic products, and product liability or other lawsuits could divert management and financial resources, result in substantial liabilities and reduce the commercial potential of our product candidates. |
• | The buy-out mechanism in our collaboration agreement with Servier may prevent or delay a takeover attempt. |
• | Our business is governed by a rigorous, complex and evolving regulatory framework, including premarketing regulatory requirements, pricing, reimbursement and cost-containment regulations, and rigorous ongoing regulation of approved products. This regulatory framework results in significant compliance costs, makes the development and approval of our product candidates time intensive and unpredictable, and may reduce the ultimate economic value and prospects for our product candidates. |
• | A Fast Track, Breakthrough Therapy or Regenerative Medicine Advanced Therapy designation by the U.S. Food and Drug Administration, or FDA, or a Priority Medicines designation by the European Medicines Agency, or EMA, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive regulatory approval. |
• | Any regulatory compliance failures could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. |
• | Because our commercial success depends, in part, on obtaining and maintaining proprietary rights to our and our licensors’ intellectual property, our ability to compete may decline if we fail to obtain protection for our products, product candidates, processes and technologies or do not adequately protect our intellectual property. |
• | Our competitive position may be adversely impacted as a result of a variety of factors, including potentially adverse determinations of complex legal and factual questions involved in patents and patent applications or insufficiently long patent lifespans in one or more jurisdictions where we obtain intellectual property protection. |
• | Because it is cost prohibitive to seek intellectual property protection on a global basis, our intellectual property protection in certain jurisdictions many not be as robust as in the United States, which may adversely impact our competitive position. |
• | Third parties may assert rights to inventions we develop or otherwise regard as our own. |
• | A dispute concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be time consuming and costly, and an unfavorable outcome could harm our business. |
• | Our business could be harmed if we lose key management personnel or cannot attract and retain other qualified personnel. |
• | The rights of shareholders in companies subject to French corporate law differ in material respects from the rights of shareholders of corporations incorporated in the United States. |
• | Our By-laws and French corporate law contain provisions that may delay or discourage a takeover attempt. |
• | Our international operations may be exposed to foreign exchange risks, U.S. federal income tax risks, and additional risks, which may adversely affect our financial condition, results of operations and cash flows. |
• | If we are classified as a PFIC for 2022 or any future taxable year, there may be adverse U.S. federal income tax consequences to U.S. holders. |
• | As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and the Nasdaq’s corporate governance standards. We expect to follow certain home country practices in relation to certain corporate governance matters, which may afford less protection than would be provided if we complied fully with the Nasdaq requirements. |
• | Holders of our ADSs do not directly hold our ordinary shares and may be subject to limitations on the transfer of their ADSs and certain voting and withdrawal rights of the underlying ordinary shares as well as limitations on their ability to exercise preferential subscription rights or receive share dividends. |
• | Share ownership is concentrated in the hands of our principal shareholders and management, who will continue to be able to exercise substantial influence. |
• | Calyxt’s ability to continue as a going concern will depend on its ability to obtain additional financing, which may not be available on acceptable terms or at all, and failure to obtain such financing may force Calyxt to delay, limit or terminate its operations. If financing is obtained through future equity offerings by Calyxt, we may experience substantial additional dilution and, in connection with our ownership level falling below 50%, we will lose certain rights under our stockholders agreement with Calyxt. |
• | Calyxt’s success depends on its ability to successfully deliver synthetic biology solutions, which will require significant resources in a highly competitive industry. Calyxt has limited operating history in this industry, and will faces challenges associated with allocating limited resources, raising capital. gaining customers and competing with companies with greater resources. |
• | For Calyxt to be successful, it must secure customer collaborations, efficiently price its offerings, and demonstrate its technical capabilities and ability for commercial scale production, which involves risks of failure inherent in the deployment of innovative and complex emerging technologies. |
• | As a result of our ownership level in Calyxt, we are exposed to the various other risks to which Calyxt is subject, including (i) additional business and operational risks associated with developing an emerging technology, Calyxt’s reliance on third parties for production and services, reliance on customers and licensees for development and commercialization efforts, and risks associated with outdoor agriculture; (ii) regulatory risks, including the navigation of ethical, legal and social concerns relating to genetically modified or edited plant cells, the complex and evolving regulatory framework, including uncertainty regarding foreign regulation, increasing regulation of hemp development activities, regulatory and compliance burdens under environmental, health and safety laws, (iii) intellectual property risks, including the corresponding risks described with respect to our intellectual property, and (iv) risk associated with attracting and maintaining key management personnel and protecting its data from cybersecurity attacks. |
• | Disruptions to, and delays in, the clinical trials for the product candidates that we are developing resulting from suspensions or delays in enrollment or difficulties in enrolling patients; increased patient withdrawals from, or restrictions imposed on, patients participating in, the clinical trials; diversion of healthcare resources away from the conduct of the clinical trials; or interruptions in data collection, monitoring and/or processing due to governmental restrictions imposed in response to the COVID-19 pandemic. |
• | Disruptions and delays to our research and development programs resulting from a shutdown of our laboratory facilities due to expanded governmental restrictions or illness among laboratory personnel as a result of COVID-19, increased absenteeism among scientific or laboratory employees, or delays with respect to raw material or starting material necessary for research and development activities. |
• | Delays with respect to operations at our manufacturing facilities resulting from increased, expanded or additional government restrictions in Paris, France or Raleigh, North Carolina, or as a result of supply chain disruptions affecting raw materials required for our manufacturing processes. |
• | Overall reduced operational productivity resulting from challenges associated with remote work arrangements, limited resources to employees, and increased cybersecurity risks as a result of remote access to our information systems. |
• | Constraints on financing opportunities resulting from dislocations in the capital markets, which may make it too costly or difficult for us to pursue public or private equity or debt financings on acceptable terms. |
• | conditions imposed by the FDA or any foreign regulatory authority regarding the scope or design of clinical trials; |
• | inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support initiation of clinical studies; |
• | delays in obtaining, or the inability to obtain, regulatory agency approval for the conduct of the clinical trials or required approvals from institutional review boards, or IRBs, or other reviewing entities at clinical sites selected for participation in our clinical trials; |
• | the identification of flaws in the design of a clinical trial; |
• | changes in regulatory requirements and guidance that necessitate amendments to clinical trial protocols; |
• | delays in sufficiently developing, characterizing or controlling manufacturing processes suitable for clinical trials; |
• | insufficient supply or deficient quality of the product candidates or other materials necessary to conduct the clinical trials, including as a result of manufacturing issues at our in-house manufacturing facilities; ; |
• | difficulty in sourcing healthy donor material of sufficient quality and in sufficient quantity to meet our development needs; |
• | lower-than-anticipated enrollment and retention rate of subjects in clinical trials for a variety of reasons, including size of patient population, sites selection, nature of trial protocol, the availability of approved effective treatments for the relevant disease and competition from other clinical trial programs for similar indications and competition from approved products; |
• | delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical study sites and obtaining required institutional review board (IRB) approval at each clinical study site; |
• | the placing of a clinical hold on our strategic licensees’ clinical trials—for example, clinical holds were placed on our AMELI-01 Study in September 2018 and on our MELANI-01 Study in July 2020 and on all of our strategic licensee Allogene’s AlloCAR T clinical trials in October 2021 and remained in place until the FDA permitted these trials to restart in November 2018, November 2020 and January 2022, respectively; |
• | unfavorable interpretations by FDA or similar foreign regulatory authorities of interim data; |
• | determinations by the FDA or similar foreign regulatory authorities that a clinical trial protocol is deficient in design to meet its stated objectives; |
• | failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; |
• | serious and unexpected safety issues, including drug-related side effects experienced by patients in clinical trials; |
• | failure of our or our strategic licensees’ third-party contractors to meet their contractual obligations in a timely manner; or |
• | lack of, or failure to, demonstrate efficacy of our products candidate. |
• | severity of the disease under investigation; |
• | incidence and prevalence of the disease under investigation; |
• | design of the clinical trial protocol; |
• | size and nature of the patient population; |
• | eligibility criteria for the trial in question; |
• | perceived risks and benefits of the product candidate under trial, including relative to other available therapies; |
• | proximity and availability of clinical trial sites for prospective patients; |
• | availability of competing therapies and clinical trials; |
• | patient referral practices of physicians; |
• | our ability to monitor patients adequately during and after treatment, and |
• | ability of the clinical sites to have sufficient resources and avoid any backlogs. |
• | failing to receive regulatory approvals required to market them as drugs; |
• | being subject to proprietary rights held by others; |
• | failing to comply with GMP requirements; |
• | being difficult or expensive to manufacture on a commercial scale; |
• | having adverse side effects that make their use less desirable; |
• | being inferior to existing approved drugs or therapies; |
• | failing to compete effectively with existing or new products or treatments commercialized by competitors; or |
• | failing to show long-term benefits sufficient to offset associated risks. |
• | the clinical indications for which product candidates are approved; |
• | the potential and perceived advantages and risks of our product candidates relative to alternative treatments; |
• | the prevalence and severity of side effects; |
• | the demonstration of the clinical efficacy and safety of the product; |
• | the approved labeling for the product and any required limitations or warnings; |
• | the timing of market introduction of the product candidate as well as of competing products; |
• | the effectiveness of educational outreach to the medical community about the product; |
• | the coverage and reimbursement policies of government and commercial third-party payors pertaining to the product; and |
• | the market price of the product relative to competing treatments. |
• | a covered benefit under applicable policies or plans; |
• | safe, effective and medically necessary; |
• | appropriate for the specific patient; |
• | cost-effective; and |
• | neither experimental nor investigational. |
• | obtaining, on a country-by-country |
• | the burden of complying with complex and changing regulatory, tax, accounting and legal requirements in each jurisdiction that we pursue; |
• | differing medical practices and customs affecting acceptance in the marketplace; |
• | import or export licensing requirements; |
• | country specific requirements related to the cells used as starting material for manufacturing; |
• | language barriers for technical training, healthcare professionals and patients documents; |
• | reduced protection of intellectual property rights in some foreign countries; |
• | foreign currency exchange rate fluctuations; |
• | potential imposition of governmental controls; and |
• | patients’ ability to obtain reimbursement for products in various markets. |
• | that we may be unable to negotiate agreements with third parties under reasonable terms or that termination or non-renewal of an agreement occurs in a manner or time that is costly or damaging to us; |
• | that such third-parties may have limited experience with our or comparable products and may require significant support from us in order to implement and maintain the infrastructure and processes required to manufacture, test or distribute our product candidates; |
• | that such third parties may not perform as agreed or in compliance with applicable laws and requirements, or may not devote sufficient resources to our products; |
• | that we may not have sufficient rights or access to the intellectual property or know how relating to improvements or developments made by our third-party service providers in the course of their providing services to us; |
• | that regulators object to or disallow the performance of specific tasks by certain third parties or disallow data provided by such third parties; |
• | that such third parties may experience business disruptions, such as bankruptcy or acquisition, or failures or deficiencies in their supply chains, that disrupt their ability to perform their obligations to us. |
• | strategic licensees may not perform or prioritize their obligations as expected; |
• | clinical trials conducted pursuant to strategic licensing agreements may not be successful; |
• | strategic licensees may not pursue development and commercialization of product candidates that achieve regulatory approval or may elect not to pursue development or commercialization of product candidates based on clinical trial results, changes in the partners’ focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; |
• | strategic licensees may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial, or abandon a product candidate; |
• | strategic licensees could develop, independently or with third parties, products that compete directly or indirectly with our product candidates; |
• | product candidates developed pursuant to strategic licensing agreements may be viewed by our partners as competitive with their independently developed product candidates or products, which may cause them to devote limited resources to the product candidate’s development or commercialization; |
• | a collaborator may not commit sufficient resources to the commercialization, marketing and distribution of any product candidate; |
• | disagreements with strategic licensees, including over proprietary rights, contract interpretation, or the preferred course of development, may cause delays or termination of the development or commercialization of such product candidates, or may result in time- consuming and expensive legal proceedings; |
• | strategic licensees may not properly obtain, maintain, protect, defend or enforce intellectual property rights or may improperly use proprietary information; |
• | disputes may arise with respect to the ownership of intellectual property developed pursuant to our strategic licensing agreements; |
• | strategic licensees may infringe, misappropriate or otherwise violate third-party intellectual property rights, which may expose us to litigation and potential liability; |
• | strategic licensing agreements may be terminated for convenience by the collaborator and, if terminated, the development of product candidates may be delayed or stopped; |
• | the negotiation of strategic licensing agreements may require substantial attention from our management team; and |
• | we could face significant competition in seeking appropriate strategic licensees, and the negotiation process is time-consuming and complex. |
• | our inability to exercise direct control over sales, distribution and marketing activities and personnel; |
• | potential failure or inability of contracted sales personnel to successfully market our products to physicians; |
• | potential disputes with third parties concerning distribution, sales and marketing expenses, calculation of royalties, and sales and marketing strategies. |
• | identifying, recruiting, integrating, maintaining and motivating additional employees; |
• | effectively managing our internal development efforts, including the clinical and regulatory review process for our product candidates; and |
• | improving our operational, financial and management controls, reporting systems and procedures. |
• | issue a warning letter asserting a violation of the law; |
• | seek an injunction or impose civil or criminal penalties or monetary fines; |
• | suspend or withdraw regulatory approval; |
• | suspend or terminate any ongoing clinical trials; |
• | refuse to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic licensees; |
• | restrict the marketing, distribution or manufacturing of the product; |
• | seize or detain product or otherwise require the withdrawal or recall of product from the market; |
• | destroy or require destruction of products; |
• | refuse to permit the import or export of products; or |
• | refuse to allow us to enter into supply contracts, including government contracts. |
• | their biological medicine is highly similar to the reference medicine, notwithstanding natural variability inherent to all biological medicines; and |
• | there are no clinically meaningful differences between the biosimilar and the reference medicine in terms of safety, quality and efficacy. |
• | the second applicant can establish that its product, although similar to the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior; |
• | the holder of the marketing authorization of the orphan medicinal product consents to a second orphan medicinal product application; or |
• | the holder of the marketing authorization of the orphan medicinal product cannot supply sufficient quantities of the orphan medicinal product. |
• | The federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration (including any kickback, bribe or rebate), directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase or lease, order or recommendation of, any item, good, facility or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid. |
• | The federal civil and criminal false claims laws and civil monetary penalties laws, which impose criminal and civil penalties, including those from civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government. |
• | The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or covering up a material fact or making false statements relating to healthcare matters. |
• | HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, which impose certain requirements on covered entities and their business associates, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. |
• | The federal transparency requirements under the Physician Payments Sunshine Act, enacted as part of the ACA, that require applicable manufacturers of covered drugs, devices, biologics and medical supplies to track and annually report to CMS payments and other transfers of value provided to physicians and teaching hospitals and certain ownership and investment interests held by physicians or their immediate family members. |
• | Analogous laws and regulations in various U.S. states, such as state anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state marketing and/or transparency laws applicable to manufacturers that may be broader in scope than U.S. federal requirements, state laws that require biopharmaceutical companies to comply with the biopharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. government, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect as HIPAA. |
• | the right to nominate a number of designees for Calyxt’s board of directors representing a majority of the directors, to designate the Chairman of the board of directors and to have at least one designated director serve on each board committee; |
• | information rights with respect to Calyxt; |
• | approval of certain changes to Calyxt’s constitutive documents; |
• | approval of Calyxt’s making of any regular or special dividends; |
• | approval of Calyxt’s commencement of any voluntary bankruptcy proceeding or any consent to any bankruptcy proceeding; |
• | approval of any appointment to or removal from the Calyxt board of directors; and |
• | approval of the consummation of any public or private offering, merger, amalgamation or consolidation of Calyxt, the spinoff of a business of Calyxt, or any sale, conveyance, transfer or other disposition of Calyxt’s assets. |
• | Adverse weather conditions, natural disasters, crop disease, pests and other natural conditions; |
• | Climate change that may cause changes in weather patterns and conditions, including changes in rainfall and storm patterns and intensities, water shortages, changes in sea levels, and changes in temperature levels; |
• | Licensee field trials may be unsuccessful; |
• | Licensee products, and food containing those products, may fail to meet standards established by third-party non-GMO verification organizations; |
• | The unintended presence of Calyxt’s traits in other products or plants may have a negative effect on the licensee’s operations. |
• | a failure to achieve commercial traction with Calyxt’s target customers; |
• | loss of customer contracts or delays in fulfilling Calyxt’s contractual obligations; |
• | damage to Calyxt’s brand reputation; |
• | product recalls or replacements; |
• | inability to attract new customers and collaboration opportunities; |
• | diversion of resources from Calyxt’s R&D and sales activities; and |
• | legal and regulatory claims against Calyxt, including product liability claims, which could be costly, time consuming to defend, result in substantial damages and result in reputational damage. |
• | we or our licensors may not have been the first to invent the technology covered by our or their pending patent applications or issued patents; |
• | we cannot be certain that we or our licensors were the first to file patent applications covering our product candidates, including their compositions or methods of use, as patent applications in the United States and most other countries are confidential for a period of time after filing; |
• | others may independently develop identical, similar or alternative products or compositions or methods of use thereof; |
• | the disclosures in our or our licensors’ patent applications may not be sufficient to meet the statutory requirements for patentability and the plausibility case law requirements that may exist in certain jurisdictions; |
• | any or all of our or our licensors’ pending patent applications may not result in issued patents; |
• | we or our licensors may not seek or obtain patent protection in countries or jurisdictions that may eventually provide us a significant business opportunity; |
• | any patents issued to us or our licensors may not provide a basis for commercially viable products, may not provide any competitive advantages, or may be successfully challenged by third parties, which may result in our or our licensors’ patent claims being narrowed, invalidated or held unenforceable; |
• | our compositions and methods may not be patentable; |
• | others may design around our or our licensors’ patent claims to produce competitive products that fall outside of the scope of our or our licensors’ patents; and |
• | others may identify prior art or other bases upon which to challenge and ultimately invalidate our or our licensors’ patents or otherwise render them unenforceable. |
• | payment of damages, potentially including treble or punitive damages if we are found to have willfully infringed a party’s patent rights; |
• | injunctive or other equitable relief that may effectively block our ability to further develop, commercialize, and sell products; |
• | our or our collaborators being required to obtain a license under third-party intellectual property, and such license may not be available on an exclusive basis, on commercially acceptable terms, or at all; or |
• | extensive discovery in which our confidential information could be compromised. |
• | the scope of rights granted under the license agreement and other interpretation-related issues; |
• | the basis of royalties and other consideration due to our licensors; |
• | the extent to which our products, product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; |
• | the sublicensing of patent and other rights under our collaborative development relationships; |
• | our diligence obligations under the license agreement and what activities satisfy those diligence obligations; |
• | the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and |
• | the priority of invention of patented technology. |
• | a merger (i.e., in a French law context, a stock-for-stock two-thirds majority of the votes cast of the shareholders present, represented by proxy or voting by mail at the relevant meeting; |
• | a merger of our company into a company incorporated outside of the European Union would require the unanimous approval of our shareholders; |
• | under French law, a cash merger is treated as a share purchase and would require the consent of each participating shareholder; |
• | our shareholders have granted and may in the future grant to our board of directors broad authorizations to increase our share capital or to issue additional ordinary shares or other securities (for example, warrants) to our shareholders, the public or qualified investors, which could be used as a possible defense following the launching of a tender offer for our shares; |
• | our shareholders have preferential subscription rights proportional to their shareholding in our company on the issuance by us of any additional shares or securities giving the right, immediately or in the future, to new shares for cash or a set-off of cash debts, which rights may only be waived by the extraordinary general meeting (by a two-thirds majority vote) of our shareholders or on an individual basis by each shareholder; |
• | our board of directors has the right to appoint directors to fill a vacancy created by the resignation or death of a director, subject to the ratification by the shareholders of such appointment at the next shareholders’ meeting, which prevents shareholders from having the sole right to fill vacancies on our board of directors; |
• | our board of directors can only be convened by its chairman (and our managing director, if different from the chairman, may request the chairman to convene the board) or, when no board meeting has been held for more than two consecutive months, by directors representing at least one-third of the total number of directors; |
• | our board of directors meetings can only be regularly held if at least half of the directors attend either physically or by way of videoconference or teleconference enabling the directors’ identification and ensuring their effective participation in the board of directors’ decisions; |
• | our shares take the form of bearer securities or registered securities, if applicable legislation so permits, according to the shareholder’s choice. Issued shares are registered in individual accounts opened by us or any authorized intermediary (depending on the form of such shares), in the name of each shareholder and kept according to the terms and conditions laid down by the legal and regulatory provisions; |
• | under French law, a non-French resident as well as any French entity controlled by non-French residents may have to file a declaration for statistical purposes with the Bank of France (Banque de France) following the date of certain direct or indirect investments in us; see the section of this Annual Report titled “Ownership of Shares and ADSs by Non-French Persons”; |
• | approval of at least a majority of the votes cast of the shareholders present, represented by a proxy, or voting by mail at the relevant ordinary shareholders’ general meeting is required to remove directors with or without cause; |
• | advance notice is required for nominations to the board of directors or for proposing matters to be acted upon at a shareholders’ meeting, except that a vote to remove and replace a director can be proposed at any shareholders’ meeting without notice; |
• | transfers of shares shall comply with applicable insider trading rules; |
• | in the event where certain ownership thresholds would be crossed, a number of disclosures should be made by the relevant shareholder in addition to other certain obligations; see the section of this Annual Report titled “Declaration of Crossing of Ownership Thresholds”; and |
• | pursuant to French law, the sections of the By-laws relating to the number of directors and election and removal of a director from office may only be modified by a resolution adopted by a two-thirds majority of the votes cast of our shareholders present, represented by a proxy or voting by mail at the meeting. |
ITEM 4. |
INFORMATION ON THE COMPANY |
• | Autologous treatments must be specifically manufactured for each patient and the resulting engineered cells may have different properties due to significant patient-to-patient T-cells; |
• | Autologous treatments can bear high costs due to the necessity of producing a bespoke treatment for each patient and the effort consumed in modifying and growing each patient’s T-cells; and |
• | At this time, autologous treatments cannot be mass produced, may involve significant delay in production time if the number of patients exceeds the number of productions that can be made in parallel, and require patients be treated at select advanced facilities. |
• | Market access |
• | Cost-effectiveness and Scalable Manufacturing |
• | Novel Features |
• | Safety. T-cell receptor (TCR), which is responsible for T-cells’ non-self antigens; and |
• | Persistence |
• | Advance our self-owned allogeneic UCART portfolio |
• | Utilize our self-owned manufacturing network |
• | Structure a commercial launch plan |
• | Continue the research and development of our hematopoietic stem cells (HSC) platform |
1 | ALLO-501 and ALLO-501A are exclusively licensed to Servier and under a joint clinical development program between Servier and Allogene. The ALPHA and ALPHA2 studies targets Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) indications, which are subtypes of NHL. |
2 | Phase 3 may not be required if Phase 2 is registrational. |
3 | ALLO-715 and ALLO-605 target BCMA which is a licensed target from Cellectis. ALLO-715 and ALLO-605 utilize TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at the BCMA target. Allogene holds global development and commercial rights for this investigational candidate. |
4 | Allogene sponsored trial in combination with SpringWorks Therapeutics. |
5 | ALLO-316 targets CD70 which is a licensed target from Cellectis. ALLO-316 utilize TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at the CD70 target. Allogene holds global development and commercial rights for this investigational candidate. |
• | In the extracellular space, one or more target binding domains, coming from ligands, such as antibodies or receptors, that can recognize their targets on the outside of the T-cell; |
• | A hinge that helps position the target binding domains relative to their targets; |
• | Trans-membrane domains that anchor the CAR at the T-cell’s surface relative to the T-cells; and |
• | A set of activating or signaling domains, which are located within the T-cell’s interior, that deliver appropriate signals to the T-cells leading to T-cell activation or repression according to the T-cell environment. Such signals may induce tumor cell killing, cytokine secretion and CAR T-cell multiplication. |
• | Market access |
• | Cost-effectiveness and Scalable Manufacturing |
• | Novel Features |
• | Safety. T-cell receptor (TCR), which is responsible for T-cells’ non-self antigens; |
• | Persistence |
• | Precision |
• | Specificity and Selectivity T-cell’s genome. |
• | Efficiency T-cells treated by TALEN to inactivate one gene bear the desired genomic modification. We believe TALEN’s high efficiency will be important to the cost-effectiveness of a manufacturing process involving the generation of gene-edited T-cells. |
• | Design – identify metabolic pathways to produce the target compound and the genes controlling these pathways, develop strategies for the optimized expression of the target genes, and design the technical approach to achieve the production of the targeted compound. A metabolic pathway is a linked series of chemical reactions occurring within a cell. The reactants, products, and intermediates of an enzymatic reaction are known as metabolites, which are modified by a sequence of chemical reactions catalyzed by enzymes. |
• | Engineer – direct changes in the plant cells using one or more genetic transformation and plant tissue culture techniques, and enhancements of genes in that plant species. |
• | Verify – use a combination of analytical tools to verify the compound produced against the customer’s specifications. The analytical tools used include natural product chemistry, metabolomics, genomics, gene expression tools, and other analytics. |
• | methods central to genome engineering and gene editing of blood cells, including gene targeting, replacement, insertions and/or knock-out by using TALE-nucleases; |
• | the main products we use in the manufacturing process, including nucleases; |
• | manufacturing steps, including cell electroporation, transformation and genetic modifications; |
• | resulting engineered cells; |
• | single-chain and multi-subunit CARs expressed at the surface of T-cells; |
• | specific gene inactivation and “suicide switch” gene expression; |
• | allogeneic and autologous treatment strategies using our T-cell products; and |
• | plant traits and methods for gene editing plant cells. |
• | the genetic editing of T-cells, using TALEN technology, covered by approximately twelve Cellectis-owned patent families and three in-licensed patent families; |
• | the insertion of transgenes into T-cells using electroporation of mRNA, covered by approximately five Cellectis-owned patent families; |
• | the appending of attributes to T-cells, covered by approximately eight Cellectis-owned patent families and one in-licensed patent family; |
• | the molecular structure of CARs, covered by approximately six Cellectis-owned patent families; and |
• | specific CARs that target selected antigen markers are covered by approximately fifteen Cellectis-owned patent applications and one in-licensed patent family. |
• | In August 2017, the FDA approved tisagenlecleucel (Kymriah ® ) from Novartis AG for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. In May 2018, the FDA approved a label extension for Kymriah® for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Sales of Kymriah® were $76 million in 2018, $278 million in 2019, $474 million in 2020 and $587 million in 2021. In October 2021, the FDA accepted for priority review Novartis’ application for Kymriah® in adult patients with relapsed or refractory follicular lymphoma (FL) after two prior lines of treatment. |
• | In October 2017, the FDA approved axicabtagene ciloleucel (Yescarta ® ) commercialized by Kite Pharma, a subsidiary of Gilead Sciences, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Sales of Yescarta® were $264 million in 2018, $456 million in 2019, $563 million in 2020 and $695 million in 2021. In April 2021, the FDA approved Yescarta® forthe treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. |
• | In July 2020, the FDA approved brexucabtagene autoleucel (Tecartus ™ ) commercialized by Kite Pharma, a subsidiary of Gilead Sciences, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. In October 2021, the FDA approved Tecartus™ for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. |
• | In December 2020, Janssen began a rolling submission of a Biologics License Application, or BLA for the anti-BCMA CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) in relapsed or refractory multiple myeloma (formerly known as LCAR-B38M and in partnership with Legend Biotech). |
• | In February 2021, the FDA approved idecabtagene vicleucel (Breyanzi ™ ) commercialized by Bristol Myers Squibb and bluebird bio for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. |
• | In March 2021, FDA approved idecabtagene vicleucel (Abecma ™ ) commercialized by Bristol Myers Squibb and bluebird bio, for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. |
• | Autologous and Allogeneic CAR T-cell space: Juno Therapeutics, Inc. (in collaboration with Editas Medicine Inc.), acquired by Celgene Corporation and acquired since by Bristol-Myers Squibb; Bluebird bio, Inc. (in collaboration with Celgene Corporation, acquired since by Bristol-Myers Squibb), Ziopharm Oncology Inc. (in collaboration with Intrexon Corporation), Kite Pharma Inc. (in collaboration with Amgen Inc. and with Sangamo Therapeutics Inc.), acquired by Gilead Sciences Inc., Novartis AG (in collaboration with Intellia Inc.), Johnson & Johnson (in collaboration with Transposagen Biopharmaceuticals Inc.), Precision Biosciences (in collaboration with Servier), Regeneron Pharmaceuticals Inc. (in collaboration with Adicet Bio Inc), Fate Therapeutics Inc. (in collaboration with Janssen), CRISPR Therapeutics Inc., Takeda Pharmaceutical Company Limited, Tmunity Therapeutics Inc., Mustang Bio, Atara Biotherapeutics Inc., (in collaboration with Bayer), Adaptimmune (in collaboration with Astellas), Poseida Therapeutics Inc., BioNTech SE, Vor Therapeutics Inc., Autolus Therapeutics plc., Bellicum Pharmaceuticals, Inc., and Celyad S.A. |
• | Gene-editing space: CRISPR Therapeutics Inc. (in collaboration with Bayer AG and Vertex Inc.), Editas Medicine, Inc. (partnered with Allergan and Celgene), Intellia Therapeutics, Inc. (partnered with Novartis), Precision BioSciences, Inc., Sangamo BioSciences, Inc. (partnered with Kite/Gilead and Pfizer), Vertex/Exonics Therapeutics (partnered with CRISPR Therapeutics), Graphite Bio Inc. and Beam Therapeutics Inc.. |
• | Cell-therapy space: Adaptimmune Ltd, Iovance Biotherapeutics, Unum Therapeutics, Inc., NantKwest, Inc., Cytovia Therapeutics, Inc., Atara Biotherapeutics, Inc., and Immunocore Ltd. |
• | completion of extensive nonclinical, sometimes referred to as pre-clinical laboratory tests, pre-clinical animal studies and formulation studies in accordance with applicable regulations, including the FDA’s GLP regulations; |
• | production and testing of clinical products according to the current Good Manufacturing Practices, or cGMP, and possible FDA product specific requirements; |
• | submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated at least annually; |
• | performance of adequate and well-controlled clinical trials in accordance with applicable IND and other clinical trial-related regulations, sometimes referred to as Good Clinical Practices, or GCPs, to establish the safety and efficacy of the proposed product candidate for each proposed indication; |
• | submission to the FDA of a BLA; |
• | satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the active pharmaceutical ingredient, or API, and finished product are manufactured to assess compliance with the IND/BLA and FDA’s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the product’s identity, strength, quality, purity and potency; |
• | FDA review and approval of the BLA prior to any commercial marketing or sale of the product in the United States. |
• | Phase 1 pre-clinical testing warrants, the initial human testing may be conducted in patients with the condition of interest. |
• | Phase 2 |
• | Phase 3 |
• | the drug is a regenerative medicine therapy, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, except for those regulated solely under Section 361 of the Public Health Service Act and part 1271 of Title 21, Code of Federal Regulations; |
• | the drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and |
• | preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition. |
• | an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs; |
• | an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and a cap on the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP; |
• | a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale |
• | extension of manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; |
• | expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers’ Medicaid rebate liability; |
• | expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and |
• | a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. |
• | The second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; |
• | The applicant consents to a second orphan medicinal product application; or |
• | The applicant cannot supply enough orphan medicinal product. |
C. |
Organizational Structure |
Group Structure as of December 31, 2021 | ||||
Subsidiary Name |
Jurisdiction of Incorporation |
Ownership & Voting Interest Held By Cellectis S.A. | ||
Calyxt, Inc. | Delaware | 61.8% (held directly) | ||
Cellectis, Inc. | Delaware | 100% (held directly) | ||
Cellectis Biologics, Inc. | Delaware | 100% (held indirectly through Cellectis, Inc.) |
D. |
Property, Plant and Equipment |
ITEM 4A. |
UNRESOLVED STAFF COMMENTS |
ITEM 5. |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS |
For the year ended December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
$ in thousands (except shares and per shares numbers) |
||||||||||||
Revenues and other income |
22,990 |
82,456 |
67,071 |
|||||||||
|
|
|
|
|
|
|||||||
Operating expenses |
||||||||||||
Cost of revenue |
(11,392 | ) | (36,275 | ) | (31,360 | ) | ||||||
Research and development expenses |
(92,042 | ) | (86,950 | ) | (129,030 | ) | ||||||
Selling, general and administrative expenses |
(43,017 | ) | (44,201 | ) | (37,869 | ) | ||||||
Other operating income and expenses |
(91 | ) | (467 | ) | 511 | |||||||
|
|
|
|
|
|
|||||||
Operating income (loss) |
(123,552 |
) |
(85,437 |
) |
(130,677 |
) | ||||||
|
|
|
|
|
|
|||||||
Loss from discontinued operations |
— |
— |
||||||||||
Financial gain (loss) |
8,340 |
(12,046 |
) |
5,570 |
||||||||
|
|
|
|
|
|
|||||||
Net income (loss) |
(115,212 |
) |
(97,483 |
) |
(125,107 |
) | ||||||
|
|
|
|
|
|
|||||||
Attributable to shareholders of Cellectis |
(102,091 | ) | (81,074 | ) | (114,197 | ) | ||||||
Attributable to non-controlling interests |
(13,121 | ) | (16,409 | ) | (10,910 | ) | ||||||
Earnings per share attributable to shareholders of Cellectis (1) |
||||||||||||
Basic and diluted (2) |
(2.41 | ) | (1.91 | ) | (2.55 | ) | ||||||
Number of shares used for computing |
||||||||||||
Basic (1) |
42,442,136 | 42,503,447 | 44,820,279 | |||||||||
Diluted (1) |
42,442,136 | 42,503,447 | 44,820,279 | |||||||||
Other operating data |
||||||||||||
Adjusted Net Income (Loss) attributable to shareholders of Cellectis (3) |
(78,849 | ) | (66,709 | ) | (101,700 | ) |
(1) | See Note 17 to our consolidated financial statements for further details on the calculation of basic and diluted loss per ordinary share. |
(2) | Potential ordinary shares resulting from the exercise of share warrants and employee warrants are antidilutive. |
(3) | Adjusted Net Income (Loss) attributable to shareholders of Cellectis is not a measure calculated in accordance with IFRS. We define Adjusted Net Income (Loss) attributable to shareholders of Cellectis as our Net Income (Loss) attributable to shareholders of Cellectis, adjusted to eliminate the impact of Non-cash stock-based compensation expense. See “Note Regarding Use of Non-IFRS Financial Measures” for important information. Please refer below for a reconciliation of Adjusted Net Income (Loss) attributable to shareholders of Cellectis to Net Income (Loss) attributable to shareholders of Cellectis, which is the most directly comparable financial measure calculated in accordance with IFRS. |
As of December 31, |
||||||||||||
2019 (1) |
2020 |
2021 |
||||||||||
$ in thousands |
||||||||||||
Current financial assets and Cash and cash equivalents |
360,907 | 268,239 | 186,135 | |||||||||
Total assets |
467,469 | 469,471 | 382,075 | |||||||||
Total shareholders’ equity |
355,471 | 308,846 | 236,474 | |||||||||
Total non-current liabilities |
49,395 | 108,610 | 96,254 | |||||||||
Total current liabilities |
62,604 | 52,015 | 49,347 |
(1) | The 2019 Consolidated Financial Statements have been prepared according to the new IFRS 16 “Leases” standard with a new “right-of-use |
As of December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
$ in thousands |
||||||||||||
Net Income (Loss) attributable to shareholders of Cellectis |
(102,091 |
) |
(81,074 |
) |
(114,197 |
) | ||||||
Adjustment of non-cash stock-based compensation expense: |
||||||||||||
Research and development expenses |
12,260 | 8,029 | 10,852 | |||||||||
Selling, general and administrative expenses |
14,621 | 8,707 | 2,266 | |||||||||
|
|
|
|
|
|
|||||||
Total non-cash stock-based compensation expense: |
26,881 | 16,736 | 13,118 | |||||||||
|
|
|
|
|
|
|||||||
Non-cash stock-based compensation expense attributable to non controlling interests |
(3,707 | ) | (2,371 | ) | (621 | ) | ||||||
|
|
|
|
|
|
|||||||
Adjusted Net Income (Loss) attributable to shareholders of Cellectis |
(78,849 |
) |
(66,709 |
) |
(101,700 |
) | ||||||
|
|
|
|
|
|
• | The AMELI-01 Study, which replaced the first clinical study for UCART123 on AML, is an open-label, Phase 1, single arm, multicenter clinical trial designed to evaluate the safety, expansion, persistence and clinical activities of UCART123 in patients with relapsed or refractory acute myeloid leukemia (r/r AML). The AMELI-01 Study is currently open for patient recruitment at University of Texas, MD Anderson Cancer Center (Houston, Texas), H. Lee Moffitt Cancer Center & Research Institute (Tampa, Florida), Dana-Farber / Partners CancerCare, Inc. (Boston, Massachusetts), New York Presbyterian / Weill Medical College of Cornell University (New York, New York), Northwestern University (Chicago, Illinois), University of Miami (Miami, Florida), the Regent of the University of California on behalf of its San Francisco Campus (San Francisco, California), and The Trustee of University of Pennsylvania (Philadelphia, Pennsylvania). |
• | The BALLI-01 Study is an open-label, Phase 1/2, single arm, multicenter clinical trial designed to evaluate the safety, expansion, persistence, and clinical activities of UCART22 in patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL). The BALLI-01 Study is currently open to patient recruitment at New York Presbyterian / Weill Medical College of Cornell University (New York, New York), Memorial Sloan Kettering Cancer Center (New York, New York), Children’s Hospital of Philadelphia (Philadelphia, Pennsylvania), the University of Chicago (Chicago, Illinois), University of Texas, MD Anderson Cancer Center (Houston, Texas), The Regents of the University of California on behalf of its Los Angeles campus (Los Angeles, California), Dana Farber/Mass General Brigham Cancer Care, Inc. (Boston, Massachusetts), and Hôpital Saint-Louis AP-HP (Paris, France). |
• | The MELANI-01 Study is an open-label, Phase 1, single arm, multicenter clinical trial designed to evaluate the safety, expansion, persistence and clinical activities of UCARTCS1 in patients with relapsed or refractory multiple myeloma. The MELANI-01 Study is currently open to patients recruitment at Hackensack University Medical Center (Hackensack, New Jersey), The University of Texas, MD Anderson Cancer Center (Houston, Texas), The regents of the University of California, on behalf of its San Francisco campus (San Francisco, California), and Mayo Clinic (Rochester, Minnesota). As of the date of this Annual Report, we are enrolling patients in the first dose level of the MELANI-01 Study. |
• | UCART20x22, which is in development as the first allogeneic dual CAR T-cell candidate product for B-cell malignancies; |
• | UCARTMESO, which is an allogeneic CAR T-cell candidate product for mesothelin expressing cancers; |
• | UCARTMUC1, which is an allogeneic CAR T-cell candidate product for mucin-1 expressing epithelial cancers; |
• | UCARTFAP, which is an allogeneic CAR-T candidate product targeting cancer associated fibroblasts (CAFs) in the tumor microenvironment. |
• | progress our sponsored clinical trials AMELI-01, BALLI-01 and MELANI-01, and initiate additional clinical trials for other self-owned product candidates; |
• | continue to advance the research and development of our current and future immuno-oncology product candidates; |
• | advance research and development efforts for our HSC product candidates; |
• | further develop and refine the manufacturing process for our product candidates; |
• | maintain our manufacturing facilities in Paris (France) and Raleigh (North Carolina, USA), continue production at our in-house manufacturing facilities and change or add additional manufacturers or suppliers of biological materials to support our in-house manufacturing capabilities; |
• | seek regulatory and marketing approvals for our product candidates, if any, that successfully complete development; |
• | establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; |
• | seek to identify and validate additional product candidates; |
• | acquire or in-license other product candidates, technologies or biological material; |
• | make milestone or other payments under any in-license agreements; |
• | maintain, protect and expand our intellectual property portfolio; |
• | seek to attract and retain new and existing skilled personnel; |
• | create additional infrastructure to support our operations as a public company; |
• | experience any delays or encounter issues with any of the above. |
• | the CIR results in a cash inflow to us from the tax authorities; |
• | a company’s corporate income tax liability does not limit the amount of the CIR; and |
• | the CIR is not included in the determination of the corporate income tax. |
• | personnel costs, including salaries, related benefits and share-based compensation, for our employees engaged in scientific research and development functions; |
• | cost of third-party contractors such as contract research organizations, or CROs, and academic institutions involved in pre-clinical or clinical trials that we may conduct, or third-party contractors involved in field trials; |
• | purchases and manufacturing of biological materials, real-estate leasing costs as well as conferences and travel costs; |
• | costs to write and support the research for filing patents and; |
• | certain other expenses, such as expenses for use of laboratories and facilities for our research and development activities. |
• | the scope, rate of progress and expense of our ongoing as well as any additional pre-clinical studies, clinical trials and other research and development activities; |
• | clinical trial and early-stage results; |
• | the terms and timing of regulatory approvals; |
• | the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; |
• | the ability to market, commercialize and achieve market acceptance for any product candidate that we may develop in the future; and |
• | the scope, rate of progress and expense of our ongoing as well as any additional studies for Calyxt’s product candidates, and other research and development activities. |
• | Revenue Recognition: Collaboration Agreements and Licenses, Sales of Products and Services (Note 3.1) |
• | Research Tax Credit (Note 3.1) |
• | Share-Based Compensation (Note 16) |
• | Provisions for risks and charges (Note 18) |
A. |
Operating Results |
For the year ended December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
($ in thousands) |
||||||||||||
Revenues and other income |
||||||||||||
Revenues |
15,190 | 73,949 | 57,293 | |||||||||
Other income |
7,800 | 8,507 | 9,778 | |||||||||
|
|
|
|
|
|
|||||||
Total revenues and other income |
22,990 |
82,456 |
67,071 |
|||||||||
|
|
|
|
|
|
|||||||
Operating expenses |
||||||||||||
Cost of revenue |
(11,392 | ) | (36,275 | ) | (31,360 | ) | ||||||
Research and development expenses |
(92,042 | ) | (86,950 | ) | (129,030 | ) | ||||||
Selling, general and administrative expenses |
(43,017 | ) | (44,201 | ) | (37,869 | ) | ||||||
Other operating income (expenses) |
(91 | ) | (467 | ) | 511 | |||||||
|
|
|
|
|
|
|||||||
Operating income (loss) |
(123,552 |
) |
(85,437 |
) |
(130,677 |
) | ||||||
|
|
|
|
|
|
|||||||
Financial income |
11,971 | 5,468 | 13,234 | |||||||||
Financial expenses |
(3,631 | ) | (17,514 | ) | (7,665 | ) | ||||||
|
|
|
|
|
|
|||||||
Net Financial gain (loss) |
8,340 |
(12,046 |
) |
5,570 |
||||||||
|
|
|
|
|
|
|||||||
Income (loss) from continuing operations |
(115,212 | ) | (97,483 | ) | (125,107 | ) | ||||||
Net income (loss) |
(115,212 |
) |
(97,483 |
) |
(125,107 |
) | ||||||
|
|
|
|
|
|
|||||||
Attributable to shareholders of Cellectis |
(102,091 | ) | (81,074 | ) | (114,197 | ) | ||||||
Attributable to non-controlling interests |
(13,121 | ) | (16,409 | ) | (10,910 | ) |
For the year ended December 31, |
% change |
|||||||||||||||||||
($ in thousands) |
2019 |
2020 |
2021 |
2019 vs 2020 |
2020 vs 2021 |
|||||||||||||||
Collaboration agreements |
6,055 | 48,823 | 29,971 | 706.3 | % | -38.6 | % | |||||||||||||
Other revenues |
9,135 | 25,126 | 27,322 | 175.1 | % | 8.7 | % | |||||||||||||
Revenues |
15,190 |
73,949 |
57,293 |
386.8 |
% |
-22.5 |
% |
For the year ended December 31, |
% change |
|||||||||||||||||||
($ in thousands) |
2019 |
2020 |
2021 |
2019 vs 2020 |
2020 vs 2021 |
|||||||||||||||
Research tax credit |
7,800 | 8,433 | 8,239 | 8.1 | % | -2.3 | % | |||||||||||||
Other income |
— | 74 | 1,539 | n.a. | 1980.2 | % | ||||||||||||||
Other income |
7,800 |
8,507 |
9,778 |
9.1 |
% |
14.9 |
% |
For the year ended December 31, |
% change |
|||||||||||||||||||
($ in thousands) |
2019 |
2020 |
2021 |
2019 vs 2020 |
2020 vs 2021 |
|||||||||||||||
Cost of goods sold |
(9,280 | ) | (34,168 | ) | (29,517 | ) | 268.2 | % | -13.6 | % | ||||||||||
Royalty expenses |
(2,112 | ) | (2,107 | ) | (1,844 | ) | -0.2 | % | -12.5 | % | ||||||||||
Cost of revenue |
(11,392 |
) |
(36,275 |
) |
(31,360 |
) |
218.4 |
% |
-13.5 |
% |
For the year ended December 31, |
% change |
|||||||||||||||||||
($ in thousands) |
2019 |
2020 |
2021 |
2019 vs 2020 |
2020 vs 2021 |
|||||||||||||||
Personnel expenses |
(34,911 | ) | (37,903 | ) | (55,080 | ) | 8.6 | % | 45.3 | % | ||||||||||
Purchases, external expenses and other |
(57,131 | ) | (49,047 | ) | (73,950 | ) | -14.1 | % | 50.8 | % | ||||||||||
Research and development expenses |
(92,042 |
) |
(86,950 |
) |
(129,030 |
) |
-5.5 |
% |
48.4 |
% |
For the year ended December 31, |
% change |
|||||||||||||||||||
($ in thousands) |
2019 |
2020 |
2021 |
2019 vs 2020 |
2020 vs 2021 |
|||||||||||||||
Personnel expenses |
(27,934 | ) | (24,524 | ) | (17,729 | ) | -12.2 | % | -27.7 | % | ||||||||||
Purchases, external expenses and other |
(15,083 | ) | (19,677 | ) | (20,140 | ) | 30.5 | % | 2.4 | % | ||||||||||
Selling, general and administrative expenses |
(43,017 |
) |
(44,201 |
) |
(37,869 |
) |
2.8 |
% |
-14.3 |
% |
For the year ended December 31, |
% change |
|||||||||||||||||||
($ in thousands) |
2019 |
2020 |
2021 |
2019 vs 2020 |
2020 vs 2021 |
|||||||||||||||
Other operating income (expenses) |
(91 | ) | (467 | ) | 511 | 413.2 | % | -209.4 | % |
For the year ended December 31, |
% change |
|||||||||||||||||||
($ in thousands) |
2019 |
2020 |
2021 |
2019 vs 2020 |
2020 vs 2021 |
|||||||||||||||
Financial income |
11,971 | 5,468 | 13,234 | -54.3 | % | 142.0 | % |
For the year ended December 31, |
% change |
|||||||||||||||||||
($ in thousands) |
2019 |
2020 |
2021 |
2019 vs 2020 |
2020 vs 2021 |
|||||||||||||||
Financial expenses |
(3,631 | ) | (17,514 | ) | (7,665 | ) | 382.3 | % | -56.2 | % |
For the year ended December 31, |
% change |
% change |
||||||||||||||||||
($ in thousands) |
2019 |
2020 |
2021 |
2019 vs 2020 |
2020 vs 2021 |
|||||||||||||||
Net income (loss) |
(115,212 | ) | (97,483 | ) | (125,107 | ) | -15.4 | % | 28.3 | % |
For the year ended December 31, |
% change |
% change |
||||||||||||||||||
($ in thousands) |
2019 |
2020 |
2021 |
2019 vs 2020 |
2020 vs 2021 |
|||||||||||||||
Gain (loss) attributable to non-controlling interests |
(13,121 | ) | (16,409 | ) | (10,910 | ) | 25.1 | % | -33.5 | % |
For the year ended December 31, 2019 |
For the year ended December 31, 2020 |
For the year ended December 31, 2021 |
||||||||||||||||||||||||||||||||||
($ in thousands) |
Plants |
Therapeutics |
Total reportable segments |
Plants |
Therapeutics |
Total reportable segments |
Plants |
Therapeutics |
Total reportable segments |
|||||||||||||||||||||||||||
External revenues |
7,294 | 7,896 | 15,190 | 22,892 | 51,057 | 73,949 | 26,946 | 30,347 | 57,293 | |||||||||||||||||||||||||||
External other income |
— | 7,800 | 7,800 | — | 8,507 | 8,507 | 1,528 | 8,250 | 9,778 | |||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
External revenues and other income |
7,294 |
15,696 |
22,990 |
22,892 |
59,564 |
82,456 |
28,475 |
38,597 |
67,071 |
|||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Cost of revenue |
(9,275 | ) | (2,117 | ) | (11,392 | ) | (34,324 | ) | (1,951 | ) | (36,275 | ) | (29,517 | ) | (1,844 | ) | (31,360 | ) | ||||||||||||||||||
Research and development expenses |
(12,390 | ) | (79,652 | ) | (92,042 | ) | (9,903 | ) | (77,048 | ) | (86,950 | ) | (11,190 | ) | (117,840 | ) | (129,030 | ) | ||||||||||||||||||
Selling, general and administrative expenses |
(26,090 | ) | (16,927 | ) | (43,017 | ) | (21,688 | ) | (22,513 | ) | (44,201 | ) | (14,987 | ) | (22,882 | ) | (37,869 | ) | ||||||||||||||||||
Other operating income and expenses |
25 | (116 | ) | (91 | ) | (103 | ) | (363 | ) | (466 | ) | 23 | 488 | 511 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Total operating expenses |
(47,730 |
) |
(98,812 |
) |
(146,542 |
) |
(66,018 |
) |
(101,875 |
) |
(167,893 |
) |
(55,671 |
) |
(142,077 |
) |
(197,748 |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Operating income (loss) before tax |
(40,436 |
) |
(83,116 |
) |
(123,552 |
) |
(43,126 |
) |
(42,311 |
) |
(85,437 |
) |
(27,196 |
) |
(103,481 |
) |
(130,677 |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Net financial gain (loss) |
294 | 8,045 | 8,340 | (776 | ) | (11,270 | ) | (12,046 | ) | (1,162 | ) | 6,731 | 5,570 | |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Net income (loss) |
(40,142 |
) |
(75,071 |
) |
(115,212 |
) |
(43,902 |
) |
(53,581 |
) |
(97,483 |
) |
(28,358 |
) |
(96,749 |
) |
(125,107 |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Non-controlling interests |
13,121 | — | 13,121 | 16,409 | — | 16,409 | 10,910 | — | 10,910 | |||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Net income (loss) attributable to shareholders of Cellectis |
(27,021 |
) |
(75,071 |
) |
(102,091 |
) |
(27,493 |
) |
(53,581 |
) |
(81,074 |
) |
(17,448 |
) |
(96,749 |
) |
(114,197 |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
R&D non-cash stock-based expense attributable to shareholder of Cellectis |
1,619 | 10,010 | 11,629 | 801 | 6,790 | 7,591 | 909 | 9,381 | 10,290 | |||||||||||||||||||||||||||
SG&A non-cash stock-based expense attributable to shareholder of Cellectis |
6,673 | 4,940 | 11,613 | 3,536 | 3,238 | 6,774 | 95 | 2,113 | 2,207 | |||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Adjustment of share-based compensation attributable to shareholders of Cellectis |
8,292 |
14,950 |
23,242 |
4,337 |
10,028 |
14,365 |
1,004 |
11,493 |
12,497 |
|||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Adjusted net income (loss) attributable to shareholders of Cellectis |
(18,729 |
) |
(60,121 |
) |
(78,849 |
) |
(23,156 |
) |
(43,553 |
) |
(66,709 |
) |
(16,444 |
) |
(85,256 |
) |
(101,700 |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||
Depreciation and amortization tangible and intangible assets |
(1,233 | ) | (5,642 | ) | (6,875 | ) | (1,869 | ) | (7,950 | ) | (9,819 | ) | (1,208 | ) | (6,371 | ) | (7,579 | ) | ||||||||||||||||||
Additions to tangible and intangible assets |
2,998 | 14,668 | 17,666 | 1,786 | 48,813 | 50,599 | 1,187 | 15,451 | 16,638 |
B. |
Liquidity and Capital Resources |
For the year ended December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
($ in thousands) |
||||||||||||
Net cash flows provided by (used in) operating activities |
(69,142 | ) | (80,262 | ) | (104,562 | ) | ||||||
Net cash flows provided by (used in) investing activities |
(35,872 | ) | (54,342 | ) | 7,279 | |||||||
Net cash flows provided by (used in) financing activities |
(3,862 | ) | 27,322 | 47,525 | ||||||||
|
|
|
|
|
|
|||||||
Total |
(108,876 |
) |
(107,282 |
) |
(49,758 |
) | ||||||
|
|
|
|
|
|
|||||||
Effect of exchange rate changes on cash |
(2,103 | ) | 7,908 | (5,754 | ) |
• | the initiation, progress, timing, costs and results of pre-clinical and clinic studies for our product candidates; |
• | the capacity of manufacturing our products in France and in the United States; |
• | the outcome, timing and cost of regulatory approvals by U.S. and non-U.S. regulatory authorities, including the possibility that regulatory authorities will require that we perform more studies than those that we currently expect; |
• | the ability of our product candidates to progress through clinical development successfully; |
• | the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; |
• | our need to expand our research and development activities; |
• | our need and ability to hire additional personnel; |
• | our need to implement additional infrastructure and internal systems, including manufacturing processes for our product candidates; |
• | the effect of competing technological and market developments; and |
• | the cost of establishing sales, marketing and distribution capabilities for any products for which we may receive regulatory approval. |
As of December 31, 2021 |
Total |
Less than 1 year |
1 - 3 years |
3 - 5 years |
More than 5 years |
|||||||||||||||
$ in thousands |
||||||||||||||||||||
Lease agreements |
108,312 | 12,855 | 24,728 | 20,281 | 50,447 | |||||||||||||||
License and collaboration agreements |
17,580 | 1,530 | 3,060 | 3,060 | 9,930 | |||||||||||||||
Clinical & Research and Development agreements |
444 | 444 | — | — | — | |||||||||||||||
IT licensing agreements |
1,101 | 445 | 655 | — | — | |||||||||||||||
State Guaranteed loan « PGE » |
21,016 | 2,246 | 10,477 | 8,294 | — | |||||||||||||||
Loan to finance leasehold improvements |
1,367 | 108 | 241 | 279 | 739 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total contractual obligations |
149,821 |
17,629 |
39,162 |
31,914 |
61,116 |
|||||||||||||||
|
|
|
|
|
|
|
|
|
|
• | Lease agreements regarding Cellectis’ corporate headquarter in Paris, France, its administrative and research and development facility in New York, New York, and its manufacturing facilities in Paris, France, and Raleigh, North Carolina, as well as leased equipment for $108.3 million, of which $12.9 million are payable in 2022, |
• | License and collaboration agreements with third parties that subject the Company to certain fixed license fees, as well as fees based on future events, such as research and sales milestones for $17.6 million, of which $1.5 million are payable in 2022, |
• | Clinical and research agreements for $0.4 million, payable in 2022, |
• | IT licensing agreements for $1.1 million, of which $0.4 million are payable in 2022, |
• | A state Guaranteed loan “PGE” of $21.0 million, of which $2.2 millions are payable in 2022, |
• | And a loan to finance leasehold improvements of $1.4 million, of which $0.1 million are payable in 2022 |
• | Liability for minimum lease payments for its corporate headquarters and lab facilities and equipment leases due within the next five years in an aggregate amount of $7.7 million, of which $1.7 million is payable in 2022; |
• | Remaining severance obligation to Mr. Blome, its former Chief Executive Officer, due within the next two years in an aggregate amount of $1.8 million, of which $1.1 million is payable in 2022. |
C. |
Research and Development, Patents and Licenses, etc. |
D. |
Trend Information |
E. |
Accounting Estimates. |
ITEM 6. |
DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES |
A. |
Directors and Senior Management |
Name |
Age |
Position(s) | ||
Executive Officers: |
||||
André Choulika, Ph.D. | 57 | Director, Chief Executive Officer and Co-Founder | ||
Carrie Brownstein, MD | 52 | Chief Medical Officer | ||
Steven Doares, Ph.D. | 62 | Senior Vice President of US Manufacturing | ||
Philippe Duchateau, Ph.D. | 59 | Chief Scientific Officer | ||
Kyung Nam-Wortman |
52 | Chief Human Resources Officer | ||
Stephan Reynier | 53 | Chief Regulatory & Pharmaceutical Compliance Officer | ||
David Sourdive, Ph.D. | 55 | Director, Deputy Chief Executive Officer, Executive Vice President, CMC and Manufacturing | ||
Arthur Stril | 33 | Chief Business Officer | ||
Marie-Bleuenn Terrier Bing Wang, Ph.D. |
40 45 |
General Counsel Chief Financial Officer | ||
Non-Employee Directors: |
||||
Jean-Pierre Garnier, Ph.D. | 74 | Chairman of the Board and Director | ||
Laurent Arthaud | 59 | Director | ||
Pierre Bastid | 67 | Director | ||
Rainer Boehm | 61 | Director | ||
Alain Godard | 76 | Director | ||
Hervé Hoppenot | 62 | Director | ||
Annick Schwebig, M.D. Donald A. Bergstrom |
71 50 |
Director Observer |
Board Diversity Matrix |
||||||||||
Country of Principal Executive Offices: | France | |||||||||
Foreign Private Issuer | Yes | |||||||||
Disclosure Prohibited under Home Country Law | No | |||||||||
Total Number of Directors and Board Observers | 10 | |||||||||
Female |
Male |
Non- Binary |
Did Not Disclose Gender |
|||||||
Part I: Gender Identity |
||||||||||
Directors | 1 | 9 | 0 | 0 | ||||||
Part II: Demographic Background |
||||||||||
Underrepresented Individual in Home Country Jurisdiction | 0 | |||||||||
LGBTQ |
0 | |||||||||
Did Not Disclose Demographic Background | 0 |
B. |
Compensation |
Directors |
Compensation (Gross Salary+Bonus)* |
Board fees* | Out-of- pocket expenses* |
Equity awards granted in 2021 |
||||||||||||
A. Choulika |
$ | 879,062 | — | — | |
155,000 SO 33,000 free shares |
| |||||||||
D. Sourdive |
$ | 580,278 | — | — | |
34,000 SO 7,000 free shares |
| |||||||||
J.P. Garnier |
— | — | — | 27,465 SO | ||||||||||||
L. Arthaud |
— | — | — | — | ||||||||||||
P. Bastid |
— | $ | 88,763 | — | — | |||||||||||
R. Boehm |
— | $ | 71,010 | — | — | |||||||||||
D. Bergstrom |
— | $ | 21,040 | — | — | |||||||||||
A. Godard |
— | $ | 88,763 | $ | 452 | — | ||||||||||
H. Hoppenot |
— | $ | 82,845 | $ | 9,406 | — | ||||||||||
A. Schwebig |
— | $ | 82,845 | — | — |
* | The conversation rate used is the average rate of the period |
• | termination (including by non-renewal) of such person’s employment other than for gross misconduct (faute lourde |
• | for any non-employee officer or US officer, any material reduction of such executive’s duties or cash compensation. |
• | employee warrants (otherwise known as bons de souscription de parts de créateur d’entreprise or BSPCE), granted only to employees of Cellectis; |
• | non-employee warrants (otherwise known as bons de souscription d’actions or BSA), granted only to non-employee directors and other service providers or consultants not eligible for employee warrants; |
• | restricted, or free, shares (otherwise known as actions gratuites); and |
• | stock options (otherwise known as options de souscription d’actions). |
• | 700 free shares have been granted to a new employee in November 2021 under the 2021 Free Share Plan and are under the vesting period of three years; |
• | 1,300 stock options have been granted a new employee in November 2021 under the 2021 Stock Option Plan and are under the vesting period of four years; |
• | 2,100 free shares have been granted to a new employee in November 2021 under the 2021 Free Share Plan and are under the vesting period of three years; |
• | 4,500 stock options have been granted to a new employee in November 2021 under the 2021 Stock Option Plan and are under the vesting period of four years; |
• | 4,500 free shares have been granted to a new employee in October 2021 under the 2021 Free Share Plan and are under the vesting period of three years; |
• | 9,000 stock options have been granted to a new employee in October 2021 under the 2021 Stock Option Plan and are under the vesting period of four years; |
• | 12,975 free shares have been granted to certain of our employees in September 2021 under the 2021 Free Share Plan and are under the vesting period of three years; |
• | 25,950 stock options have been granted to certain of our employees in September 2021 under the 2021 Stock Option Plan and are under the vesting period of four years; |
• | 158,000 free shares have been granted in May 2021 under the Second 2018 Free Share Plan with a minimum vesting period of three years. These free shares have been granted to a large number of our employees of which 16,000 free shares have been granted to our Chief Medical Officer, our Senior Vice President of US Manufacturing and our Chief Regulatory and Compliance Officer, under non-market performance vesting conditions and with a minimum vesting period of three years; |
• | 35,000 stock options have been granted to certain of our officers in May 2021: our Chief Medical Officer, our Chief Regulatory and Compliance Officer and our Senior Vice President of US Manufacturing, under the 2018 Stock Option Plan and are under the vesting period of four years; |
• | 2,000 free shares have been granted to a new employee in May 2021 under the 2018 Free Share Plan and are under the vesting period of three years; |
• | 3,500 stock options have been granted to a new employee in May 2021 under the 2018 Stock Option Plan and are under the vesting period of four years; |
• | 27,465 stock options have been granted to one of our officers (our chairman of the board of directors) in April 2021 under the 2018 Stock Option Plan and are under the vesting period of four years; |
• | 330,041 free shares have been granted to certain of our employees in March 2021 under the Second 2018 Free Share Plan and are under a vesting period of three years; of which 103,000 free shares have been granted to our Executive Officers, under non-market performance vesting conditions; |
• | 924,520 stock options have been granted to certain of our employees in March 2021 under the 2018 Stock Option Plan and are under the vesting period of four years, of which 495,000 stock option have been granted to our Executive Officers. |
• | stock options for the purchase of 200,000 shares of Calyxt’s common stock and 50,000 restricted stock units granted under Calyxt’s 2017 Omnibus Incentive Plan, in each case vesting in equal installments on the first three anniversaries of Mr. Carr’s start date at Calyxt; and |
• | performance stock units to acquire up to 600,000 shares of Calyxt’s common stock, which will vest based on Calyxt’s achievement for a period of 30 consecutive calendar days of specified trading price levels during a three-year performance period following the grant date, granted under a one-time inducement plan. |
C. |
Board Practices |
Name |
Current Position |
Year of Initial Appointment |
Term Expiration Year | |||
Jean-Pierre Garnier, M.D. |
Chairman and Director |
2020 | 2023 | |||
André Choulika, Ph.D. |
Director and CEO |
2000 | 2024 | |||
David Sourdive, Ph.D. |
Director and Deputy CEO |
2000 | 2024 | |||
Alain Godard |
Director | 2007 | 2024 | |||
Pierre Bastid |
Director | 2011 | 2023 | |||
Laurent Arthaud |
Director | 2011 | 2023 | |||
Annick Schwebig, M.D. |
Director | 2011 | 2023 | |||
Hervé Hoppenot |
Director | 2017 | 2023 | |||
Rainer Boehm |
Director | 2017 | 2023 | |||
Donald A. Bergstrom |
Observer | 2021 | 2024 |
• | review on a preliminary basis and express its opinion on the draft annual and quarterly financial statements prior to the board of directors officially receiving the financial statements; |
• | examine the critical accounting policies and practices of the Company, including their relevance and consistency used for the preparation of the Company’s consolidated financial statements and rectify any failure to comply with these policies and practices; |
• | monitor the scope of consolidation and review, where necessary, any explanations in connection thereto; |
• | interview, when necessary, the statutory auditors, the chairman of the board of directors, the chief executive officer, the chief financial officer, the employees in charge of our internal controls or any other management personnel; these discussions may take place, where required, without the presence of the chairman of our board of directors and the chief executive officer; and |
• | examine—prior to their publication—the draft annual and interim financial statements, the draft annual report and any other draft financial statements (including projected financial statements) prepared for the needs of upcoming material transactions together with the related press releases; |
• | assess the efficiency and quality of internal control systems and procedures within the consolidated Company; |
• | examine, with the persons in charge of the internal audit, and, if necessary, outside of the presence of the chairman of the board of directors and the chief executive officer, the contingency and action plans with respect to internal audit, the findings following the implementation of these actions and the recommendations and follow-up actions in connection therewith; and |
• | entrust the internal audit department with any mission which the committee deems necessary; |
• | examine any question relating to the appointment, renewal or dismissal of our statutory auditors and their fees regarding the performance of their control review functions; |
• | oversee the rules relating to the use of the statutory auditors for assignments other than the audit of the financial statements and, more generally, ensure that we comply with the principles guaranteeing the statutory auditors’ independence; |
• | at least annually, review and discuss the information provided by management and the auditors relating to the independence of the audit firm; |
• | pre-approve any services entrusted to the statutory auditors which is outside of the scope of the annual audit; |
• | review every year with the statutory auditors all fees paid to by the Company and its subsidiaries to any networks to which the auditors belong, their work plan, their findings and recommendations, as well as actions taken by us following such recommendations; |
• | review and discuss with the statutory auditors their comments on internal controls over financial reporting and any matters that have come to the attention of the statutory auditors that lead them to believe that modification to our disclosures about changes in internal control over financial reporting is necessary for management’s certifications pursuant to Section 302 of the Sarbanes-Oxley Act; |
• | discuss if necessary any points of disagreement between the statutory auditors and the officers of the Company that may arise within the scope of these operations; and |
• | review and discuss with the statutory auditors the plans for, and the scope of, the annual audit and other examinations; and |
• | review on a regular basis the financial situation, the cash position and the material risks and undertakings of the Company and its subsidiaries; and |
• | review the risk management policy and the process implemented to evaluate and manage these risks. |
• | review the compensation of our employees and managers of the Company and its subsidiaries (fixed and variable compensations, bonus, etc.) and make any recommendation to our board of directors in connection therewith; |
• | review equity incentive plans (non-employee warrants, stock options, restricted (free) shares, etc.) and make recommendations to our board of directors in connection therewith; |
• | make recommendations to our board of directors regarding the compensation, pension and insurance plans, benefits in kind and other various pecuniary rights, of officers, as well as the allocation of equity incentive instruments granted to executive officers and directors of the Company; |
• | evaluate and make recommendations on the compensation policies and programs of executive officers and on the compensation of directors; |
• | recommend the approval, adoption and amendment of all cash- and equity-based incentive compensation plans in which any of our executive officers or directors participate and all other equity-based plans; |
• | review any proposed employment agreement with, and any proposed severance or retention plans or agreements applicable to, any of our executive officers; |
• | review, at least annually, corporate goals and objectives relevant to the compensation of our executive officers; and |
• | evaluate the performance of the executive officers in light of corporate goals and objectives and recommend compensation levels for these executive officers based on those evaluations and any other factors the compensation committee deems appropriate. |
D. |
Employees |
E. |
Share Ownership |
ITEM 7. |
MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS |
A. |
Major Shareholders. |
• | each beneficial owner of more than 5% of our outstanding ordinary shares; |
• | each of our directors and executive officers; and |
• | all of our directors and executive officers as a group. |
Name of Beneficial Owner |
Ordinary Shares Beneficially Owned |
|||||||
Number |
Percentage |
|||||||
5% Shareholders: |
||||||||
Baillie Gifford & Co. (1) |
4,335,883 | 9.53 | % | |||||
Bpifrance Participations (2) |
3,686,287 | 8.10 | % | |||||
ARK Investment Management LLC (3) |
2,941,556 | 6.47 | % | |||||
Pfizer, Inc. (4) |
2,787,024 | 6.13 | % |
Name of Beneficial Owner |
Ordinary Shares Beneficially Owned |
|||||||
Number |
Percentage |
|||||||
Directors and Executive Officers: |
||||||||
André Choulika, Ph.D. (5) |
2,081,134 | 4.58 | % | |||||
David Sourdive, Ph.D. (6) |
1,813,160 | 3.99 | % | |||||
Philippe Duchateau, Ph.D. (7) |
701,526 | 1.54 | % | |||||
Marie-Bleuenn Terrier (8) |
683,441 | 1.50 | % | |||||
Stephan Reynier (9) |
322,041 | * | ||||||
Arthur Stril (10) |
21,312 | * | ||||||
Carrie Brownstein (11) |
98,500 | * | ||||||
Steven Doares (12) |
14,874 | * | ||||||
Kyung Nam-Wortman (13) |
14,906 | * | ||||||
Alain Godard (14) |
238,724 | * | ||||||
Pierre Bastid (15) |
2,082,191 | 4.58 | % | |||||
Laurent Arthaud |
— | * | ||||||
Annick Schwebig, M.D. (16) |
202,115 | * | ||||||
Hervé Hoppenot (17) |
40,000 | * | ||||||
Rainer Boehm (18) |
40,000 | * | ||||||
Jean-Pierre Garnier (19) |
7,581 | * | ||||||
Donald A. Bergstrom |
— | * | ||||||
All directors and executive officers as a group (17 persons) |
8,361,505 | 18.38 | % |
* | Represents beneficial ownership of less than one per cent. |
(1) | Amounts beneficially owned by Baillie Gifford & Co. were reported pursuant to a Schedule 13G amendment filed with the SEC on January 11, 2022 by “Baillie Gifford & Co.” The address of Baillie Gifford & Co. is Calton Square, 1 Greenside Row, Edinburgh EH1 3AN. |
(2) | Consists of (a) 3,686,287 ordinary shares and 6,565,787 voting rights beneficially owned by Bpifrance Participations S.A., (b) 3,961,387 ordinary shares and 6,840,887 voting rights beneficially owned by Caisse des Dépôts, (c) 3,686,287 ordinary shares and 6,565,787 voting rights beneficially owned by EPIC Bpifrance and (d) 3,686,287 ordinary shares and 6,565,787 voting rights beneficially owned by Bpifrance S.A. Bpifrance Participations S.A., EPIC Bprifrance and Bprifrance S.A.’s address is 27-31, avenue du Général Leclerc, 94710 Maisons-Alfort Cedex, France. Caisse Dépôts’ address is 56, rue de Lille, 75007 Paris, France. |
(3) | Amounts beneficially owned by ARK Investment Management LLC were reported pursuant to a Schedule 13G amendment filed with the SEC on February 9, 2022 by ARK Investment Management LLC. ARK Investment Management LLC’s address is 3 East 28th Street, New York, NY 10016. |
(4) | The address of Pfizer, Inc. is 235 East 42nd Street, New York, New York 10017. Shares beneficially owned by Pfizer, Inc. were acquired by Pfizer OTC B.V. on July 31, 2014 in the context of a share capital increase in connection with the entry into a research and collaboration agreement between Pfizer Inc. and Cellectis S.A. |
(5) | Includes 219,173 ordinary shares that Mr. Choulika has the right to acquire pursuant to stock options granted in March 2015 under the 2015 Stock Option Plan, 200,000 ordinary shares that Mr. Choulika has the right to acquire pursuant to stock options granted in September 2015 governed by the 2015 Stock Option Plan, 160,701 ordinary shares that Mr. Choulika has the right to acquire pursuant to stock options granted in March 2016 under the 2015 Stock Option Plan, 226,477 ordinary shares that Mr. Choulika has the right to acquire pursuant to stock options granted in October 2016 under the 2016 Stock Option Plan, 135,000 ordinary shares that Mr. Choulika has the right to acquire pursuant to stock options granted in October 2017 under the 2017 Stock Option Plan, 105,000 ordinary shares that Mr. Choulika has the right to acquire pursuant to stock options granted in April 2019 under the 2018 Stock Option Plan and 38,750 ordinary shares that Mr. Choulika has the right to acquire pursuant to stock options granted in March 2021 under the 2018 Stock Option Plan. |
(6) | Includes 175,343 ordinary shares that Mr. Sourdive has the right to acquire pursuant to stock options granted in March 2015 under the 2015 Stock Option Plan, 175,000 ordinary shares that Mr. Sourdive has the right to acquire pursuant to stock options granted in September 2015 governed by the 2015 Stock Option Plan and 140,614 ordinary shares that Mr. Sourdive has the right to acquire pursuant to stock options granted in March 2016 under the 2015 Stock Option Plan, 198,168 ordinary shares that Mr. Sourdive has the right to acquire pursuant to stock options granted in October 2016 under the 2016 Stock Option Plan, 80,000 ordinary shares that Mr. Sourdive has the right to acquire pursuant to stock options granted in October 2017 under the 2017 Stock Option Plan, 52,500 ordinary shares that Mr. Sourdive has the right to acquire pursuant to stock options granted in April 2019 under the 2018 Stock Option Plan and 8,500. ordinary shares that Mr. Sourdive has the right to acquire pursuant to stock options granted in March 2021 under the 2018 Stock Option Plan, Includes 703,041 shares held by Viveoo SARL. |
(7) | Includes 131,508 ordinary shares that Dr. Duchateau has the right to acquire pursuant to stock options granted in March 2015 under the 2015 Stock Option Plan, 150,000 ordinary shares that Dr. Duchateau has the right to acquire pursuant to stock options granted in September 2015 governed by the 2015 Stock Option Plan, 120,526 ordinary shares that Dr. Duchateau has the right to acquire pursuant to stock options granted in March 2016 under the 2015 Stock Option Plan, 169,858 ordinary shares that Dr. Duchateau has the right to acquire pursuant to stock options granted in October 2016 under the 2016 Stock Option Plan, 30,000 ordinary shares that Dr. Duchateau has the right to acquire pursuant to stock options granted in October 2017 under the 2017 Stock Option Plan, 52,500 ordinary shares that Dr. Duchateau has the right to acquire pursuant to stock options granted in April 2019 under the 2018 Stock Option Plan and 8,500 ordinary shares that Dr. Duchateau has the right to acquire pursuant to stock options granted in March 2021 under the 2018 Stock Option Plan. |
(8) | Includes 87,671 ordinary shares that Mrs. Terrier has the right to acquire pursuant to stock options granted in March 2015 under the 2015 Stock Option Plan, 90,000 ordinary shares that Mrs. Terrier has the right to acquire pursuant to stock options granted in September 2015 governed by the 2015 Stock Option Plan, 140,614 ordinary shares that Mrs. Terrier has the right to acquire pursuant to stock options granted in March 2016 under the 2015 Stock Option Plan, 198,168 ordinary shares that Mrs. Terrier has |
the right to acquire pursuant to stock options granted in October 2016 under the 2016 Stock Option Plan, 80,000 ordinary shares that Mrs. Terrier has the right to acquire pursuant to stock options granted in October 2017 under the 2017 Stock Option Plan, 52,500 ordinary shares that Mrs. Terrier has the right to acquire pursuant to stock options granted in April 2019 under the 2018 Stock Option Plan and 8,500 ordinary shares that Mrs. Terrier has the right to acquire pursuant to stock options granted in March 2021 under the 2018 Stock Option Plan. |
(9) | Includes 39,452 ordinary shares that Mr. Reynier has the right to acquire pursuant to stock options granted in March 2015 under the 2015 Stock Option Plan, 40,000 ordinary shares that Mr. Reynier has the right to acquire pursuant to stock options granted in September 2015 governed by the 2015 Stock Option Plan, 58,856 ordinary shares that Mr. Reynier has the right to acquire pursuant to stock options granted in March 2016 under the 2015 Stock Option Plan, 67,609 ordinary shares that Mr. Reynier has the right to acquire pursuant to stock options granted in October 2016 under the 2016 Stock Option Plan, 40,000 ordinary shares that Mr. Reynier has the right to acquire pursuant to stock options granted in October 2017 under the 2017 Stock Option Plan, 52,500 ordinary shares that Mr. Reynier has the right to acquire pursuant to stock options granted in April 2019 under the 2018 Stock Option Plan and 8,500 ordinary shares that Mr. Reynier has the right to acquire pursuant to stock options granted in March 2021 under the 2018 Stock Option Plan. |
(10) | Includes 4,063 ordinary shares that Mr. Stril has the right to acquire pursuant to stock options granted in October 2018 under the 2018 Stock Option Plan, 8,750 ordinary shares that Mr. Stril has the right to acquire pursuant to stock options granted in April 2019 under the 2018 Stock Option Plan and 8,500 ordinary shares that Mr. Stril has the right to acquire pursuant to stock options granted in March 2021 under the 2018 Stock Option Plan. |
(11) | Includes 70,000 ordinary shares that Mrs. Brownstein has the right to acquire pursuant to stock options granted in April 2020 under the 2018 Stock Option Plan, 8,500 ordinary shares that Mrs. Brownstein has the right to acquire pursuant to stock options granted in March 2021 under the 2018 Stock Option Plan and 20,000 ordinary shares that Mrs. Brownstein has the right to acquire pursuant to stock options granted in April 2020 under the 2018 Free Share Plan. |
(12) | Includes 6,375 ordinary shares that Mr. Doares has the right to acquire pursuant to stock options granted in July 2020 under the 2018 Stock Option Plan and 8,500 ordinary shares that Mr. Doares has the right to acquire pursuant to stock options granted in March 2021 under the 2018 Stock Option Plan. |
(13) | Includes 6,406 ordinary shares that Mrs. Nam-Wortman has the right to acquire pursuant to stock options granted in November 2020 under the 2018 Stock Option Plan and 8,500 ordinary shares that Mrs. Nam-Wortman has the right to acquire pursuant to stock options granted in March 2021 under the 2018 Stock Option Plan. |
(14) | The ordinary shares include 50,000 non-employee warrants which are exercisable since March 27, 2016, 50,000 non-employee warrants, which are exercisable since September 8, 2016, 40,175 non-employee warrants, which are exercisable since March 14, 2017, 37,000 non-employee warrants, which are exercisable since October 28, 2017 and 40,000 non-employee warrants, which are exercisable since October 11, 2018. |
(15) | The ordinary shares include 50,000 non-employee warrants which are exercisable since March 27, 2016, 50,000 non-employee warrants, which are exercisable since September 8, 2016, 40,175 non-employee warrants, which are exercisable since March 14, 2017, 40,000 non-employee warrants, which are exercisable since October 28, 2017, 40,000 non-employee warrants, which are exercisable since October 11, 2018 and includes 1,743,678 shares held by Lohas SARL and 62,438 shares held by Kotys SA. |
(16) | The ordinary shares include 30,000 non-employee warrants which are exercisable since March 27, 2016, 50,000 non-employee warrants, which are exercisable since September 8, 2016, 40,175 non-employee warrants, which are exercisable since March 14, 2017, 40,000 non-employee warrants, which are exercisable since October 28, 2017 and 40,000 non-employee warrants, which are exercisable since October 11, 2018. |
(17) | The ordinary shares include 40,000 non-employee warrants which are exercisable since October 11, 2018. |
(18) | The ordinary shares include 40,000 non-employee warrants which are exercisable since October 11, 2018. |
(19) | Includes 7,582 ordinary shares that Mr. Garnier has the right to acquire pursuant to stock options granted in April 2021 under the 2018 Stock Option Plan. |
B. |
Related Party Transactions |
• | On March 4, 2021, we granted 495,000 stock options to our executive officers, with a vesting over four years. |
• | On March 5,2021, we granted 103,000 free shares to our executive officers, with a vesting over three years and subject to performance conditions. |
• | On April 13, 2021, we granted 27,465 stock options to the chairman of our board of directors, with a vesting between three and four years. |
• | On May 28, 2021, we granted to certain of our executive officers 35,000 stock options with a vesting of four years, and 16,000 free shares with a vesting over three years and subject to performance conditions; |
• | to approve any modification to Calyxt’s or any future Calyxt subsidiary’s share capital (e.g., share capital increase or decrease), the creation of any subsidiary by Calyxt, any grant of stock-based compensation, any distributions or initial public offering, merger, spin-off, liquidation, winding up or carve-out transactions; |
• | to approve Calyxt’s annual business plan and annual budget and any modification thereto; |
• | to approve any external growth transactions of Calyxt exceeding $500,000 and not included in the approved annual business plan and annual budget; |
• | to approve any investment and disposition decisions by Calyxt exceeding $500,000 and not included in the approved annual business plan and annual budget (it being understood that this clause excludes the purchase and sale of inventory as a part of the normal course of business); |
• | to approve any related-party agreement and any agreement or transaction between the executives or shareholders of Calyxt, on the one hand, and Calyxt or any of its subsidiaries, on the other hand; |
• | to approve any decision by Calyxt pertaining to the recruitment, dismissal/removal, or increase of the compensation of executives and corporate officers; |
• | to approve any material decision by Calyxt relating to a material litigation; |
• | to approve any decision by Calyxt relating to the opening of a social or restructuring plan or pre-insolvency proceedings; |
• | to approve any buyback by Calyxt of its own shares; |
• | to approve any new borrowings or debts of Calyxt exceeding $500,000 and early repayment of loans, if any (it being understood that we will approve the entering into of contracts for revolving loans and other short-term loans and the repayment of such for financing general operating activities, such as revolving loans for inventory or factoring of receivables); |
• | to approve grants by Calyxt of any pledges on securities; |
• | to develop new activities and businesses not described in the annual business plan and annual budget; |
• | to approve entry into any material agreement or partnership; and |
• | to approve any offshore and relocation activities of Calyxt. |
• | to nominate the greater of three members of Calyxt’s Board of Directors or a majority of the directors; |
• | to designate the Chairman of Calyxt’s Board of Directors and one member to each of the audit committee of the Board of Directors, the compensation committee of the Board of Directors and the nominating and corporation governance committee of the Board of Directors; |
• | to approve any amendments to Calyxt’ amended and restated certificate of incorporation or its amended and restated by-laws that would change the name of Calyxt, its jurisdiction of incorporation, the location of its principal executive offices, the purpose or purposes for which Calyxt is incorporated or the Cellectis approval items set forth in the stockholders agreement; |
• | to approve the payment of any regular or special dividends; |
• | to approve the commencement of any proceeding for the voluntary dissolution, winding up or bankruptcy of Calyxt or a material subsidiary; |
• | to approve any public or private offering, merger, amalgamation or consolidation of Calyxt or the spinoff of a business of Calyxt or any sale, conveyance, transfer or other disposition of Calyxt’s assets; and |
• | to approve any appointment to, or removal from, Calyxt’s Board of Directors, to the extent permissible by the laws of the State of Delaware. |
• | guarantees; |
• | insurance policies; |
• | mutual releases and indemnification matters; |
• | accounting, financial reporting and internal control issues; |
• | confidentiality; |
• | ability of the parties to compete with each other; and |
• | settlement of intercompany accounts. |
• | the benefits and perceived benefits to us; |
• | the opportunity costs of alternative transactions; |
• | the materiality and character of the related party’s interest; |
• | the actual or apparent conflict of interest of the related party; and |
• | the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. |
C. |
Interests of Experts and Counsel |
ITEM 8. |
FINANCIAL INFORMATION |
A. |
Consolidated Statements and Other Financial Information |
B. |
Significant Changes |
ITEM 9. |
THE OFFER AND LISTING |
E. |
Dilution |
F. |
Expenses of the Issue |
ITEM 10. |
ADDITIONAL INFORMATION |
A. |
Share Capital |
B. |
Memorandum and Articles of Association |
• | all activities related to genetics and more specifically to genome engineering, in particular, research, development and invention, filing and use of patents and trademarks, sale and marketing, advising and assisting, in all areas, in particular in the agro-food, pharmaceutical, textile and environmental sectors; and |
• | more generally, all industrial, commercial, financial and civil transactions and transactions involving real estate or movable property relating directly or indirectly to any of the aforementioned corporate purposes or any similar or related purpose. |
• | to decrease our share capital; |
• | to meet our obligations arising from debt financial instruments issued by us that are exchangeable into shares; |
• | to meet our obligations arising from share option programs, or other allocations of shares, to our employees or to our managers or the employees or managers of our affiliate. |
• | a merger (i.e., in a French law context, a stock-for-stock two-thirds majority of the votes cast of the shareholders present, represented by proxy or voting by mail at the relevant meeting. The votes cast do not include votes attached to shares held by shareholders who did not take part in the vote, abstained or voted blank or null. |
• | a merger of our company into a company incorporated outside of the European Union would require the unanimous approval of our shareholders; |
• | under French law, a cash merger is treated as a share purchase and would require the consent of each participating shareholder; |
• | our shareholders have granted and may grant in the future our board of directors broad authorizations to increase our share capital or to issue additional ordinary shares or other securities (for example, warrants) to our shareholders, the public or qualified investors, including as a possible defence following the launching of a tender offer for our shares; |
• | our shareholders have preferential subscription rights proportional to their shareholding in our company on the issuance by us of any additional shares or securities giving the right, immediately or in the future, to new shares for cash or a set-off of cash debts, which rights may only be waived by the extraordinary general meeting (by a two-thirds majority vote) of our shareholders or on an individual basis by each shareholder; |
• | our board of directors has the right to appoint directors to fill a vacancy created by the resignation or death of a director, subject to the ratification by the shareholders of such appointment at the next shareholders’ meeting, which prevents shareholders from having the sole right to fill vacancies on our board of directors; |
• | our board of directors can only be convened by our chairman (and our managing director, if different from the chairman, may request the chairman to convene the board), or, when no board meeting has been held for more than two consecutive months, by directors representing at least one third of the total number of directors; |
• | our board of directors’ meetings can only be regularly held if at least half of the directors attend either physically or by way of videoconference or teleconference enabling the directors’ identification and ensuring their effective participation in the board of directors’ decisions; |
• | our shares take the form of bearer securities or registered securities, if applicable legislation so permits, according to the shareholder’s choice. Issued shares are registered in individual accounts opened by us or any authorized intermediary (depending on the form of such shares), in the name of each shareholder and kept according to the terms and conditions laid down by the legal and regulatory provisions; |
• | under French law, a non-French resident as well as any French entity controlled by non-French residents may have to file a declaration for statistical purposes with the Bank of France (Banque de France) following the date of certain foreign investments in us. Additionally, certain investments in a French company relating to certain strategic industries by individual or entities not residents in a member State of the European Union are subject to the prior authorization of the French Ministry of Economy — see the section of this Annual Report titled “Ownership of Shares and ADSs by Non-French Persons”; |
• | approval of at least a majority of the votes cast of our shareholders present, represented by a proxy, or voting by mail at the relevant ordinary shareholders’ general meeting is required to remove directors with or without cause; |
• | advance notice is required for nominations to the board of directors or for proposing matters to be acted upon at a shareholders’ meeting, except that a vote to remove and replace a director can be proposed at any shareholders’ meeting without notice; |
• | in the event where certain ownership thresholds would be crossed, a number of disclosures should be made by the relevant shareholder and in addition to certain obligations; see the section of this Annual Report titled “—Declaration of Crossing of Ownership Thresholds”; |
• | transfers of shares shall comply with applicable insider trading rules; |
• | pursuant to French law, the sections of the By-laws relating to the number of directors and election and removal of a director from office may only be modified by a resolution adopted by a two-thirds majority of the votes cast of our shareholders present, represented by a proxy or voting by mail at the meeting. The votes cast do not include votes attached to shares held by shareholders who did not take part in the vote, abstained or voted blank or null. |
• | Shareholders must make a declaration to us no later than the fourth trading day after such shareholder crosses the following thresholds: 5%, 10%, 15%, 20%, 25%, 30%, 33.33%, 50%, 66.66%, 90% and 95%. |
• | Shareholders must make a declaration to the AMF no later than the fourth trading day after such shareholder crosses the following thresholds: 50% and 95%. |
• | Subject to certain exemptions, any shareholder crossing, alone or acting in concert, the 50% threshold must file a mandatory public tender offer. |
• | issuing additional shares; |
• | increasing the par value of existing shares; |
• | creating a new class of equity securities; and |
• | exercising the rights attached to securities giving access to the share capital. |
• | issuances in consideration for cash; |
• | issuances in consideration for assets contributed in kind; |
• | issuances through an exchange offer; |
• | issuances by conversion of previously issued debt instruments; |
• | issuances by capitalization of profits, reserves or share premium; and |
• | subject to certain conditions, issuances by way of offset against debt incurred by us. |
C. |
Material Contracts |
D. |
Exchange Controls |
E. |
Taxation |
• | a broker; |
• | a dealer in securities, commodities or foreign currencies; |
• | a trader in securities that elects to use a mark-to-market |
• | a bank or other financial institution; |
• | a tax-exempt organization; |
• | an insurance company; |
• | a real estate investment trust; |
• | a controlled foreign corporation; |
• | a passive foreign investment company; |
• | a regulated investment company; |
• | an investor who is a U.S. expatriate, former U.S. citizen or former long term resident of the United States; |
• | a mutual fund; |
• | an individual retirement or other tax-deferred account; |
• | a holder liable for alternative minimum tax; |
• | a holder that actually or constructively owns 10% or more, by voting power or value, of our voting stock; |
• | a partnership or other pass-through entity for U.S. federal income tax purposes; |
• | a holder that holds ADSs as part of a straddle, hedging, constructive sale, conversion or other integrated transaction for U.S. federal income tax purposes; or |
• | a U.S. holder (as defined below) whose functional currency is not the U.S. Dollar. |
• | a citizen or resident of the United States; |
• | a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized under the laws of the United States, any state thereof, or the District of Columbia; |
• | an estate whose income is subject to U.S. federal income tax regardless of its source; or |
• | a trust if (1) a U.S. court can exercise primary supervision over the trust’s administration and one or more U.S. persons are authorized to control all substantial decisions of the trust or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person for U.S. federal income tax purposes. |
• | the gain is “effectively connected” with your conduct of a trade or business in the United States, and the gain is attributable to a permanent establishment (or in the case of an individual, a fixed place of business) that you maintain in the United States if that is required by an applicable income tax treaty as a condition for subjecting you to U.S. taxation on a net income basis; or |
• | you are an individual, you are present in the United States for 183 or more days in the taxable year of such sale, exchange or other disposition and certain other conditions are met. |
• | it is not a French tax resident for French tax purposes; and, |
• | it has not held more than 25% of our dividend rights, known as “ droits aux bénéfices sociaux |
• | it has not transferred ordinary shares or ADSs as part of redemption by Cellectis, in which case the proceeds may under certain circumstances be partially or fully characterized as dividends under French domestic law and, as result, be subject to French dividend withholding tax. As an exception, a U.S Holder, established, domiciled or incorporated in a non-cooperative State or territory as defined in Article 238-0 A of the FTC should be subject to a 75% withholding tax in France on any such capital gain, regardless of the fraction of the dividend rights it holds. |
F. |
Dividends and Paying Agents |
G. |
Statement by Experts |
H. |
Documents on Display |
I. |
Subsidiary Information |
ITEM 11. |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
ITEM 12. |
DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES |
A. |
Debt Securities |
B. |
Warrants and Rights |
C. |
Other Securities |
D. |
American Depositary Shares |
Service |
Fees | |
• Issuance of ADSs upon deposit of shares (excluding issuance as a result of distributions of shares) |
Up to U.S. 5¢ per ADS issued | |
• Cancellation of ADSs |
Up to U.S. 5¢ per ADS canceled | |
• Distribution of cash dividends or other cash distributions (i.e., sale of rights and other entitlements) |
Up to U.S. 5¢ per ADS held |
Service |
Fees | |
• Distribution of ADSs pursuant to (1) stock dividends or other free stock distributions, or (2) exercise of rights to purchase additional ADSs |
Up to U.S. 5¢ per ADS held | |
• Distribution of securities other than ADSs or rights to purchase additional ADSs (i.e., spin-off shares) |
Up to U.S. 5¢ per ADS held | |
• ADS Services |
Up to U.S. 5¢ per ADS held on the applicable record date(s) established by the depositary |
• | taxes (including applicable interest and penalties) and other governmental charges; |
• | the registration fees as may from time to time be in effect for the registration of ordinary shares on the share register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary or any nominees upon the making of deposits and withdrawals, respectively; |
• | certain cable, telex and facsimile transmission and delivery expenses; |
• | the expenses and charges incurred by the depositary in the conversion of foreign currency; |
• | the fees and expenses incurred by the depositary in connection with the compliance with exchange control regulations and other regulatory requirements applicable to ordinary shares, ADSs and ADRs; and |
• | the fees and expenses incurred by the depositary, the custodian, or any nominee in connection with the servicing or delivery of deposited property. |
ITEM 13. |
DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES. |
ITEM 14. |
MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS. |
ITEM 15. |
CONTROLS AND PROCEDURES. |
(a) | Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of the end of the period covered by this Form 20-F, have concluded that our disclosure controls and procedures were effective as of December 31, 2021. |
(b) | Report of Management on Internal Control Over Financial Reporting |
(c) | See report of Ernst & Young et Autres, independent registered public accounting firm, included under “Item 18. Financial Statements” on page F-3. |
(d) | We have not made any significant change in internal controls over financial reporting during the year ended December 31, 2021. |
ITEM 16. |
RESERVED |
ITEM 16A. |
AUDIT COMMITTEE FINANCIAL EXPERT |
ITEM 16B. |
CODE OF ETHICS |
ITEM 16C. |
PRINCIPAL ACCOUNTANT FEES AND SERVICES |
2020 |
2021 |
|||||||
|
|
|||||||
($, in thousands) |
||||||||
Audit Fees |
676 |
* |
838 |
* | ||||
Audit-Related Fees |
— | — | ||||||
Tax Fees |
— | — | ||||||
Other Fees |
— | — | ||||||
Total |
676 |
838 |
(*) | $306 thousand and $404 thousand for Cellectis and $370 thousand and $434 thousand for Calyxt, respectively for the years ended December 31, 2020 and 2021. |
ITEM 16D. |
EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES |
ITEM 16E. |
PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS |
ITEM 16F. |
CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT |
ITEM 16G. |
CORPORATE GOVERNANCE |
ITEM 16H. |
MINE SAFETY DISCLOSURE |
ITEM 17. |
FINANCIAL STATEMENTS |
ITEM 18. |
FINANCIAL STATEMENTS |
ITEM 19. |
EXHIBITS |
104.1 |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
† | Indicates a management contract or any compensatory plan, contract or arrangement. |
# | Indicates a document previously filed with the Commission. |
* | Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. |
** | Portions of this exhibit (indicated by asterisks) have been omitted because they are not material and would likely cause competitive harm if disclosed. |
F-2 |
||||
F-6 |
||||
F-7 |
||||
F-8 |
||||
F-9 |
||||
F-10 |
||||
F-12 |
Auditor Firm Id: |
Auditor Name: |
Auditor Location: |
Revenue recognition from contracts with customers | ||
Description of the Matter |
As discussed in the section “Collaboration agreements and licenses” of Note 3.1 “Revenues and other income” in the consolidated financial statements, the Company earns revenue under collaboration and license agreements with its customers, that consist of: the licensing of rights to technology, research and development programs, research and development cost reimbursements and royalties. Under certain collaboration and license agreements, the Company receives non-refundable upfront payments and may receive milestone payments. For the year ended December 31, 2021, the Company recognized revenue from collaboration agreements and licenses of $30.0 million.The Company evaluates its collaboration and license agreements to determine: the separate performance obligations, including performance obligations to which non-refundable upfront payments relate, the transaction price (which may include variable consideration), the allocation of the transaction price to the performance obligations, and the timing of the satisfaction of the performance obligations.Based on its analysis, the Company determined that certain non-refundable upfront payments should be recognized as revenue when the performance obligation is satisfied. For performance obligations that are satisfied at a point in time, the Company recognizes revenue when control of the goods and/or services is transferred to the customer.In 2021, the Company entered into an agreement modified by an amendment to a research collaboration and non-exclusive license agreement which included a $20.0 million non-refundable upfront payment related to a non-exclusive license on a territory to develop and commercialize certain products. Based on its analysis, the Company determined that this non-refundable upfront payment constituted a performance obligation that had been fully satisfied and recognized the revenue point in time in the year ended December 31, 2021.Auditing the Company’s determination of the performance obligation in this amendment and the satisfaction of the performance obligations related to the non-refundable upfront payment received in 2021 required a high degree of auditor judgment. The complexity consisted of determining if the performance obligation will be satisfied over time or was satisfied point in time. | |
How We Addressed the Matter in Our Audit |
We obtained an understanding of, evaluated the design and tested the operating effectiveness of controls over the Company’s revenue recognition process related to collaboration and license agreements. For example, we tested controls over management’s assessment of its contractual arrangements including its determination of the separate performance obligations, and the determination of the satisfaction of the performance obligations. To assess management’s conclusions regarding whether non-refundable upfront payments should be recognized as revenue during the year, our audit procedures included, among others, evaluating the appropriateness of the Company’s accounting analysis for the amendment by inspecting and analyzing the provisions of the initial license agreement and its amendment including consideration of the obligations of each party to the contract and the timing thereof. We inquired of operational, accounting, and executive management personnel and the Company’s in-house legal counsel to corroborate our understanding of both the nature and the timing of the goods and services transferred to the customer and assessed the disclosures in the related footnotes. |
As of |
||||||||||||
Notes |
December 31, 2020 |
December 31, 2021 |
||||||||||
ASSETS |
||||||||||||
Non-current assets |
||||||||||||
Intangible assets |
5 |
|||||||||||
Property, plant, and equipment |
7 |
|||||||||||
Right-of-use |
6 |
|||||||||||
Non-current financial assets |
8.2 |
|||||||||||
Total non-current assets |
||||||||||||
Current assets |
||||||||||||
Inventories |
9 |
— | ||||||||||
Trade receivables |
10.1 |
|||||||||||
Subsidies receivables |
10.2 |
|||||||||||
Other current assets |
10.3 |
|||||||||||
Current financial assets |
11.1 |
|||||||||||
Cash and cash equivalents |
11.2 |
|||||||||||
Total current assets |
||||||||||||
TOTAL ASSETS |
||||||||||||
LIABILITIES |
||||||||||||
Shareholders’ equity |
||||||||||||
Share capital |
15 |
|||||||||||
Premiums related to the share capital |
15 |
|||||||||||
Currency translation adjustment |
( |
) | ( |
) | ||||||||
Retained earnings |
( |
) | ( |
) | ||||||||
Net income (loss) |
( |
) | ( |
) | ||||||||
Total shareholders’ equity - Group Share |
||||||||||||
Non-controlling interests |
||||||||||||
Total shareholders’ equity |
||||||||||||
Non-current liabilities |
||||||||||||
Non-current financial liabilities |
12 |
|||||||||||
Non-current lease debts |
12 |
|||||||||||
Non-current provisions |
18 |
|||||||||||
Other non-current liabilities |
— | |||||||||||
Total non-current liabilities |
||||||||||||
Current liabilities |
||||||||||||
Current financial liabilities |
— | |||||||||||
Current lease debts |
12 |
|||||||||||
Trade payables |
12 |
|||||||||||
Deferred revenues and contract liabilities |
14 |
|||||||||||
Current provisions |
18 |
|||||||||||
Other current liabilities |
13 |
|||||||||||
Total current liabilities |
||||||||||||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
||||||||||||
For the year ended December 31, |
||||||||||||||||
Notes |
2019 |
2020 |
2021 |
|||||||||||||
Revenues and other income |
||||||||||||||||
Revenues |
3.1 |
|||||||||||||||
Other income |
3.1 |
|||||||||||||||
|
|
|
|
|
|
|||||||||||
Total revenues and other income |
||||||||||||||||
|
|
|
|
|
|
|||||||||||
Operating expenses |
||||||||||||||||
Cost of revenue |
3.2 |
( |
) | ( |
) | ( |
) | |||||||||
Research and development expenses |
3.2 |
( |
) | ( |
) | ( |
) | |||||||||
Selling, general and administrative expenses |
3.2 |
( |
) | ( |
) | ( |
) | |||||||||
Other operating income (expenses) |
( |
) | ( |
) | ||||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
( |
) |
( |
) |
( |
) | ||||||||||
|
|
|
|
|
|
|||||||||||
Operating income (loss) |
( |
) |
( |
) |
( |
) | ||||||||||
|
|
|
|
|
|
|||||||||||
Financial income |
3.3 |
|||||||||||||||
Financial expenses |
3.3 |
( |
) | ( |
) | ( |
) | |||||||||
|
|
|
|
|
|
|||||||||||
Net Financial gain (loss) |
( |
) |
||||||||||||||
|
|
|
|
|
|
|||||||||||
Net income (loss) |
( |
) |
( |
) |
( |
) | ||||||||||
|
|
|
|
|
|
|||||||||||
Attributable to shareholders of Cellectis |
( |
) | ( |
) | ( |
) | ||||||||||
Attributable to non-controlling interests |
( |
) | ( |
) | ( |
) | ||||||||||
Basic / Diluted net income (loss) per share attributable to shareholders of Cellectis |
17 |
|||||||||||||||
Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share) |
( |
) | ( |
) | ( |
) | ||||||||||
Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share) |
( |
) | ( |
) | ( |
) |
For the year ended December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
Net income (loss) |
( |
) |
( |
) |
( |
) | ||||||
|
|
|
|
|
|
|||||||
Actuarial gains and losses |
( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|||||||
Other comprehensive income (loss) that will not be reclassified subsequently to income or loss |
( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|||||||
Currency translation adjustment |
( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|||||||
Commodity derivative contracts |
— | — | ||||||||||
|
|
|
|
|
|
|||||||
Other comprehensive income (loss) that will be reclassified subsequently to income or loss |
( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|||||||
Total Comprehensive income (loss) |
( |
) |
( |
) |
( |
) | ||||||
|
|
|
|
|
|
|||||||
Attributable to shareholders of Cellectis |
( |
) | ( |
) | ( |
) | ||||||
Attributable to non-controlling interests |
( |
) | ( |
) | ( |
) |
For the year ended December 31, |
||||||||||||||||
Notes |
2019 |
2020 |
2021 |
|||||||||||||
Cash flows from operating activities |
||||||||||||||||
Net income (loss) |
|
|
( |
) | ( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Adjustment to reconcile net income (loss) to cash provided by (used in) operating activities |
|
|
||||||||||||||
Adjustments for |
|
|
||||||||||||||
Amortization and depreciation |
|
|
||||||||||||||
Net loss (income) on disposals |
|
|
||||||||||||||
Net financial loss (gain) |
|
|
( |
) | ( |
) | ||||||||||
Expenses related to share-based payments |
|
|
||||||||||||||
Provisions |
|
|
( |
) | ||||||||||||
Other non-cash items |
|
|
( |
) | ||||||||||||
|
|
|
|
|
|
|
|
|
||||||||
Gain upon the forgiveness of the Paycheck Protection Program loan |
|
|
( |
) | ||||||||||||
Realized foreign exchange gain (loss) |
|
|
( |
) | ||||||||||||
Interest (paid) / received (1) |
|
|
||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Operating cash flows before change in working capital |
|
|
( |
) |
( |
) |
( |
) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Decrease (increase) in inventories |
|
|
( |
) | ||||||||||||
Decrease (increase) in trade receivables and other current assets |
|
|
( |
) | ( |
) | ( |
) | ||||||||
Decrease (increase) in subsidies receivables |
|
|
( |
) | ||||||||||||
(Decrease) increase in trade payables and other current liabilities |
|
|
( |
) | ||||||||||||
(Decrease) increase in deferred income |
|
|
( |
) | ( |
) | ( |
) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Change in working capital |
|
|
( |
) |
( |
) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net cash flows provided by (used in) operating activities |
|
|
( |
) |
( |
) |
( |
) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Cash flows from investment activities |
|
|
||||||||||||||
Proceeds from disposal of property, plant and equipment |
|
|
— | |||||||||||||
Acquisition of intangible assets |
|
|
( |
) | ( |
) | ( |
) | ||||||||
Acquisition of property, plant and equipment |
7 |
|
|
( |
) | ( |
) | ( |
) | |||||||
Net change in non-current financial assets |
8 |
|
|
( |
) | ( |
) | |||||||||
Sale (Acquisition) of current financial assets |
8 |
|
|
( |
) | ( |
) | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Net cash flows provided by (used in) investment activities |
|
|
( |
) |
( |
) |
||||||||||
|
|
|
|
|
|
|
|
|||||||||
Cash flows from financing activities |
|
|
||||||||||||||
Proceeds from the exercise of Cellectis stock options (2) |
15 |
|
|
— | ||||||||||||
Proceeds from the exercise of Calyxt stock options |
15 |
|
|
( |
) | |||||||||||
Increase in share capital Cellectis, net of transaction costs |
15 |
|
|
— | — | |||||||||||
Increase in share capital Calyxt, net of transaction costs |
15 |
|
|
— | ||||||||||||
Increase in borrowings |
12 |
|
|
— | — | |||||||||||
Interest paid on financial debt |
|
|
( |
) | ||||||||||||
Payments on lease debts |
12 |
|
|
( |
) | ( |
) | ( |
) | |||||||
|
|
|
|
|
|
|
|
|||||||||
Net cash flows provided by (used in) financing activities |
|
|
( |
) |
||||||||||||
|
|
|
|
|
|
|
|
|||||||||
(Decrease) increase in cash and cash equivalents |
|
|
( |
) |
( |
) |
( |
) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Cash and cash equivalents at the beginning of the year |
|
|
||||||||||||||
Effect of exchange rate changes on cash |
|
|
( |
) | ( |
) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Cash and cash equivalents at the end of the period |
8 |
|
|
|||||||||||||
|
|
|
|
|
|
|
|
(1) | In line with IAS 7.31, interests (paid) / received are presented separately |
(2) | Proceeds from the exercise of Cellectis stock options exercised in December 2020 were collected in January 2021, generating a $ |
Share Capital Ordinary Shares |
Equity |
|||||||||||||||||||||||||||||||||||||
Notes |
Number of shares |
Amount |
Premiums related to share capital |
Currency translation adjustment |
Retained earnings (deficit) |
Income (Loss) |
attributable to shareholders of Cellectis |
Non- controlling interests |
Total Shareholders’ Equity |
|||||||||||||||||||||||||||||
As of January 1, 2019 |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
Net Loss |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
Other comprehensive income (loss) |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Total comprehensive income (loss) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||||
Allocation of prior period loss |
( |
) | ||||||||||||||||||||||||||||||||||||
Capital Increase |
15.1 |
( |
) | |||||||||||||||||||||||||||||||||||
Capital Increase Calyxt |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||
Exercise of share warrants, employee warrants and stock options |
16 |
|||||||||||||||||||||||||||||||||||||
Non-cash stock-based compensation expense |
16 |
|||||||||||||||||||||||||||||||||||||
Other movements |
( |
) | ||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
As of December 31, 2019 |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
As of January 1, 2020 |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
Net Loss |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
Other comprehensive income (loss) |
( |
) | ||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Total comprehensive income (loss) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Allocation of prior period loss |
( |
) | ||||||||||||||||||||||||||||||||||||
Exercise of stock options Calyxt (1) |
16 |
|||||||||||||||||||||||||||||||||||||
Capital Increase Calyxt (2) |
||||||||||||||||||||||||||||||||||||||
Transaction with subsidiaries |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||
Exercise of share and employee warrants / stock-options Cellectis |
16 |
Non-cash stock-based compensation expense |
16 |
|||||||||||||||||||||||||||||||||||||
Other movements |
( |
) | ||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
As of December 31, 2020 |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
As of January 1, 2021 |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
Net Loss |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
Other comprehensive income (loss) |
( |
) |
— |
( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Total comprehensive income (loss) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||||||||||||
Allocation of prior period loss |
( |
) | ||||||||||||||||||||||||||||||||||||
Exercise of stock options and capital increase Calyxt (1) |
||||||||||||||||||||||||||||||||||||||
Capital Increase Cellectis (ATM) |
||||||||||||||||||||||||||||||||||||||
Transaction costs (3) |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||
Transaction with subsidiaries |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||
Exercise of share warrants, employee warrants, stock-options and free-shares vesting Cellectis |
16 |
( |
) | |||||||||||||||||||||||||||||||||||
Non-cash stock-based compensation expense |
16 |
|||||||||||||||||||||||||||||||||||||
Other movements |
( |
) | ||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
As of December 31, 2021 |
( |
) |
( |
) |
( |
) |
||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) | Corresponds to the impact of Calyxt stock options exercises during the period. |
(2) | On October 20, 2020, Calyxt entered into definitive agreements with institutional investors for the purchase and sale of SEC-registered, direct offering. The financing resulted in gross proceeds of $ |
(3) | These costs correspond to the issuance costs related to Cellectis’ At-The-Market |
• | IFRS Interpretation Committee Decision on configuration or Customization Costs in a Cloud Computing Arrangement (IAS 38 Intangible Assets) (published on April 27, 2021). See note 5. |
• | Interest Rate Benchmark Reform – Phase 2: Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16. The amendments provide temporary reliefs which address the financial reporting effects when an interbank offered rate (IBOR) is replaced with an alternative nearly risk-free interest rate (RFR). |
• | Amendments to IFRS 16 Leases: COVID-19-Related |
• | IFRS Interpretation Committee Decision Attributing Benefit to Periods of Service (IAS 19) (published on May 24, 2021). |
• | Amendments to IAS 37 – Onerous Contracts: Cost of Fulfilling a Contract (Effective for the accounting periods as of January 1, 2022) |
• | Amendments to IAS 16 – Property, Plant and Equipment: Proceeds before Intended Use (Effective for the accounting periods as of January 1, 2022) |
• | Amendments to IFRS 3 – Reference to the Conceptual Framework (Effective for the accounting periods as of January 1, 2022) |
• | IFRS 9 Financial Instruments – Fees in the ’10 per cent’ Test for Derecognition of Financial Liabilities (Effective for the accounting periods as of January 1, 2022) |
• | IFRS 17 – Insurance Contracts (Effective for the accounting periods as of January 1, 2023) |
• | Amendments to IAS 8 – Definition of Accounting Estimates (issued on 12 February 2021 and Effective for the accounting periods as of January 1, 2023) |
• | Amendments to IAS 1 and IFRS Practice Statement 2 –Disclosure of Accounting Policies (Effective for the accounting periods as of January 1, 2023) |
• | Amendments to IAS 1 – Classification of Liabilities as Current or Non-current (Effective for the accounting periods as of January 1, 2023) |
• | Amendments to IAS 12 – Income Taxes: Deferred Tax related to Assets and Liabilities arising from a Single Transaction (issued on 8 May 2021 and Effective for the accounting periods as of January 1, 2023) |
• | the differential between the average exchange rate and the period end rates applied to the cash flows of the period; |
• | the differential between the opening exchange rates and the period end exchanges rate applied on our opening cash and cash equivalents balance denominated in dollars; and |
• | the foreign exchange rate impact of the conversion of the financial statements of our US subsidiaries. |
• | Revenue Recognition: Collaboration Agreements and Licenses, Sales of Products and Services (Note 3.1) |
• | Research Tax Credit (Note 3.1) |
• | Share-Based Compensation (Note 16) |
• | Provisions for risks and charges (Note 18) |
For the year ended December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
$ in thousands |
||||||||||||
From France |
||||||||||||
From USA |
||||||||||||
|
|
|
|
|
|
|||||||
Revenues |
||||||||||||
|
|
|
|
|
|
|||||||
Research tax credit |
||||||||||||
Subsidies and other (1) |
||||||||||||
|
|
|
|
|
|
|||||||
Other income |
||||||||||||
|
|
|
|
|
|
|||||||
Total revenues and other income |
||||||||||||
|
|
|
|
|
|
(1) | For the year ended December 2021, this includes only Calyxt’s PPP loan, which has been forgiven and recognized as other income in April 2021, as disclosed in note 12.1. |
For the year ended December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
$ in thousands |
||||||||||||
Recognition of previously deferred upfront payments |
||||||||||||
Other revenues from collaboration agreements |
||||||||||||
|
|
|
|
|
|
|||||||
Collaboration agreements |
||||||||||||
|
|
|
|
|
|
|||||||
Licenses |
||||||||||||
Products & services |
||||||||||||
|
|
|
|
|
|
|||||||
Total revenues |
||||||||||||
|
|
|
|
|
|
For the year ended December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
$ in thousands |
||||||||||||
Cost of revenue |
||||||||||||
Cost of goods sold |
( |
) | ( |
) | ( |
) | ||||||
Royalty expenses |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Cost of revenue |
( |
) |
( |
) |
( |
) | ||||||
|
|
|
|
|
|
For the year ended December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
|
|
|
||||||||||
$ in thousands |
||||||||||||
Research and development expenses |
||||||||||||
Wages and salaries |
( |
) | ( |
) | ( |
) | ||||||
Social charges on stock option grants |
( |
) | ( |
) | ( |
) | ||||||
Non-cash stock-based compensation expense |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Personnel expenses |
( |
) |
( |
) |
( |
) | ||||||
|
|
|
|
|
|
|||||||
Purchases and external expenses |
( |
) | ( |
) | ( |
) | ||||||
Other |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Total research and development expenses |
( |
) |
( |
) |
( |
) | ||||||
|
|
|
|
|
|
For the year ended December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
|
|
|
||||||||||
$ in thousands |
||||||||||||
Selling, general and administrative expenses |
||||||||||||
Wages and salaries |
( |
) | ( |
) | ( |
) | ||||||
Social charges on stock option grants |
( |
) | ( |
) | ( |
) | ||||||
Non-cash stock-based compensation expense |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Personnel expenses |
( |
) |
( |
) |
( |
) | ||||||
|
|
|
|
|
|
|||||||
Purchases and external expenses |
( |
) | ( |
) | ( |
) | ||||||
Other |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Total selling, general and administrative expenses |
( |
) |
( |
) |
( |
) | ||||||
|
|
|
|
|
|
For the year ended December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
|
|
|
||||||||||
$ in thousands |
||||||||||||
Personnel expenses |
||||||||||||
Wages and salaries |
( |
) | ( |
) | ( |
) | ||||||
Social charges on free shares and stock option grants |
( |
) | ( |
) | ( |
) | ||||||
Non-cash stock-based compensation expense |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Total personnel expenses |
( |
) |
( |
) |
( |
) | ||||||
|
|
|
|
|
|
• | Interest income from savings accounts and fixed term bank deposits; |
• | Interest expense from leases; |
• | Foreign exchange gain (loss) from transactions in foreign currencies; and |
• | Other financial income and expenses, mainly derived from fair value adjustments related to our financial assets and derivative instruments. |
For the year ended December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
Interest income |
||||||||||||
Foreign exchange gain |
||||||||||||
Other financial revenues |
||||||||||||
|
|
|
|
|
|
|||||||
Total financial revenues |
||||||||||||
|
|
|
|
|
|
|||||||
Interest expenses |
( |
) | ( |
) | ( |
) | ||||||
Interest expenses for leases |
( |
) | ( |
) | ( |
) | ||||||
Foreign exchange loss |
( |
) | ( |
) | ( |
) | ||||||
Other financial expenses |
( |
) | ( |
) | ( |
) | ||||||
|
|
|
|
|
|
|||||||
Total financial expenses |
( |
) |
( |
) |
( |
) | ||||||
|
|
|
|
|
|
|||||||
Total |
( |
) |
||||||||||
|
|
|
|
|
|
For the year ended December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
|
|
|
||||||||||
$ in thousands |
||||||||||||
Income (loss) before taxes from continuing operations |
( |
) | ( |
) | ( |
) | ||||||
Theoretical group tax rate |
% | % | % | |||||||||
|
|
|
|
|
|
|||||||
Theoretical tax benefit (expense) |
||||||||||||
|
|
|
|
|
|
|||||||
Increase/decrease in tax benefit arising from: |
||||||||||||
Permanent differences |
( |
) | ( |
) | ( |
) | ||||||
Research tax credit |
||||||||||||
Share-based compensation & other IFRS adjustments |
( |
) | ( |
) | ( |
) | ||||||
Non recognition of deferred tax assets related to tax losses and temporary differences |
( |
) | ( |
) | ( |
) | ||||||
Other differences |
||||||||||||
|
|
|
|
|
|
|||||||
Effective tax expense |
||||||||||||
|
|
|
|
|
|
|||||||
Effective tax rate |
% | % | % |
As of December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
|
|
|
||||||||||
$ in thousands |
||||||||||||
Credits and net operating loss carryforwards |
||||||||||||
Pension commitments |
||||||||||||
Leases |
||||||||||||
Impairment of assets |
||||||||||||
Revenue recognition |
( |
) | — | |||||||||
Other |
( |
) | ||||||||||
Total unrecognized deferred tax assets, net |
( |
) | ( |
) | ( |
) |
• | The Chief Executive Officer; |
• | The Executive Vice President Strategic Initiatives; |
• | The Executive Vice President Global Quality (until March 31, 2021); |
• | The Senior Vice President Europe Technical Operations (until November 29, 2021); |
• | The Senior Vice President of US Manufacturing; |
• | The Chief Scientific Officer; |
• | The Chief Financial Officer (until December 2, 2021) (1); |
• | The General Counsel; |
• | The Chief Business Officer; |
• | The Chief Regulatory & Pharmaceutical Compliance Officer; |
• | The Chief Medical Officer; and |
• | The Chief Human Resources Officer. |
(1) | The new Chief Financial Officer was appointed on February 10, 2022. |
• | Therapeutics: T-cells product candidates (UCART) in the field of immuno-oncology (UCART) and (ii) gene-edited hematopoietic stem cells (HSC) product candidates in other therapeutic indications. These approaches are based on our core proprietary technologies. All these activities are supported by Cellectis S.A., Cellectis, Inc. and Cellectis Biologics, Inc. The operations of Cellectis S.A., the parent company, are presented entirely in the Therapeutics segment which also comprises research and development, management and support functions. |
• | Plants: ™ production system. It corresponds to the activity of our U.S.-based majority-owned subsidiary, Calyxt, which is currently based in Roseville, Minnesota. |
For the year ended December 31, 2019 |
For the year ended December 31, 2020 |
For the year ended December 31, 2021 |
||||||||||||||||||||||||||||||||||
($ in thousands) |
Plants |
Therapeutics |
Total reportable segments |
Plants |
Therapeutics |
Total reportable segments |
Plants |
Therapeutics |
Total reportable segments |
|||||||||||||||||||||||||||
External revenues |
||||||||||||||||||||||||||||||||||||
External other income |
||||||||||||||||||||||||||||||||||||
External revenues and other income |
||||||||||||||||||||||||||||||||||||
Cost of revenue |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Research and development expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Selling, general and administrative expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Other operating income and expenses |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Total operating expenses |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||
Operating income (loss) before tax |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||
Net financial gain (loss) |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||||
Net income (loss) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||
Non-controlling interests |
||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to shareholders of Cellectis |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||
R&D non-cash stock-based expense attributable to shareholder of Cellectis |
||||||||||||||||||||||||||||||||||||
SG&A non-cash stock-based expense attributable to shareholder of Cellectis |
||||||||||||||||||||||||||||||||||||
Adjustment of share-based compensation attributable to shareholders of Cellectis |
||||||||||||||||||||||||||||||||||||
Adjusted net income (loss) attributable to shareholders of Cellectis |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) |
( |
) | ||||||||||||||||||
Depreciation and amortization tangible and intangible assets |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||||||||
Additions to tangible and intangible assets |
• | technical feasibility necessary for the completion of the development project; |
• | intention on our part to complete the project and to utilize it; |
• | capacity to utilize the intangible asset; |
• | proof of the probability of future economic benefits associated with the asset; |
• | availability of the technical, financial, and other resources for completing the project; and |
• | reliable evaluation of the development expenses. |
• | Software: from |
• | Patents: amortized from acquisition until legal protection expires, maximum of |
$ in thousands |
Software and Patents |
Assets under construction |
Total |
|||||||||
Net book value as of January 1, 2019 |
||||||||||||
Additions to intangible assets |
( |
) | ||||||||||
Disposal of intangible assets |
( |
) | ( |
) | ||||||||
Reclassification |
||||||||||||
Depreciation expense |
( |
) | ( |
) | ||||||||
Translation adjustments |
( |
) | ( |
) | ( |
) | ||||||
Net book value as of December 31, 2019 |
||||||||||||
Gross value at end of period |
||||||||||||
Accumulated depreciation and impairment at end of period |
( |
) | ( |
) | ||||||||
Net book value as of January 1, 2020 |
||||||||||||
Additions to intangible assets |
( |
) | ||||||||||
Disposal of intangible assets |
||||||||||||
Reclassification |
||||||||||||
Depreciation expense |
( |
) | ( |
) | ||||||||
Translation adjustments |
||||||||||||
Net book value as of December 31, 2020 |
||||||||||||
Gross value at end of period |
||||||||||||
Accumulated depreciation and impairment at end of period |
( |
) | ( |
) | ||||||||
Net book value as of January 1, 2021 |
||||||||||||
Additions to intangible assets |
||||||||||||
Disposal of intangible assets |
( |
) | ( |
) | ||||||||
Reclassification |
( |
) | ||||||||||
Depreciation expense |
( |
) | ( |
) | ||||||||
Translation adjustments |
( |
) | ( |
) | ( |
) | ||||||
Net book value as of December 31, 2021 |
||||||||||||
Gross value at end of period |
||||||||||||
Accumulated depreciation and impairment at end of period |
( |
) | ( |
) |
• | an asset representing a right of use of the asset leased during the lease term of the contract “right-of-use”; |
• | a liability related to the payment obligation “lease debt”. |
• | the amount of the initial measurement of the lease liability, to which is added, if applicable, any lease payments made at or before the commencement date, less any lease incentives received; |
• | where relevant, any initial direct costs incurred by the lessee for the conclusion of the contract. These are incremental costs which would not have been incurred if the contract had not been concluded; and |
• | estimated costs for restoration of the leased asset according to the terms of the contract. |
• | fixed payments (including in-substance fixed payments meaning that even if they are variable in form, they are in-substance unavoidable); |
• | variable lease payments that depend on an index or a rate, initially measured using the index or the rate in force at the lease commencement date; amounts expected to be payable by the lessee under residual value guarantees; and |
• | payments of penalties for terminating the lease, if the lease term reflects the lessee exercising an option to terminate the lease. |
• | the liability is increased by the accrued interests resulting from the discounting of the lease liability, at the beginning of the lease period; and |
• | payments made are deducted. |
• |
the occurrence of a change in the lease term or a modification related to the assessment of the reasonably certain nature (or not) of the exercise of an option, |
• |
a remeasurement linked to residual value guarantees, |
• |
the occurrence of an adjustment to the rates and indices according to which the rents are calculated when rent adjustments occur. |
Building |
Office and laboratory equipment |
Total |
||||||||||
$ in thousands |
||||||||||||
Net book value as of January 1, 2020 |
||||||||||||
Additions to right-of-use assets |
||||||||||||
Depreciation expense |
( |
) | ( |
) | ( |
) | ||||||
Translation adjustments |
( |
) | ||||||||||
Net book value as of December 31, 2020 |
||||||||||||
Gross value at end of period |
||||||||||||
Accumulated depreciation at end of period |
( |
) | ( |
) | ( |
) | ||||||
Net book value as of January 1, 2021 |
||||||||||||
Additions to right-of-use assets |
( |
) | ||||||||||
Depreciation expense |
( |
) | ( |
) | ( |
) | ||||||
Translation adjustments |
( |
) | ( |
) | ( |
) | ||||||
Net book value as of December 31, 2021 |
||||||||||||
Gross value at end of period |
||||||||||||
Accumulated depreciation at end of period |
( |
) | ( |
) | ( |
) |
• | Buildings and other outside improvements | ||
• | Leasehold improvements | ||
• | Office furniture | ||
• | Laboratory equipment | ||
• | Office equipment | ||
• | IT equipment |
Lands and Buildings |
Technical equipment |
Fixtures, fittings and other equipment |
Assets under construction |
Total |
||||||||||||||||
$ in thousands |
||||||||||||||||||||
Net book value as of January 1, 2019 |
||||||||||||||||||||
Additions to tangible assets |
||||||||||||||||||||
Disposal of tangible assets |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Reclassification |
( |
) | ( |
) | ||||||||||||||||
Depreciation expense |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Translation adjustments |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Net book value as of December 31, 2019 |
||||||||||||||||||||
Gross value at end of period |
||||||||||||||||||||
Accumulated depreciation and impairment at end of period |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||
Net book value as of January 1, 2020 |
||||||||||||||||||||
Additions to tangible assets |
||||||||||||||||||||
Disposal of tangible assets |
( |
) | ( |
) | ||||||||||||||||
Reclassification |
( |
) | ( |
) | ||||||||||||||||
Depreciation expense |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Translation adjustments |
||||||||||||||||||||
Net book value as of December 31, 2020 |
||||||||||||||||||||
Gross value at end of period |
||||||||||||||||||||
Accumulated depreciation and impairment at end of period |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||
Net book value as of January 1, 2021 |
||||||||||||||||||||
Additions to tangible assets |
||||||||||||||||||||
Disposal of tangible assets |
( |
) | ( |
) | ||||||||||||||||
Reclassification |
( |
) | ( |
) | ( |
) | ||||||||||||||
Depreciation expense |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Translation adjustments |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||
Net book value as of December 31, 2021 |
||||||||||||||||||||
Gross value at end of period |
||||||||||||||||||||
Accumulated depreciation and impairment at end of period |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) |
• | financial assets measured at amortized cost or; |
• | financial assets measured at fair value through profit or loss. |
Accounting category |
Book value on the statement of financial position |
Fair Value |
||||||||||||||
2020 |
Fair value through profit and loss |
Amortized cost |
||||||||||||||
$ in thousands |
||||||||||||||||
Financial assets |
||||||||||||||||
Non-current financial assets |
— | |||||||||||||||
Trade receivables |
— | |||||||||||||||
Subsidies receivables |
— | |||||||||||||||
Current financial assets |
— | |||||||||||||||
Cash and cash equivalents |
— | |||||||||||||||
Total financial assets |
||||||||||||||||
Financial liabilities |
||||||||||||||||
Non-current lease debt |
— | |||||||||||||||
Other non-current financial liabilities |
— | |||||||||||||||
Current lease debts |
— | |||||||||||||||
Trade payables |
— | |||||||||||||||
Other current liabilities |
— | |||||||||||||||
Total financial liabilities |
— |
|||||||||||||||
Accounting category |
Book value on the statement of financial position |
Fair Value |
||||||||||||||
2021 |
Fair value through profit and loss |
Amortized cost |
||||||||||||||
$ in thousands |
||||||||||||||||
Financial assets |
||||||||||||||||
Non-current financial assets |
||||||||||||||||
Trade receivables |
||||||||||||||||
Subsidies receivables |
||||||||||||||||
Current financial assets |
||||||||||||||||
Cash and cash equivalents |
||||||||||||||||
Total financial assets |
||||||||||||||||
Financial liabilities |
||||||||||||||||
Non-current lease debts |
||||||||||||||||
Non-current financial liabilities |
||||||||||||||||
Current lease debts |
||||||||||||||||
Current financial liabilities |
— | |||||||||||||||
Trade payables |
||||||||||||||||
Other current liabilities |
||||||||||||||||
Total financial liabilities |
||||||||||||||||
As of December 31, |
As of December 31, |
|||||||
2020 |
2021 |
|||||||
$ in thousands |
||||||||
Trade receivables |
||||||||
Valuation allowance |
( |
) | ( |
) | ||||
Total net value of trade receivables |
||||||||
As of December 31, |
As of December 31, |
|||||||
2020 |
2021 |
|||||||
$ in thousands |
||||||||
Research tax credit |
||||||||
Total subsidies receivables |
||||||||
As of December 31, |
As of December 31, |
|||||||
2020 |
2021 |
|||||||
$ in thousands |
||||||||
VAT receivables |
||||||||
Prepaid expenses and other prepayments |
||||||||
Tax and social receivables |
||||||||
Deferred expenses and other current assets |
||||||||
Total other current assets |
||||||||
As of December 31, 2020 |
Carrying amount |
Unrealized Gains/(Losses) |
Estimated fair value |
|||||||||
$ in thousands |
||||||||||||
Current financial assets |
— | |||||||||||
Cash and cash equivalents |
— | |||||||||||
Current financial assets and cash and cash equivalents |
— |
|||||||||||
As of December 31, 2021 |
Carrying amount |
Unrealized Gains/(Losses) |
Estimated fair value |
|||||||||
$ in thousands |
||||||||||||
Current financial assets |
— | |||||||||||
Cash and cash equivalents |
— | |||||||||||
Current financial assets and cash and cash equivalents |
— |
|||||||||||
• |
Financial assets including embedded derivatives for which Cellectis elected to designate at fair value through profit or loss; |
• |
Financial assets managed on a fair value basis; and |
• |
Derivative instruments that are not documented in hedging relationships. |
As of December 31, |
As of December 31, |
|||||||
2020 |
2021 |
|||||||
$ in thousands |
||||||||
Cash and bank accounts |
||||||||
Money market funds |
||||||||
Fixed bank deposits |
||||||||
Total cash and cash equivalents |
||||||||
As of December 31, |
As of December 31, |
|||||||
2020 |
2021 |
|||||||
$ in thousands |
||||||||
Lease debts |
||||||||
State Guaranteed loan « PGE » |
||||||||
PPP loan |
— | |||||||
Non-current financial liabilities |
||||||||
Total non-current financial liabilities and non-current lease debts |
||||||||
Lease debts |
||||||||
State Guaranteed loan « PGE » |
— | |||||||
Current financial liabilities |
— | |||||||
Total current financial liabilities and current lease debts |
||||||||
Trade payables |
||||||||
Other current liabilities |
||||||||
Total Financial liabilities |
||||||||
Balance as of December 31, 2021 |
Book Value |
Less than One Year |
One to Five Years |
More than Five Years |
||||||||||||
$ in thousands |
||||||||||||||||
Lease debts |
||||||||||||||||
Financial liabilities |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Financial liabilities |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Trade payables |
— | — | ||||||||||||||
Other current liabilities |
— | — | ||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total financial liabilities |
||||||||||||||||
|
|
|
|
|
|
|
|
As of December 31, |
As of December 31, |
|||||||
2020 |
2021 |
|||||||
$ in thousands |
||||||||
VAT Payables |
||||||||
Accruals for personnel related expenses |
||||||||
Other |
||||||||
|
|
|
|
|||||
Total |
||||||||
|
|
|
|
As of December 31, 2020 |
As of December 31, 2021 |
|||||||
$ in thousands |
||||||||
Deferred revenues and contract liabilities |
||||||||
|
|
|
|
|||||
Total Deferred revenue and contract liabilities |
||||||||
|
|
|
|
Nature of the Transactions |
Share Capital |
Share premium |
Number of shares |
Nominal value |
||||||||||||
$ in thousands |
in $ |
|||||||||||||||
Balance as of J anuary 1, 2019 |
||||||||||||||||
Capital Increase |
— | |||||||||||||||
Exercise of share warrants, employee warrants and stock options |
— | |||||||||||||||
Non-cash stock-based compensation expense |
— | — | — | |||||||||||||
Other movements |
— | — | — | |||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Balance as of December 31, 2019 |
||||||||||||||||
Exercise of share warrants, employee warrants and stock options |
— | |||||||||||||||
Non-cash stock-based compensation expense |
— | — | — | |||||||||||||
Other movements |
— | ( |
) | — | — | |||||||||||
|
|
|
|
|
|
|
|
|||||||||
Balance as of December 31, 2020 |
||||||||||||||||
Capital increase (ATM) |
||||||||||||||||
Exercise of share warrants, employee warrants and stock options |
— | |||||||||||||||
Non-cash stock-based compensation expense |
— | — | — | |||||||||||||
Transaction costs |
— | ( |
) | |||||||||||||
Other movements |
— | ( |
) | — | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Balance as of December 31, 2021 |
• | During the full year ended December 31, 2021, At-The-Market non-employee warrants, $ |
• | During the full year ended December 31, 2020, |
• | During the full year ended December 31, 2019, |
• | |
• | |
• | |
Date |
Type |
Number of warrants/shares outstanding as of 01/01/2021 |
Number of warrants/shares granted |
Number of warrants/shares vested/exercised |
Number of warrants/shares voided |
Number of warrants/shares outstanding as of 12/31/2021 |
Maximum of shares to be issued |
Number of warrants/shares exercisable as of 12/31/2021 |
Strike price per share in euros |
|||||||||||||||||||||||||
— | — | |||||||||||||||||||||||||||||||||
— | — | — | ||||||||||||||||||||||||||||||||
— | — | — | ||||||||||||||||||||||||||||||||
— | — | — | ||||||||||||||||||||||||||||||||
— | — | |||||||||||||||||||||||||||||||||
— | — | — | ||||||||||||||||||||||||||||||||
— | ||||||||||||||||||||||||||||||||||
— | — | |||||||||||||||||||||||||||||||||
— | ||||||||||||||||||||||||||||||||||
— | — | — | ||||||||||||||||||||||||||||||||
— | ||||||||||||||||||||||||||||||||||
— | — | |||||||||||||||||||||||||||||||||
— | — | — | — | — | ||||||||||||||||||||||||||||||
— | ||||||||||||||||||||||||||||||||||
— | — | — | — | — | ||||||||||||||||||||||||||||||
— | — | — | — | — | ||||||||||||||||||||||||||||||
— | — | — | ||||||||||||||||||||||||||||||||
— | — | — | — | |||||||||||||||||||||||||||||||
— | — | — | — | |||||||||||||||||||||||||||||||
— | — | — | — | |||||||||||||||||||||||||||||||
— | — | — | — | |||||||||||||||||||||||||||||||
— | — | — | — | |||||||||||||||||||||||||||||||
— | — | — | ||||||||||||||||||||||||||||||||
— | — | — | ||||||||||||||||||||||||||||||||
— | — | — | ||||||||||||||||||||||||||||||||
— | — | — | — | |||||||||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||||||||
— |
— |
|||||||||||||||||||||||||||||||||
— |
— |
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
— |
— |
— |
— |
— |
||||||||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||||||||
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||||||||
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||||||||
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||||||||
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||||||||
— |
— |
— |
||||||||||||||||||||||||||||||||
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
— |
— |
— |
— |
|||||||||||||||||||||||||||||||
Total |
• | In 2021, our subsidiary Calyxt granted stock options, restricted stock unit and performance stock unit in Calyxt representing as of December 31, 2021 a |
• | In 2020, our subsidiary Calyxt granted stock options, restricted stock unit and performance stock unit in Calyxt representing as of December 31, 2020 a |
• | In 2019, our subsidiary Calyxt granted stock options, restricted stock unit and performance stock unit in Calyxt representing as of December 31, 2019 a |
CALYXT |
||||||||
2020 |
2021 |
|||||||
$ in thousands |
||||||||
Revenue |
||||||||
Net Profit (Loss) |
( |
) | ( |
) | ||||
Net Profit (Loss) attributable to NCI |
( |
) |
( |
) | ||||
Other comprehensive income |
( |
) | ( |
) | ||||
Total comprehensive income |
( |
) | ( |
) | ||||
Total comprehensive income attributable to NCI |
( |
) |
( |
) | ||||
Current assets |
||||||||
Non-current assets |
||||||||
Current liabilities |
||||||||
Non-current liabilities |
||||||||
Net assets |
||||||||
Net assets attributable to NCI |
||||||||
2019 |
2020 |
2021 | ||||
Weighted-Average fair values of stock options granted |
||||||
Assumptions: |
||||||
Risk-free interest rate |
- |
|||||
Share entitlement per options |
||||||
Exercise price |
||||||
Grant date share fair value |
||||||
Expected volatility |
||||||
Expected term (in years) |
||||||
Vesting conditions |
||||||
Vesting period |
Options Exercisable |
Weighted- Average Exercise Price Per Share |
Options Outstanding |
Weighted- Average Exercise Price Per Share |
Remaining Average Useful Life |
||||||||||||||||
Balance as of December 31, 2019 |
€ |
€ |
||||||||||||||||||
Granted |
— | — | € | |||||||||||||||||
Exercised |
— | — | ( |
) | € | |||||||||||||||
Forfeited or Expired |
— | — | ( |
) | € | |||||||||||||||
Balance as of December 31, 2020 |
€ |
€ |
||||||||||||||||||
Granted |
€ | |||||||||||||||||||
Exercised |
( |
) | € | |||||||||||||||||
Forfeited or Expired |
( |
) | € | |||||||||||||||||
Balance as of December 31, 2021 |
€ |
€ |
2016 |
2017 | |||
Weighted-Average fair values of warrants granted |
||||
Assumptions: |
||||
Risk-free interest rate |
||||
Share entitlement per options |
||||
Exercise price |
||||
Grant date share fair value |
||||
Expected volatility |
||||
Expected term (in years) |
||||
Vesting conditions |
||||
Vesting period |
Warrants Exercisable |
Weighted- Average Exercise |
Warrants Outstanding |
Weighted- Average Exercise |
Remaining Average Useful |
||||||||||||||||
Balance as of December 31, 2019 |
€ |
€ |
||||||||||||||||||
Granted |
||||||||||||||||||||
Exercised |
( |
) | € | |||||||||||||||||
Forfeited or Expired |
||||||||||||||||||||
Balance as of December 31, 2020 |
€ |
€ |
||||||||||||||||||
Granted |
||||||||||||||||||||
Exercised |
( |
) | € | |||||||||||||||||
Forfeited or Expired |
||||||||||||||||||||
Balance as of December 31, 2021 |
€ |
€ |
Number of Free shares Outstanding |
Weighted- Average Grant Date Fair Value |
|||||||
Unvested balance at December 31, 2019 |
€ | |||||||
Granted (1) |
€ | |||||||
Vested |
( |
) | € | |||||
Cancelled |
( |
) | € | |||||
Unvested balance at December 31, 2020 |
€ | |||||||
Granted |
€ | |||||||
Vested |
( |
) | € | |||||
Cancelled |
( |
) | € | |||||
Unvested balance at December 31, 2021 |
€ |
(1) | non-market performance vesting conditions and with a minimum vesting period of non-market performance vesting conditions. These free shares have been granted to a large number of our employees. |
2019 |
2020 |
2021 |
||||||||||
Weighted-Average fair values of stock options granted |
$ |
$ |
$ |
|||||||||
Assumptions: |
||||||||||||
Risk-free interest rate |
% - |
% - |
% - |
|||||||||
Share entitlement per options |
||||||||||||
Exercise price |
$ |
$ |
$ |
|||||||||
Grant date share fair value |
$ |
$ |
$ |
|||||||||
Expected volatility |
% - |
|||||||||||
Expected term (in years) |
||||||||||||
Vesting conditions |
||||||||||||
Vesting period |
Options Exercisable |
Weighted- Average Exercise Price Per Share |
Options Outstanding |
Weighted- Average Exercise Price Per Share |
Remaining Average Useful Life |
||||||||||||||||
Balance as of December 31, 2019 |
$ |
$ |
||||||||||||||||||
Granted |
$ | |||||||||||||||||||
Exercised |
( |
) | $ | |||||||||||||||||
Forfeited or Expired |
( |
) | $ | |||||||||||||||||
Balance as of December 31, 2020 |
$ |
$ |
||||||||||||||||||
Granted |
$ | |||||||||||||||||||
Exercised |
( |
) | $ | |||||||||||||||||
Forfeited or Expired |
( |
) | $ | |||||||||||||||||
Balance as of December 31, 2021 |
$ |
$ |
Number of Restricted Stock Units Outstanding |
Weighted-Average Grant Date Fair Value |
|||||||
Unvested balance at December 31, 2019 |
$ |
|||||||
Granted |
$ | |||||||
Vested |
( |
) | $ | |||||
Cancelled |
( |
) | $ | |||||
Unvested balance at December 31, 2020 |
$ |
|||||||
Granted |
$ | |||||||
Vested |
( |
) | $ | |||||
Cancelled |
( |
) | $ | |||||
Unvested balance at December 31, 2021 |
$ |
Date of grant |
06/28/2019 |
|||
Estimated fair values of performance stock units granted |
$ | |||
Assumptions: |
||||
Risk-free interest rate |
% | |||
Expected volatility |
% | |||
Expected term (in years) |
Date of grant |
07/01/2021 |
|||
Estimated fair values of performance stock units granted: |
||||
At least $12 per share |
$ | |||
At least $15 per share |
$ | |||
At least $20 per share |
$ | |||
Assumptions: |
||||
Expected term (in years) |
||||
Expected volatility |
% | |||
Risk-free interest rate |
% |
Number of Performance Stock Units Outstanding |
||||
Unvested balance at December 31, 2019 |
||||
Granted |
||||
Vested |
||||
Cancelled |
||||
Unvested balance at December 31, 2020 |
||||
Granted |
||||
Vested |
||||
Cancelled |
( |
) | ||
Unvested balance at December 31, 2021 |
For the year ended December 31, |
||||||||||||
2019 |
2020 |
2021 |
||||||||||
Net income (loss) attributable to shareholders of Cellectis ($ in thousands) |
( |
) | ( |
) | ( |
) | ||||||
Adjusted weighted average number of outstanding shares, used to calculate both basic and diluted net result per share |
||||||||||||
Basic / Diluted net income (loss) per share attributable to shareholders of Cellectis |
||||||||||||
Basic net income (loss) attributable to shareholders of Cellectis per share ($ /share) |
( |
) | ( |
) | ( |
) | ||||||
Diluted net income (loss) attributable to shareholders of Cellectis per share ($ /share) |
( |
) | ( |
) | ( |
) |
• | When the entity can no longer withdraw the offer of those benefits; and |
• | When the entity recognizes costs for a restructuring that is within the scope of IAS 37 Provisions and involves the payment of termination benefits. |
01/01/2020 |
Additions |
Amounts used during the period |
Reversals |
OCI |
12/31/2020 |
|||||||||||||||||||
$ in thousands |
||||||||||||||||||||||||
Pension |
||||||||||||||||||||||||
Loss on contract |
( |
) | ||||||||||||||||||||||
Employee litigation and severance |
( |
) | ( |
) | ||||||||||||||||||||
Commercial litigation |
( |
) | ( |
) | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total |
( |
) |
( |
) |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Non-current provisions |
||||||||||||||||||||||||
Current provisions |
( |
) | ( |
) |
01/01/2021 |
Additions |
Amounts used during the period |
Reversals |
OCI |
12/31/2021 |
|||||||||||||||||||
$ in thousands |
||||||||||||||||||||||||
Pension |
( |
) | ||||||||||||||||||||||
Employee litigation and severance |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
Commercial litigation |
( |
) | ( |
) | ( |
) | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total |
( |
) |
( |
) |
( |
) |
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Non-current provisions |
( |
) | ||||||||||||||||||||||
Current provisions |
( |
) | ( |
) | ( |
) |
• |
Seniority conditions: the employee must be entitled to an indemnity of 8 working months against one year before. |
• |
Calculation of the allowance: 1/4 of a month of salary per year of seniority up to 10 years, against 1/5 before, and no change beyond the 11th year. |
2019 |
2020 |
2021 | ||||
% social security contributions |
||||||
Salary increases |
||||||
Discount rate |
||||||
Terms of retirement |
||||||
Retirement age |
$ in thousands |
||||
As of January 1, 2019 |
( |
) | ||
|
|
|||
Current service cost |
( |
) | ||
Interest cost |
( |
) | ||
Benefit paid |
||||
Actuarial gains and losses |
( |
) | ||
Reclassification/CTA |
||||
As of December 31, 2019 |
( |
) | ||
|
|
|||
Current service cost |
( |
) | ||
Interest cost |
( |
) | ||
Benefit paid |
||||
Actuarial gains and losses |
( |
) | ||
Reclassification/CTA |
( |
) | ||
As of December 31, 2020 |
( |
) | ||
|
|
|||
Current service cost |
( |
) | ||
Interest cost |
( |
) | ||
Benefit paid |
||||
Actuarial gains and losses |
||||
Reclassification/CTA |
||||
As of December 31, 2021 |
( |
) | ||
|
|
As of December 31, 2021 |
Total |
Less than 1 year |
1 - 3 years |
3 - 5 years |
More than 5 years |
|||||||||||||||
$ in thousands |
||||||||||||||||||||
License and collaboration agreements |
||||||||||||||||||||
Clinical & Research and Development agreements |
— | — | — | |||||||||||||||||
IT licensing agreements |
— | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
Total commitments |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
CELLECTIS S.A. | ||
/s/ André Choulika | ||
By: |
André Choulika | |
Title: |
Chief Executive Officer |
Exhibit 1.1
CELLECTIS
French société anonyme (corporation) with share capital of 2,274,215.50
Registered office : 8 rue de la Croix Jarry, 75013 Paris
Paris Trade and Companies Registry no. 428 859 052
BYLAWS
Updated as of November 17, 2021
Copy certified as true to the original by
the Chief Executive Officer
André Choulika
ARTICLE 1 - FORM
The Company is a corporation (société anonyme), governed by Book II of the French commercial code (code de commerce) and by the present bylaws.
ARTICLE 2 - NAME
The name of the Company is:
CELLECTIS
In all deeds and documents emanating from the Company and addressed to third parties, this name must always be immediately preceded or followed by the words société anonyme or the initials S.A. and by the mention of the amount of the share capital.
ARTICLE 3 - PURPOSES
The Companys purposes, both in France and abroad, are all activities relating to genetics and more particularly to genome engineering and, notably, research, development and invention, filing and use of patents and trademarks, valorization, sale and marketing, advice and assistance in any field, and more particularly in the fields of agrifood, pharmaceuticals, textile and environment; and generally, all industrial, commercial, financial, civil, and personal or real property operations that may be directly or indirectly related to the purposes above or any similar or connected purposes.
ARTICLE 4 - REGISTERED OFFICE
The registered office of the Company is located at 8 rue de la Croix Jarry, 75013 Paris.
It may be transferred anywhere else in French territory by a decision of the Board of Directors, subject to the ratification of such decision by the next ordinary general meeting, and elsewhere by virtue of a resolution of the extraordinary general meeting.
If a transfer is decided by the Board of Directors, the Board is authorized to amend the bylaws and perform the publication and filing formalities required as a result, provided it is stated that the transfer is subject to the aforementioned ratification.
ARTICLE 5 - DURATION
The term of the Company shall be ninety-nine (99) years starting from the date of its registration with the Trade and Companies Registry, except in the event it is dissolved before the expiration of its term or if said term is extended by an extraordinary general shareholders meeting.
ARTICLE 6 - SHARE CAPITAL
The Company has a share capital of 2,274,215.50. It is divided into 45.484.310 shares with a par value of 0.05 each, all fully paid-up.
It may be increased or reduced as provided by the French commercial code (code de commerce).
On October 28, 2011, the shareholders general meeting approved the contribution to the Company of 11,111,089 shares of Cellartis, a Swedish Company with a share capital of SEK 2,222,217.80, which registered office is located at Arvid Wallgrens Backe 20, SE-41346 Göteborg (Sweden). This contribution, valued at 17,399,997, resulted in a share capital increase of a nominal amount of 96,666.65 and the issuance of 1,933,333 shares at a price of 9 each (share premium included), with a par value of 0.05 each, allocated to Cellartis shareholders in exchange for their respective contributions.
ARTICLE 7 - LEGAL FORM
Fully paid-up shares are either held in registered or bearer form at the option of each shareholder, subject to the applicable legal provisions regarding the form of shares held by certain natural or legal persons. Non fully paid-up shares must be held in registered form.
Shares are registered in an account under the conditions and in the manner prescribed by applicable laws and regulations.
Ownership of the shares delivered in registered form results from their registration in a registered account.
ARTICLE 8 SHARE TRANSFERS IDENTIFYING THE SHAREHOLDERS
8.1 Shares registered in accounts are freely transferable from one account to another through a wire, in accordance with applicable laws and regulations.
8.2 The Company may also, subject to applicable laws and regulations, at its own expense, request from an authorized agency at any time, the name, or, in the case of a legal entity, the corporate name, nationality, and address of holders of securities granting an immediate or future right to vote at its shareholders meetings, and the number of securities held by each of them and, if applicable, any restrictions to which these securities may be subject.
ARTICLE 9 - RIGHTS AND OBLIGATIONS PERTAINING TO SHARES
The rights and obligations attached to a share follow the share to any transferee to whom it may be transferred and the transfer includes all unpaid dividends due and dividends to be paid, as well as, as the case may be, the pro-rata portion of the reserve funds and provisions.
The ownership of a share implies ipso facto the owners approval of the present bylaws and the decisions adopted by general shareholders meetings.
In addition to the voting right attached to shares in accordance with applicable law, each share gives right to a pro-rata portion of corporate assets, profits, and of liquidation surplus, proportional to the portion of the share capital it represents.
Whenever it is necessary to hold several shares to exercise any right, shareholders or securities holders shall take it upon themselves to pool the number of shares or securities required.
In accordance with the provisions of the French commercial code (code de commerce), all fully paid-up shares which have been held in registered form for at least two years by the same shareholder will be granted double voting rights in comparison to the voting right attached to other shares which shall be equal to amount of share capital it represents.
ARTICLE 10 PAYING UP OF THE SHARES
Amounts to be paid as payment for shares subscribed pursuant to a share capital increase shall represent not less than one-fourth of their par value and the entire amount of the premium (as the case may be).
The Board of Directors shall make calls for payment of the balance, in one or more installments, within a period of five years from the date the capital increase is completed.
Each shareholder shall be notified of the amounts called and the date on which the corresponding sums are to be paid at least fifteen days before the due date.
Shareholders who do not pay amounts owed on the shares they hold by the due date shall automatically and without the need for a formal demand for payment owe the Company late payment interest calculated on a daily basis, on the basis of a 360 day year, starting as of the due date at the legal rate in commercial matters, plus three points, without prejudice to the Companys personal action against such defaulting shareholder and the enforcement measures authorized by law.
ARTICLE 11 BOARD OF DIRECTORS
11.1. Composition
The Company is managed by a Board of Directors composed of individuals or legal entities, the number of which is determined by the ordinary general shareholders meeting within the limits of law.
At the time they are appointed, legal entities shall designate an individual as their permanent representative to the Board of Directors. The term of office of the permanent representative shall be the same as the term of office of the legal entity it represents. If a legal entity removes its permanent representative from office, it shall immediately appoint a replacement. The same provision shall also apply in the event of the death or resignation of the permanent representative.
The term of directors office shall be three years (3), with a year being defined as the period between two consecutive ordinary general shareholders meetings. Directors term of office shall occur at the end of the ordinary general shareholders meeting which voted on the financial statements for the past fiscal year and held in the year during which said directors term of office occurs.
Directors are always eligible for reappointment. They may be removed from office at any time by a decision of a general shareholders meeting.
In the event of one or more vacancies on the Board of Directors due to death or resignation, the Board may make temporary appointments between two general shareholders meetings.
Appointments made by the Board pursuant to the preceding paragraph shall be submitted for ratification by the next ordinary general shareholders meeting.
If such appointments are not ratified, decisions adopted and acts performed by the Board shall nevertheless remain valid.
If the number of directors falls below the statutory minimum, the remaining directors shall immediately convene an ordinary general shareholders meeting in order to supplement the Board.
A director appointed to replace another director if the term of the latters office has not yet expired shall serve only for the remaining portion of his predecessors term of office.
Companys employees may be appointed as directors. However, their employment contracts must correspond to actual employment. In such case, employees do not lose the benefit of their employment contracts.
The number of directors who have employment contracts with the Company shall not exceed one-third of the directors in office.
The number of directors over the age of 75 shall not exceed one-third of the directors in office. If this limit is exceeded during the directors terms of office, the oldest director shall automatically be deemed to have resigned at the end of the next ordinary general shareholders meeting.
11.2 Chairman
The Board of Directors shall elect a Chairman from among its members, who shall be an individual. The Board shall determine its term of office, which shall not exceed its term of office as director, and may remove him from office at any time. The Board shall set his compensation.
The Chairman shall organize and manage the work of the Board and report it to the general shareholders meetings. The Chairman is responsible for the good functioning of the Companys corporate bodies and, notably, sees that the directors are able to carry out their functions.
The Chairman of the Board cannot be more than 75 years old. If the Chairman reaches this age limit during his term of office as Chairman, he shall automatically be deemed to have resigned at the end of the current office. Subject to this provision, the Chairman of the Board is always eligible for reappointment.
11.3 Observers
The ordinary shareholders meeting may, upon suggestion from the Board of Directors, appoint one or several observers. The Board of Directors may also directly appoint the members, subject to ratification by the following general meeting.
The number of observers may not exceed five. They are freely chosen in light of their abilities.
They are appointed for a term of three (3) years.
The observers review questions that the Board of Directors or its Chairman submit for their opinion. The observers attend the Board of Directors meetings and participate in the discussions only with a consultative voice. Their absence shall have no effect on the validity of the vote.
They are convened to Board meetings under the same conditions as the Board members.
The Board of Directors may compensate the observers and take such compensation from the amount of attendance fees (jetons de présence) if any, authorized by the general shareholders meeting for the purposes of compensating directors.
ARTICLE 12 MEETING OF THE BOARD
12.1. The Board of Directors shall meet as often as required for the interest of the Company.
12.2. Directors are convened to the Board meetings by the Chairman of the Board. The Chairman convenes meetings of the Board of Directors by any means, in oral or written form.
The Chief Executive Officer may also ask the Chairman to convene the Board on a specific agenda.
When a works council (comité dentreprise) has been formed, the representatives of such committee, appointed in accordance with the provisions of the French labor code (code du travail), shall be convened to all the Board meetings.
The Board meetings are held either at the registered office or at any other place, in France or abroad as indicated at the time of the convening.
12.3. The Board can only validly take decisions if half of its members are present.
The Boards decisions are taken at the majority of votes of its members present or represented by proxy; in the case of deadlock; the Chairman shall have the casting vote.
12.4. Internal regulations may be adopted by the Board of Directors providing, among others, that for the calculation of the quorum and of the majority, the directors participating in the meeting of the board by means of visioconference consistent with applicable regulations, shall be considered as having attended the meeting in person. This provision is not applicable for the adoption of a resolution relating to L. 232-1 and L. 232-16 of French commercial code (code de commerce).
12.5. Each director receives the information necessary to perform its duties and office and may ask to be provided with any other documents it deems necessary.
12.6. Any director may give to another director, by letter, cable, email or telex, a proxy to be represented at a meeting of the board. However, each director can only represent one director during each meeting.
12.7. The Board of Directors may also take the following decisions within the scope of the Boards own powers by written consultation with the directors:
- provisional appointment of members of the Board as provided for in Article L. 225-24 of the French Commercial Code,
- authorization of sureties, endorsements and guarantees provided for in the last paragraph of Article L. 225-35 of the French Commercial Code,
- decision taken on the basis of the delegation granted by the Extraordinary General Meeting in accordance with the second paragraph of Article L. 225-36 of the French Commercial Code, to amend the Articles of Association to bring them into compliance with the legal and regulatory provisions,
- convening shareholders general meetings, and
- transfer of the head office to the same department.
When the decision is taken by written consultation, the text of the proposed resolutions accompanied by a voting form is sent by the Chairman to each member of the Board of Directors by electronic means (with acknowledgement of receipt).
The directors have a period of 3 working days following receipt of the text of the proposed resolutions and the voting form to complete and send the voting form, dated and signed, to the chairman by electronic means (with acknowledgement of receipt), ticking a single box for each resolution corresponding to the meaning of its vote.
If no or more than one box has been ticked for the same resolution, the vote will be null and void and will not be taken into account for the calculation of the majority.
Any Director who has not sent his answer within the above-mentioned time limit will be considered absent and his vote will therefore not be taken into account for the calculation of the quorum and the majority.
During the time limit for reply, any director may require any additional explanations from the initiator of the consultation.
Within five (5) working days following receipt of the last ballot paper, the Chairman shall draw up and date the minutes of the deliberations, to which the ballot papers shall be appended and which shall be signed by the Chairman and a director who participated in the written consultation. »
12.8. The copies or abstracts of the minutes are certified by the Chairman of the Board of Directors, the Chief Executive Officer and the director temporarily delegated in the duties of Chairman or by a representative duly authorized for that purpose.
ARTICLE 13 POWERS OF THE BOARD OF DIRECTORS
The Board of Directors shall establish the Companys business policies and ensure that they are carried out. Subject to the powers expressly granted to shareholders meetings, and within the limits of the corporate purpose, the Board of Directors may consider any issue relating to the proper operation of the Company and shall resolve on matters that relate to the Company.
With regards to third parties, the Company shall be bound by the acts of the Board of Directors that exceed the scope of the corporate purpose, unless the Company proves that the third party was aware, or that in light of the circumstances could not have been unaware, that the act was not within the corporate purpose; however, the mere publication of the bylaws is not sufficient to constitute such proof.
The Board of Directors can carry out all controls and verifications it deems necessary.
Furthermore, the Board of Directors shall exercise the special powers conferred by law.
ARTICLE 14 GENERAL MANAGEMENT
14.1.1. The Companys executive management functions shall be performed, under its responsibility, by the Chairman of the Board of Directors or another individual appointed by the Board of Directors, who shall hold the title of Chief Executive Officer.
The Chief Executive Officer is vested with the most extensive powers to act under all circumstances on behalf of the Company. The Chief Executive Officer performs his powers within the limits of the purpose of the Company, except for those powers expressly granted by law to the meetings of shareholders and to the Board of Directors.
The Chief Executive Officer shall represent the Company in its relations with third parties. The Company shall be bound by acts of the Chief Executive Officer that exceed the scope of the corporate purpose, unless the Company is able to prove that the third party was aware, or that in light of the circumstances could not have been unaware, that the act was not within the corporate purpose; however, the mere publication of the bylaws is not sufficient to constitute such proof.
14.1.2. The Chief Executive Officer cannot be more than 75 years old. If the Chief Executive Officer reaches this age limit, he shall automatically be deemed to have resigned. However, the Chief Executive Officers term of office shall be prolonged until the next Board of Directors meeting, at which a new Chief Executive Officer shall be appointed.
14.1.3. If the Chief Executive Officer is a director, the term of his office shall not exceed his term of office as director.
The Board of Directors may remove the Chief Executive Officer from office at any time. If the removal from office is decided without fair cause, the Chief Executive Officer removed from office may claim damages unless the Chief Executive Officer is also Chairman of the Board of Directors.
14.1.4. By a decision adopted by a majority vote of the directors present or represented by proxy, the Board of Directors shall choose between the two options of exercise of the general management described in Article 14.1.1, paragraph 1. The shareholders and third parties shall be informed of such choice in the manner prescribed by applicable laws and regulations.
The choice made by the Board of Directors shall remain in effect until a contrary decision of the Board or, at the Boards discretion, for the duration of the Chief Executive Officers term of office.
If the Companys executive management functions are carried out by the Chairman of the Board of Directors, the provisions concerning the Chief Executive Officer shall apply to him.
In accordance with the provisions of Article L. 706-43 of the French code of criminal procedure (code de procédure pénale), the Chief Executive Officer may validly delegate to any individual of his choice the power to represent the Company in connection with criminal proceedings that may be filed against the Company.
14.2.1. Upon proposal of the Chief Executive Officer, the Board of Directors may authorize one or more individuals to assist the Chief Executive Officer in the capacity of Deputy Chief Executive Officer.
In accordance with the Chief Executive Officer, the Board of Directors shall determine the scope and duration of the powers granted to the Deputy Chief Executive Officers. The Board of Directors shall set their compensation. If a Deputy Chief Executive Officer is also a director, the term of his office shall not exceed his term of office as director.
No more than five Deputy Chief Executive Officers shall be appointed.
Pursuant to a proposal of the Chief Executive Officer, the Deputy Chief Executive Officer(s) may be removed from office by the Board of Directors at any time. If the removal from office is decided without fair cause, a Deputy Chief Executive Officer removed from office may claim damages.
Deputy Chief Executive Officers cannot be more than 75 years old. If a Deputy Chief Executive Officer in office reaches this age limit, he shall automatically be deemed to have resigned. The Deputy Chief Executive Officers term of office shall be prolonged until the next Board of Directors meeting, at which a new Deputy Chief Executive Officer may be appointed.
If the Chief Executive Officer ceases its office or is unable to perform its duties, unless otherwise decided by the Board of Directors, the Deputy Chief Executive Officer(s) shall remain in office and retain their powers until the appointment of a new Chief Executive Officer.
Vis-à-vis third parties, the Deputy Chief Executive Officers shall have the same powers as the Chief Executive Officer.
ARTICLE 15 - AGREEMENTS SUBJECT TO AUTHORIZATION
15.1. Any sureties, endorsements and guarantees granted by the Company shall be authorized by the Board of Directors in accordance with the requirements prescribed by law.
15.2. Any agreement to be entered into, whether directly or indirectly or through an intermediary, between the Company and its Chief Executive Officer, one of its Deputy Chief Executive Officer(s), one of its directors, one of its shareholders holding more that 10 % of the voting rights or, in the case of a Company being a shareholder, the Company controlling it within the meaning of article L 233-3 of the commercial code, must be submitted for the prior authorization of the Board of Directors. .
The same applies for agreements in which one of the persons referred to in the above paragraph is indirectly interested.
Such prior authorization is also required for agreements between the Company and another Company, should the general manager, one of the Deputy Chief Executive Officer or one of the directors of the Company be owner, partner with unlimited liability, manager, director, member of the supervisory board or, in general, manager of said Company.
The prior authorization of the Board of Directors shall be delivered in accordance with the requirements prescribed by law.
The above provisions do not apply to agreements relating to current transactions entered into under ordinary conditions or to agreements entered into between two companies, one of which holds, directly or indirectly, all of the capital of the other, minus, if applicable, the minimum number of shares required to satisfy the requirements of article 1832 of the French civil code or articles L. 225-1 and L. 226-1 of the French commercial code.
ARTICLE 16 - PROHIBITED AGREEMENTS
Directors, other than legal entities, are forbidden to contract loans from the Company in any form whatsoever, to secure an overdraft from it, as a current account or otherwise, and to have the Company guarantee or secure their commitments toward third parties.
The same prohibition applies to the Chief Executive Officer, the Deputy Chief Executive Officers and to the permanent representatives of directors that are legal entities. The foregoing provision also applies to the spouses, ascendants and descendants of the persons referred to in this article, as well as to all intermediaries.
ARTICLE 17 - STATUTORY AUDITORS
Audits of the Company shall be carried out, as provided by law, by one or more statutory auditors legally entitled to be elected as such. When the conditions provided by law are met, the Company must appoint at least two supervisory auditors.
The statutory auditor(s) shall be appointed by the ordinary general meeting.
The ordinary general meeting shall appoint, in the cases provided for by law, one or more alternate statutory auditors, which shall be called upon to replace the primary statutory auditors in the event of refusal, impediment, resignation or death.
Should the general ordinary meeting of the shareholders fail to elect a statutory auditor, any shareholder can claim in court that one be appointed, provided that the President of the Board of Directors be duly informed. The term of office of the statutory auditor appointed in court will end upon the appointment of the statutory auditor(s) by the general ordinary meeting of the shareholders.
ARTICLE 18 - GENERAL SHAREHOLDERS MEETING QUORUM VOTE NUMBER OF VOTES
General shareholders meetings shall be convened and held as provided by law.
If the Company wishes to convene the meeting by electronic means in lieu and place of the postal mail, it has to obtain the prior approval of the interested shareholders which will indicate their electronic address.
Meetings shall be held at the registered office or at any other location specified in the convening notice.
The right to participate in general shareholders meetings is determined by the applicable laws and regulations and is conditioned upon the registration of shares under the shareholders name or under an intermediarys name acting on its behalf, on the second business day prior to the general shareholders meeting at midnight (Paris time), either in the registered shares accounts held by the Company or in the bearer shares accounts held by the authorized intermediary.
If a shareholder does not attend the meeting in person, it can grant a proxy to another shareholder, to its spouse or partner of French pacte civil de solidarité (PACS) or any other individual or legal entity. It can also send vote by correspondence or send a proxy to the Company without indicating the beneficiary, in accordance with applicable laws.
In accordance with the requirements prescribed by the laws and regulations in force, the Board of Directors may arrange for shareholders to participate and vote by videoconference or means of telecommunication, including internet, that allow them to be identified. If the Board of Directors decides to exercise this right for a particular shareholders meeting, such decision shall be mentioned in the meeting notice (avis de réunion) and/or convening notice (avis de convocation) of the meeting. Shareholders who participate in shareholders meetings be videoconference or any of the other means of telecommunication referred to above, as selected by the Board of Directors, shall be deemed present for the purposes of calculating the quorum and majority. Shareholders who
use the electronic voting form provided on the website set up by the meetings centralizing agent are deemed to be present. The electronic form can be entered and signed directly on this site by means of an identification code and a password. The proxy or the vote thus expressed before the meeting by this electronic means, as well as the acknowledgement of receipt which is given, will be considered as non-revocable writings and opposable to all.
Shareholders meetings shall be chaired by the Chairman of the Board of Directors or, in its absence, by the Chief Executive Officer or by a Deputy Chief Executive Officer if he is a director, or by a director specifically appointed for such purposes by the Board. If no president has been appointed, the shareholders meeting shall elect its own chairman.
The duties of scrutineers shall be performed by the two members of the shareholders meeting who are present and hold the greatest number of votes, and who agree to perform such duties. The officers shall appoint a secretary, who may but need not be a shareholder.
An attendance sheet is drawn up, in accordance with the requirements prescribed by law.
Upon first notice, an ordinary general shareholders meeting may validly deliberate only if the shareholders present or represented by proxy own at least one-fifth of the shares entitled to vote. Upon second notice, no quorum is required.
Resolutions of the ordinary general meeting shall be passed by a majority of the votes cast by the shareholders present or represented. The votes cast do not include those attached to shares for which the shareholder did not take part in the vote, abstained from voting or voted blank or null and void.
Upon first notice, an extraordinary general shareholders meeting may validly deliberate only if the shareholders present or represented by proxy own at least one-fourth of the shares entitled to vote. Upon second notice, an extraordinary general shareholders meeting may validly deliberate only if the shareholders present or represented by proxy own at least one-fifth of the shares entitled to vote.
Resolutions of the Extraordinary General Meeting shall be passed by a two-thirds majority of the votes cast by the shareholders present or represented. The votes cast do not include those attached to shares for which the shareholder did not take part in the vote, abstained or voted blank or null and void.
Copies or extracts of shareholder meeting minutes may be validly certified by the Chairman of the Board of Directors, a director who holds the position of Chief Executive Officer or Deputy Chief Executive Officer or by the secretary of the meeting.
Ordinary and extraordinary general shareholders meetings shall exercise their respective powers in accordance with the requirements prescribed by law.
ARTICLE - 19 FISCAL YEAR
Each fiscal year shall last one year, starting on January 1 and ending on December 31.
ARTICLE 20 - PROFITS STATUTORY RESERVE FUND
Out of the profit of a fiscal year, reduced by prior losses if any, an amount equal to at least 5 % thereof is first deducted in order to form the legal reserve fund provided by law. This deduction is no longer required when the legal reserve fund amounts to one tenth of the capital of the Company.
Distributable profit is the profit of a fiscal year, reduced by prior losses and by the deduction provided for in the preceding paragraph and increased by the profits carried forward.
ARTICLE 21- DIVIDENDS
If there results a distributable profit from the accounts of the fiscal year, as approved by the general meeting, the general meeting may decide to allocate it to one or several reserve funds, the appropriation or use of which it shall determine, or to carry it forward or to distribute it as dividends.
Furthermore, after having established the existence of reserves which it may dispose of, the general meeting may decide the distribution of amounts paid out of such reserves. In such case, the payments shall be made. However, the dividends shall be set off by priority on the distributable profit of the fiscal year.
The general meeting shall determine the terms of payment of dividends ; failing such determination, these terms shall be determined by the Board of Directors.
However, the dividends must be declared payable no more than nine months following the close of the fiscal year.
The general meeting deciding upon the accounts of a fiscal year will be entitled to grant to each shareholder, for all or part of the distributed dividends, an option between payment in cash or in shares.
Similarly, should the ordinary general meeting resolve the distribution of interim dividends pursuant to article L. 232-12 of the French commercial code (code de commerce) , it will be entitled to grant to each shareholder an interim dividend and, for whole or part of the said interim dividend, an option between payment in cash or in shares.
The offer of payment in shares, the price and the conditions as to the issuing of such shares, together with the request for payment in shares and the conditions of the completion of the capital increase will be governed by the law and regulations.
When a balance sheet, drawn up during, or at the end of the fiscal year, and certified by the statutory auditor, shows that the Company, since the close of the preceding fiscal year, after having made the necessary depreciations and provisions and after deduction of the prior losses, if any, as well as of the amounts which are to be allocated to the reserve fund provided by law or by the by-laws and taking into account the profits carrying forward, has made profits, the Board of Directors may resolve the distribution of interim dividends prior to the approval of the accounts of the fiscal year, and may determine the amount thereof and the date of such distribution. The amount of such interim dividends cannot exceed the amount of the profits as defined in this paragraph. In this case, the option described in the preceding paragraph shall not be available.
ARTICLE 22 - EARLY DISSOLUTION
An extraordinary general shareholders meeting may, at any time, decide to dissolve the Company before the expiration of its term.
ARTICLE 23 - LOSS OF ONE HALF OF SHARE CAPITAL
If, as a consequence of losses showed by the Companys accounts, the net assets (capitaux propres) of the Company are reduced below one half of the capital of the Company, the Board of Directors must, within four months from the approval of the accounts showing this loss, convene an extraordinary general meeting of shareholders in order to decide whether the Company ought to be dissolved before its statutory term.
If the dissolution is not declared, the capital must, at the latest at the end of the second fiscal year following the fiscal year during which the losses were established and subject to the legal provisions concerning the minimum capital of sociétés anonymes, be reduced by an amount at least equal to the losses which could not be charged on reserves, if during that period the net assets have not been restored up to an amount at least equal to one half of the capital.
In the absence of a meeting of shareholders, or in the case where the Company has not been able to validly act, any interested party may institute legal proceedings to dissolve the Company.
ARTICLE 24 - EFFECT OF THE DISSOLUTION
The Company is in liquidation as soon as it is dissolved for any reason whatsoever. It continues to exist as a legal entity for the needs of this liquidation until the liquidation is completed.
During the period of the liquidation, the general meeting shall retain the same powers it exercised during the life of the Company.
The shares shall remain transferable until the completion of the liquidation proceedings.
The dissolution of the Company is only valid vis-à-vis third parties as from the date at which it is published at the Trade and Companies Registry.
ARTICLE 25 - APPOINTMENT OF LIQUIDATORS POWERS
When the Companys term expires or if the Company is dissolved before the expiration of its term, a general shareholders meeting shall decide the method of liquidation, appoint one or more liquidators and determine their powers. The liquidators will exercise their duties in accordance with the law. The appointment of liquidators shall cause the duties of the directors, Chairman, Chief Executive Officer and Deputy Chief Executive Officers to end.
ARTICLE 26 - LIQUIDATION - CLOSING
After payment of the liabilities, the remaining assets shall be used first for the payment to the shareholders of the amount paid for their shares and not amortized.
The balance, if any, shall be divided among all the shareholders.
The shareholders shall be convened at the end of the liquidation in order to decide on the final accounts, to discharge the liquidator from liability for his acts of management and the performance of his office, and to take notice of the closing of the liquidation.
The closing of the liquidation is published as provided by law.
ARTICLE 27 - NOTIFICATIONS
All notifications provided for in the present bylaws shall be made either by registered mail with acknowledgment of receipt or by process server. Simultaneously a copy of the notification shall be sent to the recipient by ordinary mail.
ooOoo
Exhibit 2.3
DESCRIPTION OF SECURITIES
REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT
As of December 31, 2021, Cellectis S.A. (the Company, we, us, and our) had the following series of securities registered pursuant to Section 12(b) of the Exchange Act:
Title of Each Class |
Trading Symbol |
Name of each exchange on which registered | ||
American Depositary Shares, each representing 1 share, nominal value 0.05 per share
Ordinary Shares, nominal value 0.05 per share* |
CLLS | NASDAQ Global Market |
* | Not for trading, but only in connection with the registration of American Depositary Shares. |
American Depositary Shares (ADSs), each representing one ordinary share, nominal value 0.05 per share of Cellectis S.A. (the shares), have been available in the United States through an American Depositary Receipt (ADR) program. This program was established pursuant to the deposit agreement that we entered into with Citibank, N.A. (Citibank), as depositary (Deposit Agreement) in 2015 in connection with our initial public offering. Each ADS represents one ordinary share deposited with Citibank Europe plc, located at 388 Greenwich Street, New York, New York 10013, or any successor, as custodian for the depositary (the Custodian).
Our ADSs have been listed on the NASDAQ Global Market (NASDAQ) since March 2015 and are traded under the symbol CLLS. In connection with this NASDAQ listing (but not for trading), the shares are registered under Section 12(b) of the Exchange Act. Our ordinary shares have been trading on Euronext Growth market of Euronext Paris under the symbol ALCLS since February 7, 2007. Prior to that date, there was no public trading market for our ordinary shares. The transfer agent and registrar for our ordinary shares is Société Générale Securities Services.
This exhibit contains a description of the rights of (i) the holders of shares and (ii) ADR holders. Shares underlying the ADSs are held by Citibank, the depositary, and holders of ADSs will not be treated as holders of the shares.
The following summaries are not intended to be exhaustive and, in the case of our ordinary shares, such summary is subject to, and qualified in its entirety by, Cellectis By-Laws and by French law and in the case of our ADSs, such summary is subject to, and qualified in its entirety by, the terms of the Deposit Agreement. Such summaries do not address all of the provisions of the By-laws or French law or of the Deposit Agreement, and do not purport to be complete. Our By-laws and the Deposit Agreement are each attached as exhibits to our Annual Report.
Capitalized terms not otherwise defined in this exhibit have the meanings given to them in Cellectis annual report on Form 20-F for which this exhibit is provided (the Annual Report).
ORDINARY SHARES
The description below reflects certain terms of our By-laws, and summarizes the material rights of holders of our ordinary shares under French law.
General
As of December 31, 2021, our outstanding share capital consisted of a total of 45,484,310 issued and outstanding ordinary shares, with nominal value 0.05 per share. We have no preferred shares outstanding.
Rights, Preferences and Restrictions Attaching to Ordinary Shares
Dividends. We may only distribute dividends out of our distributable profits, plus any amounts held in our reserves that the shareholders decide to make available for distribution, other than those reserves that are specifically required to be maintained by law. Distributable profits consist of our unconsolidated net profit in each fiscal year, as increased or reduced by any profit or loss carried forward from prior years, less any contributions to the reserve accounts pursuant to French law (see below under Legal Reserve).
Legal Reserve. Pursuant to French law, we must allocate at least 5% of our unconsolidated net profit for each year to our legal reserve fund before dividends may be paid with respect to that year. Such allocation is compulsory until the amount in the legal reserve is equal to 10% of the aggregate par value of our issued and outstanding share capital. This restriction on the payment of dividends also applies to our French subsidiaries on an unconsolidated basis.
Approval of Dividends. Pursuant to French law, our board of directors may propose a dividend and/or reserve distribution for approval by the shareholders at the annual ordinary general meeting.
Upon recommendation of our board of directors, our shareholders may decide to allocate all or part of any distributable profits to special or general reserves, to carry them forward to the next fiscal year as retained earnings or to allocate them to the shareholders as dividends. However, dividends may not be distributed when as a result of such distribution our net assets are or would become lower than the amount of the share capital plus the amount of the legal reserves which, under French law, may not be distributed to shareholders.
Our board of directors may distribute interim dividends after the end of the fiscal year but before the approval of the financial statements for the relevant fiscal year when the interim balance sheet, established during such year and examined by an auditor, reflects that we have earned distributable profits since the close of the last financial year, after recognizing the necessary depreciation and provisions and after deducting prior losses, if any, and the sums to be allocated to reserves, as required by law or the By-laws, and including any retained earnings. The amount of such interim dividends may not exceed the amount of the profit so defined.
Distribution of Dividends. Dividends are distributed to shareholders proportionally to their shareholding interests. In the case of interim dividends, distributions are made to shareholders on the date set by our board of directors during the meeting in which the distribution of interim dividends is approved. The actual dividend payment date is decided by the shareholders at an ordinary general shareholders meeting or by our board of directors in the absence of such a decision by the shareholders. Shareholders that own shares on the actual payment date are entitled to the dividend.
Dividends may be paid in cash or, if the shareholders meeting so decides, in kind, provided that all the shareholders receive a whole number of assets of the same nature paid in lieu of cash. Our By-laws provide that, subject to a decision of the shareholders meeting taken by ordinary resolution, each shareholder may be given the choice to receive such shareholders dividend in cash or in shares.
Timing of Payment. Pursuant to French law, dividends must be paid within a maximum period of nine months following the end of the relevant fiscal year. An extension of such timeframe may be granted by court order. Dividends that are not claimed within a period of five years after the payment date will be deemed to expire and revert to the French state.
Voting Rights. Each of our ordinary shares entitles its holder to vote and be represented in the shareholders meetings in accordance with the provisions of French law and of our By-laws. The ownership of a share implies the acceptance of our By-laws and any decision of our shareholders.
In general, each shareholder is entitled to one vote per share at any general shareholders meeting. However, our By-Laws provide that all shares held in registered form (actions nominatives) for more than two years will be granted double voting rights.
Under French law, treasury shares or shares held by entities controlled by us are not entitled to voting rights and are not taken into account for purposes of quorum calculation.
Under French law, directors are elected at the ordinary general shareholders meeting by a simple majority vote, and may be removed from office, with or without cause, at any shareholders meeting without notice or justification, by a simple majority vote. Our By-laws provide that members of our board of directors are elected for a tenure of three years, with terms beginning upon the year of a directors initial appointment. Pursuant to French law, the sections of the By-laws relating to the number of directors and election and removal of a director from office may only be modified by a resolution adopted by a two-thirds majority of the votes cast by our shareholders present, represented by a proxy or voting by mail at the meeting. The votes cast do not include votes attached to shares held by shareholders who did not take part in the vote, abstained or voted blank or null.
Rights to Share in Our Profit. Under French law, each ordinary share entitles its holder to a portion of the corporate profits and assets proportional to the amount of share capital represented thereby.
Rights to Share in the Surplus in the Event of Liquidation. If we are liquidated, any assets remaining after payment of our debts, liquidation expenses and all of our remaining obligations will first be used to repay in full the par value of our outstanding shares. Any surplus will then be distributed among shareholders proportionally to their shareholding in our company.
Repurchase and Redemption of Shares. Under French law, we may acquire our own shares. Such acquisition may be challenged on the ground of market abuse regulations. However, Market Abuse Regulation (UE) No. 596/2014 of April 16, 2014 and its related delegated regulations (MAR) provides for safe harbor exemptions when the acquisition is made (i) under a buy-back program to be authorized by the shareholders in accordance with the provisions of Article L. 22-10-62 of the French Commercial Code and with the General Regulations of the French Financial Markets Authority (Autorité des marchés financiers or AMF) and (ii) for one of the following purposes which shall be provided for in the buy-back program:
| to decrease our share capital, provided that such a decision is not driven by losses and that a purchase offer is made to all shareholders on a pro rata basis, with the approval of the shareholders at an extraordinary general meeting; in this case, the shares repurchased must be cancelled within one month from their repurchase date; |
| to meet our obligations arising from debt financial instruments issued by us that are exchangeable into shares; |
| to meet our obligations arising from share option programs, or other allocations of shares, to our employees or to our managers or the employees or managers of our affiliate. In this case the shares repurchased must be distributed within 12 months from their repurchase, after which they must be cancelled. |
In addition, we benefit from a simple exemption when the acquisition is made under a liquidity contract complying with the general regulations of, and market practices accepted by, the AMF. All other purposes, and especially share buy-backs made for external growth operations in pursuance of Article L. 22-10-62 of the French Commercial Code, while not forbidden, must be pursued in strict compliance of market manipulation and insider dealing rules.
Under MAR and in accordance with the General Regulations of the AMF, a corporation shall report to the AMF, no later than by the end of the seventh daily market session following the date of the execution of the transaction, all transactions relating to the buy-back program, in a detailed form and in an aggregated form. In addition, we shall provide to the AMF, on a monthly basis, and to the public, on a quarterly basis, a summary report of any transactions made under a liquidity contract.
The decision to repurchase shares in order to decrease our share capital shall not be driven by losses and a purchase offer shall be made to all shareholders on a pro rata basis, with the approval of the shareholders at the extraordinary general meeting deciding the capital reduction; in this case, the shares repurchased must be cancelled within one month from their repurchase date.
In any case, no such repurchase of shares may result in us holding, directly or through a person acting on our behalf, more than (i) 10% of our issued share capital, or (ii) 5% of our issued share capital in case of repurchase of shares to be used in payment or in exchange in the context of a merger, division or transfer of assets. Shares repurchased by us continue to be deemed issued under French law but are not entitled to dividends and/or voting rights so long as we hold them directly or indirectly, and we may not exercise the preemptive rights attached to them.
Sinking Fund Provisions. Our By-laws do not provide for any sinking fund provisions.
Liability to Further Capital Calls. Shareholders are liable for corporate liabilities only up to the par value of the shares they hold; they are not liable to further capital calls.
Requirements for Holdings Exceeding Certain Percentages. There are no such requirements, except as described under Form, Holding and Transfer of SharesOwnership of Shares and ADSs by Non-French Persons.
Actions Necessary to Modify Shareholders Rights
Shareholders rights may be modified as allowed by French law. Only the extraordinary shareholders meeting is authorized to amend any and all provisions of our By-laws. It may not, however, increase any of the shareholders commitments without the prior approval of each shareholder.
Special Voting Rights of Warrant Holders
Under French law, the holders of warrants of the same class (i.e., warrants that were issued at the same time and with the same rights), including and warrants (BSA), are entitled to vote as a separate class at a general meeting of that class of warrant holders under certain circumstances, principally in connection with any proposed modification of the terms and conditions of the class of warrants or any proposed issuance of preferred shares or any modification of the rights of any outstanding class or series of preferred shares.
Rules for Admission to and Calling Annual Shareholders Meetings and Extraordinary Shareholders Meetings
Access to, Participation in and Voting Rights at Shareholders Meetings. The right to participate in a shareholders meeting is granted to all the shareholders, regardless of the number of shares they hold, whose shares are fully paid up and for whom a right to attend shareholders meetings has been established by registration of their shares in the names or names of the authorized intermediary acting on their behalf on the second business day prior to the shareholders meeting at midnight (Paris time), either in the registered shares accounts held by the Company or in the bearer shares accounts held by the authorized intermediary.
Each shareholder may attend the meetings and vote (1) in person, or (2) by granting a proxy to any person, or (3) by sending a proxy to us without indication of the beneficiary (in which case such proxy shall be cast in favor of the resolutions supported by the board of directors), or (4) by correspondence, or (5) by videoconference or another means of telecommunication organized by the board of directors and allowing identification of the relevant shareholder in accordance with applicable laws.
Shareholders may, in accordance with legal and regulatory requirements, send their vote or proxy, either by hard copy or via telecommunications means. Such vote or proxy must be received (1) at least three days prior to the meeting, in the case of hard copies, (2) by 3:00 p.m. (Paris time) on the day before the meeting, in the case of, electronic votes by email, (3) by the date of the meeting, in the case of a proxy granted to a designated person, and
(4) by 3:00 p.m. (Paris time) on the day before the meeting, in the case of proxies without a designated attorney and therefore granted to the chairman of the meeting.
Shareholders sending their vote within the applicable time limit, using the form provided to them by us for this purpose, are deemed present or represented at the shareholders meeting for purposes of quorum and majority calculation.
The voting by correspondence form addressed by a shareholder is only valid for a single meeting or for successive meetings convened with the same agenda. To better understand the voting rights of the ADSs, see Description of American Depositary Shares below.
Notice of Annual Shareholders Meetings. Shareholders meetings are convened by our board of directors, or, failing that, by our statutory auditors, or by a court appointed agent or liquidator in certain circumstances, or by the majority shareholder in capital or voting rights following a public tender offer or exchange offer or the transfer of a controlling block on the date decided by the board of directors or the relevant person. Meetings are held at our registered offices or at any other location indicated in the convening notice. A meeting notice (avis de réunion) is published in the French Journal of Mandatory Statutory Notices (BALO) at least 35 days prior to the date of the shareholders meeting.
Additionally, a convening notice (avis de convocation) is published at least fifteen days prior to the date of the meeting in a legal gazette of the department in which the registered office of the company is located and in the French Journal of Mandatory Statutory Notices (BALO). Further, shareholders having held registered shares (actions nominatives) for at least one month at the time of the convening notice must be convened individually, by regular letter (or by registered letter if requested by the relevant shareholder) sent to their last known address.
When the shareholders meeting cannot deliberate due to the lack of the required quorum, the second meeting must be called at least ten days in advance in the same manner as used for the first notice.
All notices to the shareholders must further specify the conditions under which the shareholders may vote by correspondence.
Agenda and Conduct of Annual Shareholders Meetings. The agenda of the shareholders meeting shall appear in the notice to convene the meeting. The shareholders meeting may only deliberate on the items on the agenda except for the removal of directors and the appointment of their successors, which may be put to vote by any shareholder during any shareholders meeting. One or more shareholders representing the percentage of share capital required by French law (currently 5%), and acting in accordance with legal requirements and within applicable time limits, may request the inclusion of items or proposed resolutions on the agenda.
Shareholders meetings shall be chaired by the Chairman of the board of directors or, in his or her absence, by a director appointed for this purpose by the board of directors; failing which, the meeting itself shall elect a Chairman. Vote counting shall be performed by the two members of the meeting who are present and accept such duties, who represent, either on their own behalf or as proxies, the greatest number of votes.
Ordinary Shareholders Meeting. Ordinary shareholders meetings are those meetings called to make any and all decisions that do not result in a modification of our By-laws. An ordinary shareholders meeting shall be convened at least once a year within six months of the end of each fiscal year in order to approve the annual and consolidated accounts for the relevant fiscal year or, in case of postponement, within the period established by court order. Upon first notice, the meeting may validly deliberate only if the shareholders present or represented by proxy or voting by mail represent at least one-fifth of the shares entitled to vote. Upon second notice, no quorum is required. Decisions are made by a majority of the votes cast by the shareholders present, represented by proxy, or voting by mail. The votes cast do not include votes attached to shares held by shareholders who did not take part in the vote, abstained or voted blank or null.
Extraordinary Shareholders Meeting. Only an extraordinary shareholders meeting is authorized to amend our By-laws. It may not, however, increase shareholders commitments without the approval of each shareholder. Subject to the legal provisions governing share capital increases from reserves, profits or share premiums, the resolutions of the extraordinary meeting will be valid only if the shareholders present, represented by proxy or voting by mail represent at least one-fourth of all shares entitled to vote upon first notice, or one-fifth upon second notice. If the latter quorum is not reached, the second meeting may be postponed to a date no later than two months after the date for which it was initially called. Decisions are made by a two-thirds majority of the votes cast by the shareholders present, represented by proxy, or voting by mail. The votes cast do not include votes attached to shares held by shareholders who did not take part in the vote, abstained or voted blank or null.
In addition to the right to obtain certain information regarding us at any time, any shareholder may, from the date on which a shareholders meeting is convened until the fourth business day preceding the date of the shareholders meeting, submit written questions relating to the agenda for the meeting to our board of directors.
Our board of directors is required to respond to these questions during the meeting, except if the answers of the board are posted on the website of the Company at the latest at the end of the shareholders meeting. The board of directors may delegate one of its members, the chief executive officer or a deputy chief executive officer, as the case may be, to respond.
Temporary measures for Board of Directors Meetings due to COVID-19 crisis
Due to the COVID-19 pandemic the French government adopted several ordinances and decrees adapting the rules governing meetings and deliberations of shareholders and governing bodies of legal entities held until July 31, 2022. The ordinances and decrees provide the possibility of holding meetings of the board of directors remotely for all decisions that previously required a physical meeting.
The above legislation provides that shareholders (and all the persons who may attend the general meeting of shareholders) may participate in the meeting by means of a teleconference or audio-visual conference call if this conference allows for the identification of the participants, transmits at least the voice of the participants and allows the continuous and simultaneous retransmission of the debates.
Provisions Having the Effect of Delaying, Deferring or Preventing a Change in Control of the Company
Provisions contained in our By-laws and the corporate laws of France, the country in which we are incorporated, could make it more difficult for a third-party to acquire us, even if doing so might be beneficial to our shareholders. In addition, provisions of French law and our By-laws impose various procedural and other requirements which could make it more difficult for shareholders to effect certain corporate actions. These provisions include the following:
| provisions of French law allowing the owner of 90% of the share capital or voting rights of a public company to force out the minority shareholders following a tender offer made to all shareholders are only applicable to companies listed on a regulated market or a multilateral trading facility in a Member State of the EU or in a state party of the European Economic Area Agreement, including the main French stock exchange, and will therefore be applicable to us only if we continue to dual-list in France; |
| a merger (i.e., in a French law context, a stock-for-stock exchange after which our company would be dissolved without being liquidated into the acquiring entity and our shareholders would become shareholders of the acquiring entity) of our company into a company incorporated in the European Union would require the approval of our board of directors as well as a two-thirds majority of the votes cast by the shareholders present, represented by proxy or voting by mail at the relevant meeting. The votes cast do not include votes attached to shares held by shareholders who did not take part in the vote, abstained or voted blank or null; |
| a merger of our company into a company incorporated outside of the European Union would require the unanimous approval of our shareholders; |
| in a French law context, a cash merger is treated as a share purchase and would require the consent of each participating shareholder; |
| our shareholders have granted and may grant in the future our board of directors broad authorizations to increase our share capital or to issue additional ordinary shares or other securities (for example, warrants) to our shareholders, the public or qualified investors, including as a possible defense following the launching of a tender offer for our shares; |
| our shareholders have preferential subscription rights proportional to their shareholding in our company on the issuance by us of any additional shares or securities giving the right, immediately or in the future, to new shares for cash or a set-off of cash debts, which rights may only be waived by the extraordinary general meeting (by a two-thirds majority vote) of our shareholders or on an individual basis by each shareholder; |
| our board of directors has the right to appoint directors to fill a vacancy created by the resignation or death of a director, subject to ratification by the shareholders of such appointment at the next shareholders meeting, which prevents shareholders from having the sole right to fill vacancies on our board of directors; |
| our board of directors can only be convened by our chairman (and our managing director, if different from the chairman, may request the chairman to convene the board), or, when no board meeting has been held for more than two consecutive months, by directors representing at least one third of the total number of directors; |
| our board of directors meetings can only be regularly held if at least half of the directors attend either physically or by way of videoconference or teleconference enabling the directors identification and ensuring their effective participation in the board of directors decisions; |
| our shares take the form of bearer securities or registered securities, if applicable legislation so permits, according to the shareholders choice. Issued shares are registered in individual accounts opened by us or any authorized intermediary (depending on the form of such shares), in the name of each shareholder and kept according to the terms and conditions laid down by the legal and regulatory provisions; |
| under French law, a non-French resident as well as any French entity controlled by non-French residents may have to file a declaration for statistical purposes with the Bank of France (Banque de France) following the date of certain foreign investments in us. Additionally, certain investments in a French company relating to certain strategic industries by individual or entities not residents in a member State of the European Union are subject to the prior authorization of the French Ministry of Economy see Ownership of Shares and ADSs by Non-French Persons; |
| approval of at least a majority of the votes cast by the shareholders present, represented by a proxy, or voting by mail at the relevant ordinary shareholders general meeting is required to remove directors with or without cause; |
| advance notice is required for nominations to the board of directors or for proposing matters to be acted upon at a shareholders meeting, except that a vote to remove and replace a director can be proposed at any shareholders meeting without notice; |
| in the event where certain ownership thresholds would be crossed, a number of disclosures should be made by the relevant shareholder in addition to certain obligations; see Declaration of Crossing of Ownership Thresholds; |
| transfers of shares must comply with applicable insider trading rules; |
| pursuant to French law, the sections of the By-laws relating to the number of directors and election and removal of a director from office may only be modified by a resolution adopted by a two-thirds majority of the votes cast by our shareholders present, represented by a proxy or voting by mail at the meeting. The votes cast do not include votes attached to shares held by shareholders who did not take part in the vote, abstained or voted blank or null. |
Declaration of Crossing of Ownership Thresholds
Subject to requirements of French law, our By-laws do not require any specified disclosure by shareholders that cross ownership thresholds with respect to our share capital, except as described under Form, Holding and Transfer of SharesOwnership of Shares and ADSs by Non-French Persons.
The absence of specific requirement in our By-laws is without prejudice to the following disclosures which are applicable to us according to French legal and regulatory provisions, it being provided that the following is a summary which is therefore not intended to be a complete description of applicable rules under French law:
| Shareholders must make a declaration to us no later than the fourth trading day after such shareholder crosses the following thresholds: 5%, 10%, 15%, 20%, 25%, 30%, 33.33%, 50%, 66.66%, 90% and 95%. |
| Shareholders must make a declaration to the AMF no later than the fourth trading day after such shareholder crosses the following thresholds: 50% and 95%. |
The above obligations of declaration apply when crossing each of the above-mentioned thresholds in an upward or downward direction.
In case of failure to declare shares or voting rights exceeding the fraction that should have been declared, such shares shall be deprived of voting rights at shareholders meetings for any meeting that would be held until the expiry of a period of two years from the date of regularization of the notification in accordance with Article L. 233-14 of the French Commercial Code. Additional sanctions may apply pursuant to Article L. 621-15 of the French Monetary and Financial Code.
Subject to certain exemptions, any shareholder crossing, alone or acting in concert, the 50% threshold must file a mandatory public tender offer.
Changes in Share Capital
Increases in Share Capital. Pursuant to French law, our share capital may be increased only with shareholders approval at an extraordinary general shareholders meeting following the recommendation of our board of directors. The shareholders may delegate to our board of directors either the authority (délégation de compétence) or the power (délégation de pouvoir) to carry out any increase in share capital in accordance with applicable laws.
Increases in our share capital may be effected by:
| issuing additional shares; |
| increasing the par value of existing shares; |
| creating a new class of equity securities; and |
| exercising the rights attached to securities giving access to the share capital. |
Increases in share capital by issuing additional securities may be effected through one or a combination of the following:
| issuances in consideration for cash; |
| issuances in consideration for assets contributed in kind; |
| issuances through an exchange offer; |
| issuances by conversion of previously issued debt instruments; |
| issuances by capitalization of profits, reserves or share premium; and |
| subject to certain conditions, issuances by way of offset against debt incurred by us. |
Decisions to increase the share capital through the capitalization of reserves, profits and/or share premium require shareholders approval at an extraordinary general shareholders meeting, acting under the quorum and majority requirements applicable to ordinary shareholders meetings. Increases in share capital effected by an increase in the par value of shares require unanimous approval of the shareholders, unless effected by capitalization of reserves, profits or share premium. All other capital increases require shareholders approval at an extraordinary general shareholders meeting acting under the regular quorum and majority requirements for such meetings.
Reduction in Share Capital. Pursuant to French law, any reduction in our share capital requires shareholders approval at an extraordinary general shareholders meeting. The share capital may be reduced either by decreasing the par value of the outstanding shares or by reducing the number of outstanding shares. The number of outstanding shares may be reduced by the repurchase and cancellation of shares. Holders of each class of shares must be treated equally unless each affected shareholder agrees otherwise.
Preferential Subscription Rights (Preemptive Rights). According to French law, if we issue additional shares or securities giving right, immediately or in the future, to new shares for cash, current shareholders will have preferential subscription rights to these securities on a pro rata basis. Preferential subscription rights entitle the individual or entity that holds them to subscribe proportionally to the number of shares held by them to the issuance of any securities increasing, or that may result in an increase of, our share capital by means of a cash payment or a set-off of cash debts. The preferential subscription rights may be transferred and/or sold during the subscription period relating to a particular offering. Pursuant to French law, the preferential subscription rights will be transferable during a period starting two working days prior to the opening of the subscription period and ending two working days prior to the closing of the subscription period.
The preferential subscription rights with respect to any particular offering may be waived at an extraordinary general meeting by a two-thirds majority of the votes cast by our shareholders, or individually by each shareholder. Our board of directors and our independent auditors are required by French law to present reports to the shareholders meeting that specifically address any proposal to waive the preferential subscription rights.
Further, to the extent permitted under French law, we may seek, during an extraordinary general shareholders meeting, the approval of the shareholders to waive their preferential subscription rights in order to authorize the board of directors to issue additional shares and/or other securities convertible or exchangeable into shares.
Form, Holding and Transfer of SharesOwnership of Shares and ADSs by Non-French Persons
Form of Shares. Pursuant to our By-laws, shares may be held in registered or bearer form, at each shareholders discretion.
Further, in accordance with applicable legal and regulatory provisions, we may request at any time from the authorized intermediary responsible for holding our shares the name or, in the case of a legal entity, the corporate name, nationality and address of holders of securities, giving immediate or future access to voting rights at our shareholders meetings, the number of securities they own and, where applicable, the restrictions attaching to such securities.
Holding of Shares. In accordance with French law concerning the dematerialization of securities, the ownership rights of shareholders are represented by book entries instead of share certificates. Shares are registered in individual accounts opened by us or any authorized intermediary, in the name of each shareholder and kept according to applicable legal and regulatory provisions.
Ownership of Shares and ADSs by Non-French Persons. Neither the French Commercial Code nor our By-laws presently impose any restrictions on the right of non-French residents or non-French shareholders to own and vote shares.
However, (a) any non-French citizen, (b) any French citizen not residing in France, (c) any non-French entity or (d) any French entity controlled by one of the aforementioned persons or entities may have to file a declaration for statistical purposes with the Bank of France (Banque de France) within twenty working days following the date of certain direct foreign investments in us, including any purchase of our ADSs. In particular, such filings are required in connection with investments exceeding 15,000,000 that lead to the acquisition of at least 10% of our Companys share capital or voting rights or cross such 10% threshold. Violation of this filing requirement may be sanctioned by five years of imprisonment and a fine of up to twice the amount of the relevant investment. This amount may be increased fivefold if the violation is made by a legal entity.
Further, any investment (i) by an individual or entity located in a country that is not a member State of the European Union or of a member State of the European Economic Area having entered into a convention on administrative assistance against tax evasion and fraud with France, or by a French citizen not residing in France, and (ii) that will result in the relevant investor acquiring the control of, all or part of a business of, or more than 25% (reduced to 10% for the biotech sector from July 1, 2020 to December 31, 2021) of the share capital or voting rights of, a company registered in France and developing activities in certain strategic industries, such as, energy, public health, biotech, telecommunications, artificial intelligence, cybersecurity, robotics, data collection or dual-use goods and technology is subject to the prior authorization by the French Ministry of Economy. In the absence of such authorization, the relevant investment shall be deemed null and void.
Assignment and Transfer of Shares. Shares are freely negotiable, subject to applicable legal and regulatory provisions (including, in particular, the prohibition on insider trading).
Differences in Corporate Law
The laws applicable to French sociétés anonymes differ from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the French Commercial Code applicable to us and the Delaware General Corporation Law relating to shareholders rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and French law.
France |
Delaware | |||
Number of Directors |
Under French law, a société anonyme must have at least three and may have up to 18 directors. The number of directors is fixed by or in the manner provided in the by-laws. | Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the by-laws (unless fixed by the certificate of incorporation). | ||
Director Qualifications |
Under French law, a corporation may prescribe qualifications for directors under its by-laws. In addition, under French law, members of a board of directors of a corporation may be legal entities, and such legal entities may designate an individual to represent them and to act on their behalf at meetings of the board of directors. | Under Delaware law, a corporation may prescribe qualifications for directors under its certificate of incorporation or by-laws. Under Delaware law, only individuals may be members of a corporations board of directors. | ||
Removal of Directors |
Under French law, directors may be removed from office, with or without cause, at any shareholders meeting without notice or justification, by a simple majority vote. | Under Delaware law, directors may be removed from office, with or without cause, by a majority stockholder vote, except (1) unless otherwise provided in the certificate of incorporation, in the case of a corporation whose board is classified, stockholders may effect such removal only for cause, or (2) in the case of a company that has cumulative voting, if less than the entire board is to be removed, no director may be removed without cause if the votes cast against such directors removal would be sufficient to elect such director if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which such director is a part. |
Vacancies on the Board of Directors |
Under French law, vacancies on the board of directors resulting from death or a resignation, provided that at least three directors remain in office, may be filled by a majority of the remaining directors pending ratification by the next shareholders meeting. | Under Delaware law, unless provided otherwise by the certificate of incorporation or bylaws, vacancies on a corporations board of directors, including those caused by an increase in the number of directors, may be filled by a majority of the directors then in office, provided that the court may order an annual meeting upon the application of a director or stockholder if a corporation has not held a meeting within 13 months after the latest of the companys organization, the last annual meeting or the last action by written consent to elect directors. | ||
Annual General Meeting |
Under French law, the annual general meeting of shareholders shall be held at such place, on such date and at such time as decided each year by the board of directors and notified to the shareholders in the convening notice of the annual meeting, within six months after the close of the relevant fiscal year unless such period is extended by court order. | Under Delaware law, the annual meeting of stockholders shall be held at such place as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the by-laws and on such date and at such time as provided in the by-laws. | ||
General Meeting |
Under French law, general meetings of the shareholders may be called by the board of directors or, failing that, by the statutory auditors, or by a court appointed agent or liquidator in certain circumstances, or by the majority shareholder in capital or voting rights following a public tender offer or exchange offer or the transfer of a controlling block on the date decided by the board of directors or the relevant person. | Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the by-laws. |
Notice of General Meetings |
A meeting notice (avis de réunion) is published in the French Journal of Mandatory Statutory Notices (BALO) at least 35 days prior to the date of the shareholders meeting. Additionally, a convening notice (avis de convocation) is published at least fifteen days prior to the date of the meeting in a legal gazette of the department in which the registered office of the company is located and in the French Journal of Mandatory Statutory Notices (BALO). Further, shareholders having held registered shares (actions nominatives) for at least one month at the time of the convening notice must be convened individually, by regular letter (or by registered letter if requested by the relevant shareholder) sent to their last known address.
The meeting notice must indicate the conditions under which the shareholders may vote by correspondence and the places and conditions in which they can obtain voting forms by mail. |
Under Delaware law, written notice of any meeting of the stockholders must be given to each stockholder entitled to vote at the meeting not less than 10 nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the meeting. | ||
Proxy |
Each shareholder may attend the meetings and vote (1) in person, or (2) by granting proxy to any person, or (3) by sending a proxy to us without indication of the beneficiary (in which case such proxy shall be cast in favor of the resolutions supported by the board of directors), or (4) by correspondence, or (5) by videoconference or another means of telecommunication allowing identification of the relevant shareholder in accordance with applicable laws. The proxy is only valid for a single meeting or successive meetings convened with the same agenda. It can also be granted for two meetings, one ordinary, the other extraordinary, held within a period of fifteen days. | Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period. | ||
Shareholder action by written consent |
Under French law, shareholders action by written consent is not permitted in a société anonyme. | Under Delaware law, unless otherwise provided in a corporations certificate of incorporation, stockholders may act by written consent signed by stockholders having the minimum number of votes that would be necessary to take such action at a meeting. |
Preemptive Rights |
Under French law, in case of issuance of additional shares or securities giving right, immediately or in the future, to new shares for cash or set-off against cash debts, the existing shareholders have preferential subscription rights to these securities on a pro rata basis unless such rights are waived by a two-thirds majority of the votes cast by the shareholders present, represented by proxy or voting by mail at the extraordinary meeting deciding or authorizing the capital increase. In case such rights are not waived by the extraordinary general meeting, each shareholder may individually either exercise, assign or not exercise its preferential rights. Preferential subscription rights may only be exercised during the subscription period. In accordance with French law, the exercise period shall not be less than five trading days. Thus, the preferential subscription rights are transferable during a period equivalent to the subscription period but starting two business days prior to the opening of the subscription period and ending two business days prior to the closing of the subscription period. | Under Delaware law, unless otherwise provided in a corporations certificate of incorporation, a stockholder does not, by operation of law, possess preemptive rights to subscribe to additional issuances of the corporations stock. | ||
Sources of Dividends |
Under French law, dividends may only be paid by a French société anonyme out of distributable profits, plus any distributable reserves and distributable premium that the shareholders decide to make available for distribution, other than those reserves that are specifically required by law.
Distributable profits consist of the unconsolidated net profits of the relevant corporation for each fiscal year, as increased or reduced by any profit or loss carried forward from prior years.
Distributable premium refers to the contribution paid by the shareholders in addition to the par value of their shares for their subscription that the shareholders decide to make available for distribution.
Except in the case of a share capital reduction, no distribution can be made to the shareholders when the net equity is, or would become, lower than the amount of the share capital plus the reserves which cannot be distributed in accordance with the law or the by-laws. |
Under Delaware law, subject to any restrictions under a corporations certificate of incorporation, dividends may be declared by the board of directors and paid by a Delaware corporation either out of (1) surplus or (2) in case there is no surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year, except when the capital is diminished by depreciation in the value of its property, or by losses, or otherwise, to an amount less than the aggregate amount of capital represented by issued and outstanding stock having a preference on the distribution of assets. |
Repurchase of Shares |
Under French law, a corporation may acquire its own shares for the following purposes only:
to decrease its share capital, provided that such decision is not driven by losses and that a purchase offer is made to all shareholders on a pro rata basis, with the approval of the shareholders at the extraordinary general meeting deciding the capital reduction;
with a view to distributing within one year of their repurchase the relevant shares to employees or managers under a profit-sharing, free share or share option plan; or
under a buy-back program to be authorized by the shareholders in accordance with the provisions of Article L. 22-10-62 of the French Commercial Code and with the general regulations of the AMF.
No such repurchase of shares may result in the company holding, directly or through a person acting on its behalf, more than 10% of its issued share capital. |
Under Delaware law, a corporation may generally redeem or repurchase shares of its stock except under certain circumstances, including where the capital of the corporation is impaired or such redemption or repurchase would impair the capital of the corporation (other than certain preference shares or certain shares to be retired). | ||
Liability of Directors and Officers |
Under French law, the By-laws may not include any provisions limiting the liability of directors. | Under Delaware law, a corporations certificate of incorporation may generally include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for monetary damages arising from a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for:
any breach of the directors duty of loyalty to the corporation or its stockholders;
acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
intentional or negligent payment of unlawful dividends or stock purchases or redemptions;
claims with respect to unlawful payment of dividends and unlawful stock purchases and redemptions; or
any transaction from which the director derives an improper personal benefit |
Voting Rights |
French law provides that, unless otherwise provided in the by-laws, each shareholder is entitled to one vote for each share of capital stock held by such shareholder. | Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder. | ||
Shareholder Vote on Certain Transactions |
Generally, under French law, completion of a merger, dissolution, sale, lease or exchange of all or substantially all of a corporations assets requires: approval by a two-thirds majority of the votes cast by the shareholders present, represented by proxy or voting by mail at the relevant meeting, or in the case of a merger with a non-EU company, approval of all the shareholders of the corporation. | Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock or under other certain circumstances, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporations assets or dissolution requires:
the approval of the board of directors; and
approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the matter. |
Dissent or Dissenters Apparaisal Rights |
French law does not provide for any such right but provides that a merger is subject to shareholders approval by a two-thirds majority of the votes cast as stated above. | Under Delaware law, a holder of shares of any class or series has the right, in specified circumstances, to dissent from a merger or consolidation by demanding payment in cash for the stockholders shares equal to the fair value of those shares, as determined by the Delaware Chancery Court in an action timely brought by the dissenting stockholder. Delaware law grants these appraisal rights only in the case of mergers or consolidations and not in the case of a sale or transfer of assets or a purchase of assets for stock. Further, no appraisal rights are available for shares of any class or series that is listed on a national securities exchange or held of record by more than 2,000 stockholders, unless the agreement of merger or consolidation requires the holders to accept for their shares anything other than:
shares of stock of the surviving corporation;
shares of stock of another corporation that are either listed on a national securities exchange or held of record by more than 2,000 stockholders;
cash in lieu of fractional shares of the stock described in the two preceding bullet points; or
any combination of the above.
In addition, appraisal rights are not available to holders of shares of the surviving corporation in specified mergers that do not require the vote of the stockholders of the surviving corporation. | ||
Standard of Conduct for Directors |
French law does not contain specific provisions setting forth the standard of conduct of a director. However, directors have a duty to act without self-interest, on a well-informed basis and they cannot make any decision against a corporations corporate interest (intérêt social). | Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the stockholders. |
Shareholder Suits |
French law provides that a shareholder, or a group of shareholders, may initiate a legal action to seek indemnification from the directors of a corporation in the corporations interest if it fails to bring such legal action itself. If so, any damages awarded by the court are paid to the corporation and any legal fees relating to such action are borne by the relevant shareholder or the group of shareholders. The plaintiff must remain a shareholder throughout the duration of the legal action. There is no other case where shareholders may initiate a derivative action to enforce a right of a corporation. A shareholder may alternatively or cumulatively bring an individual legal action against the directors, provided he has suffered distinct damages from those suffered by the corporation. In this case, any damages awarded by the court are paid to the relevant shareholder. | Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself. The complaint must: state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiffs shares thereafter devolved on the plaintiff by operation of law; and allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiffs failure to obtain the action; or state the reasons for not making the effort. Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery. | ||
Amendment of Certificate of Incorporation |
Unlike companies incorporated under Delaware law, the organizational documents of which comprise both a certificate of incorporation and by-laws, companies incorporated under French law only have by-laws (statuts) as organizational documents. As indicated in the paragraph below, only the extraordinary shareholders meeting is authorized to adopt or amend the by-laws under French law. |
Under Delaware law, generally a corporation may amend its certificate of incorporation if: its board of directors has adopted a resolution setting forth the amendment proposed and declared its advisability, and the amendment is adopted by the affirmative votes of a majority (or greater percentage as may be specified by the certificate of incorporation) of the outstanding shares entitled to vote on the amendment and a majority (or greater percentage as may be specified by the certificate of incorporation) of the outstanding shares of each class or series of stock, if any, entitled to vote on the amendment as a class or series. | ||
Amendment of By-laws |
Under French law, only the extraordinary shareholders meeting is authorized to adopt or amend the by-laws. | Under Delaware law, the stockholders entitled to vote have the power to adopt, amend or repeal by-laws. A corporation may also confer, in its certificate of incorporation, that power upon the board of directors. |
AMERICAN DEPOSITARY SHARES
The description below reflects certain terms of the Deposit Agreement, and summarizes the material rights of holders of our ADSs.
General
Each ADS represents the right to receive, and to exercise the beneficial interests in one ordinary share that are on deposit with the depositary and/or Custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary bank or the Custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. The Custodian, the depositary and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary, the Custodian or their nominees.
Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the beneficial owners of the ADSs. The depositary, the Custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. A beneficial owner of ADSs may or may not be the holder of such ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests, in the deposited property only through the registered holders of the ADSs, the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary, and the depositary (on behalf of the owners of the corresponding ADSs) directly, or indirectly, through the Custodian or their respective nominees, in each case upon the terms of the deposit agreement.
An owner of ADSs will not be treated as one of our shareholders and will not have direct shareholder rights. The depositary will hold on such owners behalf the shareholder rights attached to the ordinary shares underlying such owners ADSs. Accordingly, an owner of ADSs will be able to exercise the shareholders rights for the ordinary shares represented by such owners ADSs through the depositary only to the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement, an ADS owner will need to arrange for the cancellation of such owners ADSs and become a direct shareholder.
This summary description assumes ADSs are owned directly by means of an ADS registered in the owners name and, as such, such owner is referred to as the holder. ADSs may also be held by means of an ADR registered in an owners name, through a brokerage or safekeeping account, or through an account established by the depositary in such owners name reflecting the registration of uncertificated ADSs directly on the books of the depositary, commonly referred to as the direct registration system, or DRS.
Dividends and Distributions
A holder of ADSs generally has the right to receive the distributions we make on the securities deposited with the Custodian. A holders receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of a specified record date, after deduction of the applicable fees, taxes and expenses.
Distributions of Cash
Whenever we make a cash distribution for the securities on deposit with the Custodian, we will deposit the funds with the Custodian. Upon receipt of confirmation of the deposit of the requisite funds, the depositary will arrange for the funds to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders, subject to French laws and regulations.
The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States. The depositary will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the Custodian in respect of securities on deposit.
The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. The depositary will hold any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States.
Distributions of Shares
Whenever we make a free distribution of ordinary shares for the securities on deposit with the Custodian, we will deposit the applicable number of ordinary shares with the Custodian. Upon receipt of confirmation of such deposit, the depositary will either distribute to holders new ADSs representing the ordinary shares deposited or modify the ADS-to-ordinary share ratio, in which case each ADS a holder holds will represent rights and interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed; fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution.
The distribution of new ADSs or the modification of the ADS-to-ordinary share ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary may sell all or a portion of the new ordinary shares so distributed.
No such distribution of new ADSs will be made if it would violate a law (e.g., the U.S. securities laws) or if it is not operationally practicable. If the depositary does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a distribution of cash.
Distributions of Rights
Whenever we intend to distribute rights to purchase additional ordinary shares, we will give prior notice to the depositary and we will assist the depositary in determining whether it is lawful and practicable to distribute rights to purchase additional ADSs to holders.
The depositary will establish procedures to distribute rights to purchase additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the transaction). A holder may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of such holders rights. The depositary is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to purchase new ordinary shares other than in the form of ADSs.
The depositary will not distribute the rights to a holder if:
| we do not timely request that the rights be distributed to holders or we request that the rights not be distributed to holders; or |
| we fail to deliver satisfactory documents to the depositary; or |
| it is not practicable to distribute the rights. |
The depositary will sell the rights that are not exercised or not distributed if such sale is lawful and practicable. The proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary is unable to sell the rights, it will allow the rights to lapse.
Elective Distributions
Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary and will indicate whether we wish the elective distribution to be made available to holders. In such case, we will assist the depositary in determining whether such distribution is lawful and practicable.
The depositary will make the election available to holders only if it is practicable and if we have provided all of the documentation contemplated in the deposit agreement. In such case, the depositary will establish procedures to enable holders to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement.
If the election is not made available to holders, such holders will receive either cash or additional ADSs, depending on what a shareholder in France would receive upon failing to make an election, as more fully described in the deposit agreement.
Other Distributions
Whenever we intend to distribute property other than cash, ordinary shares or rights to purchase additional ordinary shares, we will notify the depositary in advance and will indicate whether we wish such distribution to be made to holders. If so, we will assist the depositary in determining whether such distribution to holders is lawful and practicable.
If it is practicable to distribute such property to holders and if we provide all of the documentation contemplated in the deposit agreement, the depositary will distribute the property to the holders in a manner it deems practicable.
The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes and governmental charges, the depositary bank may sell all or a portion of the property received.
The depositary will not distribute the property to holders and will sell the property if:
| we do not request that the property be distributed to holders or if we ask that the property not be distributed to holders; or |
| we do not deliver satisfactory documents to the depositary bank; or |
| the depositary determines that all or a portion of the distribution to holders is not practicable. |
The proceeds of such a sale will be distributed to holders as in the case of a cash distribution.
Redemption
Whenever we decide to redeem any of the securities on deposit with the Custodian, we will notify the depositary in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary will provide notice of the redemption to the holders.
The Custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary will convert the redemption funds received into U.S. dollars upon the terms of the deposit agreement and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary. Holders may have to pay fees, expenses, taxes and other governmental charges upon the redemption of their ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a pro rata basis, as the depositary may determine.
Changes Affecting Ordinary Shares
The ordinary shares held on deposit for a holders ADSs may change from time to time. For example, there may be a change in nominal or par value, a split-up, cancellation, consolidation or reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets.
If any such change were to occur, such holders ADSs would, to the extent permitted by law, represent the right to receive the property received or exchanged in respect of the ordinary shares held on deposit. The depositary may in such circumstances deliver new ADSs to such holder, amend the deposit agreement, the ADRs and the applicable registration statement(s) on Form F-6, call for the exchange of such holders existing ADRs for new ADRs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the ordinary shares held in deposit for such holders ADSs. If the depositary bank may not lawfully distribute such property to such holder, the depositary may sell such property and distribute the net proceeds to such holder as in the case of a cash distribution.
Issuance of ADSs upon Deposit of Ordinary Shares
The depositary may create ADSs on a holders behalf if such holder or such holders broker deposits ordinary shares with the Custodian. The depositary will deliver these ADSs to the person such holder indicates only after such holder pays any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the Custodian. A holders ability to deposit ordinary shares and receive ADSs may be limited by U.S. and French legal considerations applicable at the time of deposit.
The issuance of ADSs may be delayed until the depositary or the Custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the Custodian.
The depositary will only issue ADSs in whole numbers.
When a holder makes a deposit of ordinary shares, such holder will be responsible for transferring good and valid title to the depositary. Accordingly, such holder will be deemed to represent and warrant that:
| The ordinary shares are duly authorized, validly issued, fully paid, non-assessable and legally obtained. |
| All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or exercised. |
| Such holder is duly authorized to deposit the ordinary shares. |
| The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, restricted securities (as defined in the deposit agreement). |
| The ordinary shares presented for deposit have not been stripped of any rights or entitlements. |
If any of the representations or warranties are incorrect in any way, we and the depositary may, at such holders cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations.
Transfer, Combination and Split Up of ADRs
An ADR holder will be entitled to transfer, combine or split up such holders ADRs and the ADSs evidenced thereby. For transfers of ADRs, a holder will have to surrender the ADRs to be transferred to the depositary and also must:
| ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer; |
| provide such proof of identity and genuineness of signatures as the depositary deems appropriate; |
| provide any transfer stamps required by the State of New York or the United States; and |
| pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit agreement, upon the transfer of ADRs. |
To have ADRs either combined or split up, a holder must surrender the ADRs in question to the depositary with such holders request to have them combined or split up, and such holder must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a combination or split up of ADRs.
Withdrawal of Ordinary Shares Upon Cancellation of ADSs
A holder will be entitled to present such holders ADSs to the depositary for cancellation and then receive the corresponding number of underlying ordinary shares at the Custodians offices. A holders ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and French legal considerations applicable at the time of withdrawal. In order to withdraw the ordinary shares represented by a holders ADSs, such holder will be required to pay to the depositary the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares being withdrawn. Holders assume the risk for delivery of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement.
If a holder holds ADSs registered in such holders name, the depositary may ask such holder to provide proof of identity and genuineness of any signature and such other documents as the depositary may deem appropriate before it will cancel such holders ADSs. The withdrawal of the ordinary shares represented by a holders ADSs may be delayed until the depositary receives satisfactory evidence of compliance with all applicable laws and regulations. The depositary will only accept ADSs for cancellation that represent a whole number of securities on deposit.
A holder will have the right to withdraw the securities represented by such holders ADSs at any time except for:
| temporary delays that may arise because (1) the transfer books for the ordinary shares or ADSs are closed, or (2) ordinary shares are immobilized on account of a shareholders meeting or a payment of dividends; |
| obligations to pay fees, taxes and similar charges; or |
| restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit. |
The deposit agreement may not be modified to impair a holders right to withdraw the securities represented by such holders ADSs except to comply with mandatory provisions of law.
Voting Rights
A holder generally has the right under the deposit agreement to instruct the depositary to exercise the voting rights for the ordinary shares represented by such holders ADSs.
At our request, the depositary will distribute to holders any notice of shareholders meeting received from us together with information explaining how to instruct the depositary to exercise the voting rights of the securities represented by ADSs.
If the depositary timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holders ADSs in accordance with such voting instructions.
The ability of the depositary to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit.
If the depositary receives voting instructions from a holder of ADSs that fail to specify the manner in which the depositary is to vote, the depositary will deem such holder (unless otherwise specified in the notice distributed to holders) to have instructed the depositary to vote in favor of all resolutions endorsed by our board of directors. With respect to securities represented by ADSs for which no timely voting instructions are received by the depositary from the holder, the depositary will (unless otherwise specified in the notice distributed to holders) deem such holder to have instructed the depositary to give a discretionary proxy to a person designated by us to vote the securities. However, no such discretionary proxy will be given by the depositary with respect to any matter to be voted upon as to which we inform the depositary that we do not wish such proxy to be given, substantial opposition exists, or the rights of holders of securities may be materially adversely affected.
Fees and Charges
Holders will be required to pay certain fees under the terms of the depositary agreement. Holders will be notified in advance of all applicable fees by us or the depositary.
Holders will also be responsible to pay certain fees and expenses incurred by the depositary and certain taxes and governmental charges such as:
| taxes (including applicable interest and penalties) and other governmental charges; |
| the registration fees as may from time to time be in effect for the registration of ordinary shares on the share register and applicable to transfers of ordinary shares to or from the name of the Custodian, the depositary or any nominees upon the making of deposits and withdrawals, respectively; |
| certain cable, telex and facsimile transmission and delivery expenses; |
| the expenses and charges incurred by the depositary in the conversion of foreign currency; |
| the fees and expenses incurred by the depositary in connection with the compliance with exchange control regulations and other regulatory requirements applicable to ordinary shares, ADSs and ADRs; and |
| the fees and expenses incurred by the depositary, the Custodian, or any nominee in connection with the servicing or delivery of deposited property. |
ADS fees and charges payable upon (1) deposit of ordinary shares against issuance of ADSs and (2) surrender of ADSs for cancellation and withdrawal of ordinary shares are charged to the person to whom the ADSs are delivered (in the case of ADS issuances) and to the person who delivers the ADS, for cancellation (in the case of ADS cancellations). In the case of ADSs issued by the depositary into DTC or presented to the depositary via DTC, the ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs or the DTC participant(s) surrendering the ADSs for cancellation, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account(s) of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participant(s) as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (1) distributions other than cash and (2) the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs.
In the event of refusal to pay the depositary fees, the depositary may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the holder.
The depositary may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary agree from time to time.
Amendments and Termination
We may agree with the depositary to modify the deposit agreement at any time without holders consent. We undertake to give holders 30 days prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to holders substantial rights any modifications or supplements that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges holders are required to pay. In addition, we may not be able to provide holders with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law.
Holders will be bound by the modifications to the deposit agreement if they continue to hold ADSs after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent holders from withdrawing the ordinary shares represented by their ADSs (except as permitted by law).
We have the right to direct the depositary to terminate the deposit agreement. Similarly, the depositary may in certain circumstances on its own initiative terminate the deposit agreement. In either case, the depositary must give notice to the holders at least 30 days before termination. Until termination, holders rights under the deposit agreement will be unaffected.
After termination, the depositary will continue to collect distributions received (but will not distribute any such property until a holder requests the cancellation of such holders ADSs) and may sell the securities held on deposit. After the sale, the depositary will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a non-interest bearing account. At that point, the depositary will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction of applicable fees, taxes and expenses).
Books of Depositary
The depositary will maintain holder records at its depositary office. A holder may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement.
The depositary will maintain in New York facilities to record and process the issuance, cancellation, combination, split-up and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law.
Limitations on Obligations and Liabilities
The deposit agreement limits our obligations and the depositarys obligations to holders. Note the following:
| We and the depositary are obligated only to take the actions specifically stated in the deposit agreement without negligence or bad faith. |
| The depositary disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. |
| The depositary disclaims any liability for any failure to determine the lawfulness or practicality of any action, for the content of any document forwarded to holders on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give notice. |
| We and the depositary will not be obligated to perform any act that is inconsistent with the terms of the deposit agreement. |
| We and the depositary disclaim any liability if we or the depositary are prevented or forbidden from or subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by reason of present or future provision of any provision of our By-laws, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control. |
| We and the depositary disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided for in the deposit agreement or in our By-laws or in any provisions of or governing the securities on deposit. |
| We and the depositary further disclaim any liability for any action or inaction in reliance on the advice or information received from legal counsel, accountants, any person presenting ordinary shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice or information. |
| We and the depositary also disclaim liability for the inability by a holder to benefit from any distribution, offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to holders. |
| We and the depositary may rely without any liability upon any written notice, request or other document believed to be genuine and to have been signed or presented by the proper parties. |
| We and the depositary also disclaim liability for any consequential or punitive damages for any breach of the terms of the deposit agreement. |
| No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement. |
Pre-Release Transactions
Subject to the terms and conditions of the deposit agreement, the depositary may issue to broker/dealers ADSs before receiving a deposit of ordinary shares or release ordinary shares to broker/dealers before receiving ADSs for cancellation. These transactions are commonly referred to as pre-release transactions, and are entered into between the depositary and the applicable broker/dealer. The deposit agreement limits the aggregate size of pre-release transactions (not to exceed 30% of the ordinary shares on deposit in the aggregate) and imposes a number of conditions on such transactions (e.g., the need to receive collateral, the type of collateral required and the representations required from brokers). The depositary may retain the compensation received from the pre-release transactions.
Taxes
A holder will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the depositary and the Custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. A holder will be liable for any deficiency if the sale proceeds do not cover the taxes that are due.
The depositary may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary and the Custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on holders behalf. However, a holder may be required to provide to the depositary and to the Custodian proof of taxpayer status and residence and such other information as the depositary and the Custodian may require to fulfill legal obligations. A holder is required to indemnify us, the depositary and the Custodian for any claims with respect to taxes based on any tax benefit obtained for such holder.
Foreign Currency Conversion
The depositary will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. A holder may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements.
If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable cost or within a reasonable period, the depositary may take the following actions in its discretion:
| convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and distribution is lawful and practical; |
| distribute the foreign currency to holders for whom the distribution is lawful and practical; and |
| hold the foreign currency (without liability for interest) for the applicable holders. |
Governing Law/Waiver of Jury Trial
The deposit agreement and the ADRs will be interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary shares (including ordinary shares represented by ADSs) are governed by the laws of France.
Exhibit 4.3
CHANGE OF CONTROL PLAN
The executive and employee change of control plan (the Plan) has been adopted by our board of directors on September 4, 2014 and was subsequently amended on December 11, 2014.
The Plan is effective as from September 4, 2014 with respect to the concerned executives and will be effective towards the concerned employees upon the execution by each concerned employee of an amendment to his or her employment agreement to this effect.
Subsequently, on each of March 4, 2020 and November 5, 2020, the coverage of the Plan was extended for the benefit of any members of the executive committee of Cellectis not already covered by the Plan as of such respective date.
A free translation of the relevant excerpt of the minutes of our board of directors meeting held on December 11, 2014 is presented on the following page.
CELLECTIS
A French société anonyme with a share capital of EUR 1,470,986.05
Registered office: 8, rue de la Croix Jarry 75013 Paris - France
428 859 052 R.C.S. Paris
Translated excerpt of the minutes of the board of directors
held on December 11, 2014
During its meeting held on December 11, 2014, the board of directors of Cellectis (the Company) has made the following decision:
Modifications of the circumstances in which a severance package should be paid by the Company to managers upon a change of control
The chairman reports that his attention has been drawn to the need to clarify the circumstances in which the severance package approved by the board of directors held on September 4, 2014 should be paid to the managers of the group upon a change of control.
The chairman reminds the directors the list of the relevant managers together with their respective compensation levels:
First name | Last name | Position | Annual compensation (gross) |
Bonus (% of annual compensation) |
Comments | |||||||||||
André |
Choulika | Chairman of the board of directors and CEO |
240,000 | 80 | % | |||||||||||
Mathieu |
Simon | EVP | 245,000 | 40 | % | contractual | ||||||||||
David |
Sourdive | EVP | 180,000 | 40 | % | |||||||||||
Philippe |
Duchateau | CSO | 120,000 | 40 | % | |||||||||||
Marie-Bleuenn |
Terrier | GC | 85,000 | 14 | % | (non contractual 2013 bonus) | ||||||||||
Philippe |
Valachs | CS | 144,000 | 40 | % | |||||||||||
Thierry |
Moulin | CFO | 140,000 | 40 | % | |||||||||||
Delphine |
Jay | HR | 110,000 | 12 | % | (non contractual 2013 bonus 2013) | ||||||||||
Julia |
Berretta | BusDev | 70,000 | 12 | % | (non contractual 2013 bonus) | ||||||||||
Laurent |
Poirot | Innovation Manager | 70,000 | 17 | % | (non contractual 2013 bonus) | ||||||||||
Julianne |
Smith | VP CART Platform | 80,000 | 21 | % | (non contractual 2013 bonus) |
The chairman also reminds the directors that the board of directors has, during its meeting held on September 4, 2014, set this severance package at an amount equal to 24 months of gross fixed salary (or for executives, 24 months of compensation) increased by an amount equal to the maximum target bonus to which the employees or executives concerned may be entitled for the year of their departure, or, in the absence of such a target bonus, 1.5 times the last annual bonus paid to them by the Company during the 12 months prior to their departure.
Notwithstanding the above, the board of directors, upon recommendation of the compensation committee, decides that the severance package to be paid to André Choulika, chief executive officer of Cellectis SA, shall amount to two years of compensation and two years of maximal target bonus to take into account the fact that André Choulika is not entitled to any legal or conventional severance payments in the absence of an employment agreement having been entered into between himself and the Company.
This amount would be in addition to any legal and conventional severance payments owed by the Company to the employees or executives concerned.
The Chairman suggests:
| to extend the definition of a « change of control » triggering the payment of such a severance package from the crossing of the threshold of 50% of the share capital or voting rights only to all circumstances qualifying as a change of control within the meaning of article L. 233-3 of the French Commercial code; and |
| with respect to managers having entered into an employment agreement with the Company, to clarify that their departure as a result of a significant reduction of their responsabilities would trigger the payment of the abovementioned severance package only to the extent that such departure occurs within the 12-month period following a change of control; and |
| to extend from 12 to 36 months following a change of control the period during which the concerned managers would benefit from this severance package. |
This amount would thus be paid by the Company should any of the following events occur, it being provided that such triggering events replace and supersede the triggering events approved by the board of directors during its meeting held on September 4, 2014:
| with respect to all managers, whether they are executives of the Company or have entered into an employment agreement with the Company: should the employees or executives concerned not be renewed or be dismissed other than for gross misconduct (faute lourde) within the meaning of French labor law within the 36-month period following a change of control of the Company within the meaning of article L. 233-3 of the French Commercial code. |
| with respect to executives only: should they resign within the abovementioned 36-month period as a result of a significant reduction of their duties or compensation. |
The president indicates that the granting to David Sourdives, deputy chief executive officer, and to himself of the severance package qualifies as a related party agreement which is therefore subject to the prior approval of the board of directors.
The board of directors, after discussions, unanimously:
| approves to put into place the abovementioned amendments relating to the circumstances in which a severance package shall be paid to managers of the Company upon a change of control, it being specified that André Choulika et David Sourdives, did not participate to the vote, |
* * *
Translated excerpt of the minutes of the board of directors
held on March 4, 2020
During its meeting held on March 4, 2020, the board of directors of the Company has made the following decision:
The chairman reminds the directors that the board of directors has, during its meeting held on September 4, 2014, approved the implementation of a severance package to the benefit of certain managers upon a change of control of the Company. In order to ensure the retention of the members of the executive committee, the chairman, upon recommendation of the compensation committee, proposes to the board that the benefit of this severance package be extended to the members of the current executive committee who do not benefit from it.
The board of directors, after discussions, unanimously:
| considering that providing comfort to the groups main executives as to their situation in the event of a change of control of the Company, and thereby ensuring their continued presence within the group, is fully in line with the Companys interests, approves the implementation of a severance package, upon a change of control of the Company, for the benefit of members of the companys executive committee who do not already enjoy one, which shall not be more favorable than the package approved in 2014 |
* * *
Translated excerpt of the minutes of the board of directors
held on November 5, 2020
During its meeting held on November 5, 2020, the board of directors of the Company has made the following decision:
The chairman reminds the directors that the board of directors has, during its meeting held on March 4, 2020, approved the implementation of a severance package to the benefit of members of the companys executive committee who do not already enjoy one. The chairman, proposes to the board that this severance package benefits to new employees having joined the current executive committee since March 4, 2020.
The board of directors, after discussions, unanimously:
| considering that providing comfort to the groups main executives as to their situation in the event of a change of control of the Company, and thereby ensuring their continued presence within the group, is fully in line with the Companys interests, approves the implementation of a severance package, upon a change of control of the Company, for the benefit of members of the companys executive committee who do not already enjoy one, which shall not be more favorable than the package approved in 2014 |
* *
*
Exhibit 8.1
Subsidiaries of Cellectis S.A.
Name of Subsidiary |
State or Other Jurisdiction of Incorporation | |
Cellectis, Inc. |
Delaware | |
Calyxt, Inc. |
Delaware | |
Cellectis Biologics, Inc. |
Delaware |
Exhibit 12.1
Certification by the Principal Executive Officer pursuant to
Securities Exchange Act Rules 13a-14(a) and 15d-14(a)
as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, André Choulika, certify that:
1. | I have reviewed this annual report on Form 20-F of Cellectis S.A.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report; |
4. | The Companys other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the Companys disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the Companys internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Companys internal control over financial reporting; and |
5. | The Companys other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Companys auditors and the audit committee of the Companys board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Companys ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the Companys internal control over financial reporting. |
Date: March 3, 2022 | ||
/s/ André Choulika | ||
Name: | André Choulika | |
Title: | Chief Executive Officer (Principal Executive Officer) |
Exhibit 12.2
Certification by the Principal Financial Officer pursuant to
Securities Exchange Act Rules 13a-14(a) and 15d-14(a)
as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Bing Wang, certify that:
1. | I have reviewed this annual report on Form 20-F of Cellectis S.A.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report; |
4. | The Companys other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the Companys disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the Companys internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the Companys internal control over financial reporting; and |
5. | The Companys other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Companys auditors and the audit committee of the Companys board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Companys ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the Companys internal control over financial reporting. |
Date: March 3, 2022
/s/ Bing Wang | ||
Name: | Bing Wang | |
Title: | Chief Financial Officer (Principal Financial Officer) |
EXHIBIT 13.1
Certification by the Principal Executive Officer pursuant to
18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Annual Report of Cellectis S.A. (the Company) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, André Choulika, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 3, 2022 | ||
/s/ André Choulika | ||
Name: | André Choulika | |
Title: | Chief Executive Officer (Principal Executive Officer) |
A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
EXHIBIT 13.2
Certification by the Principal Financial Officer pursuant to
18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Annual Report of Cellectis S.A. (the Company) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Bing Wang, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 3, 2022 | ||
/s/ Bing Wang | ||
Name: | Bing Wang | |
Title: | Chief Financial Officer (Principal Financial Officer) |
A signed original of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Exhibit 15.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-8 No. 333-204205) pertaining to the 2015 Stock Option Plan and the 2015 Free Share Plan of Cellectis S.A.; |
(2) | Registration Statement (Form S-8 No. 333-214884) pertaining to the 2016 Stock Option Plan of Cellectis S.A.; and |
(3) | Registration Statement (Form S-8 No. 333-222482) pertaining to the 2017 Stock Option Plan of Cellectis S.A., the Summary of BSA Plan and the Free Share 2018 Plan of Cellectis S.A.; |
(4) | Registration Statement (Form S-8 No. 333-227717) pertaining to the 2018 Stock Option Plan of Cellectis S.A., the Summary of BSA Plan and the Second Free Share 2018 Plan of Cellectis S.A.; |
(5) | Registration Statement (Form S-8 No. 333-258514) pertaining to the 2021 Stock Option Plan of Cellectis S.A., and the 2021 Free Shares Plan of Cellectis S.A.; and |
(6) | Registration Statement (Form F-3 No. 333-238881) of Cellectis S.A.; |
of our reports dated March 3, 2022, with respect to the consolidated financial statements of Cellectis S.A. and the effectiveness of internal control over financial reporting of Cellectis S.A., included in this annual report (Form 20-F) of Cellectis S.A. for the year ended December 31, 2021.
/s/ ERNST & YOUNG et Autres |
Paris La Défense, France |
March 3, 2022 |